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PMA Paracetamol mercapturic acid
PS Paracetamol sulphate
PSH D-Penicillamine
PSSC D-Penicillamine L-cysteine disulfide
PSSP D-Penicillamine disulfide
SA Salicylic acid
SAG Salicyl acyl glucuronide
(iii)
SPEC Visible spectrophotanetry
SPG Salicyl phenolic glucuronide
SUA Salicyluric acid
SUPG Salicyluric phenolic glucuronide
RA Rheumathoid arthritis
TCAA Trichloroacetic acid -
SUMMARY
Urinary analysis of paracetamol and aspirin frcm patients 
taking overdoses have been carried out by high resolution 
NMR spectroscopy, HPLC and spectrophotometry. The results of 
the three methods were compared. Quantification of paracetamol 
by NMR proved to be reliable compared to HPLC. ^H NMR has 
the advantages of being nondestructive and noninvasive 
permiting a rapid and simultaneous analysis of concurrently 
administered drugs, their metabolites and endogenous 
components which is not the case by other methods. The 
detection of metabolites in unprocessed urine samples are 
possible provided they have suitable resonances and are 
present in at least submillimolar concentrations. In order to 
concentrate the metabolites for analysis when concentrations 
are below this, lyophilized urine samples were used.This 
procedure was used to measure urinary indomethacin, giving 
good recoveries and reliable results. This method may be 
applicable for other drugs.
D-Penicill amine frcm pooled EDTA-plasma collected frcm RA 
patients has been examined by ^H NMR. Protein binding and the 
immobility of macrcmolecules of plasma made quantification of 
metabolites unreliable. Acid extraction to remove plasma 
proteins in plasma provided more resolved resonances. However, 
the low concentration of D-penicillamine and its metabolites 
in the acid extracted and lyophilized EDTA-plasma, combined 
with the high 'chemical noise' in the region of interest did 
not permit quantitative analysis. Despite these problems,
(V)
1H NMR analysis of plasma samples may be possible for other 
drugs present in concentrations greater than 0.1 mM.
3. A study of in vitro metabolism in rat liver preparation has
been carried out by NMR spectroscopy. The time courses of
the metabolism of aminopyrine (DMAP) and daunorubicin (DA)
have been monitored by NMR following the disappearance of 
parent drug and the appearance of its metabolites. The 
differences between phenobarbitone (PB) and
3-methylcholanthrene (3MC) treated rat livers were distinct in 
the rate of metabolism observed by NMR of DMAP and DA. This 
fact allcws enzyme induction to be characterized in terms of 
cytochrane P-450 and cytochrcme P-448 using aminopyrine and 
daunorubicin. This method could be adapted to study in vitro 
metabolism using other inducers or other model drugs, and 




Nuclear Magnetic Resonance (NMR) spectroscopy was first
reported independently in 1946 by Bloch et al.^  and Purcell et 
2
al'. , and the demonstration of this phenomenon as an analytical and
research tool has been established since then. Examination of
biological material began in the early 1950's with measurement of
the water signal in various samples including yeast cells,
3-6
mammalian blood fractions, fat, liver and muscle tissue . In
1959, Singer^ first demonstrated a method of relating the amplitude
of a proton signal to blood flew measurement. This approach is now
being coupled with NMR imaging to measure blood flew in large
8
arteries and veins with better accuracy than other methods .
9
Bratton et al.(196 5) observed a broadening of line width for the
water resonance in muscle using pulse NMR techniques to measure T^
and T^ relaxation times (described later in section 1.3.3). These
initial experiments formed the basis for later development of NMR
for biological research and as a diagnostic tool in medicine, such
as in the investigations of human cervical mucus, body fluids and 
10-12
tissues . Modern high field pulse Fourier Transform NMR
instruments have increased sensitivity and the use of specialised 
pulse sequences has allowed proton NMR studies to be extended frcm 
the observation of water to a range of endogenous and exogenous 
metabolites. Drug metabolism can be followed in vivo by proton NMR 
analysis of urine and other body fluids while cellular suspensions 
and cell free extracts are used for in vitro studies.
Nuclei other than protons have also been studied. Cope 
(196 5) published the first ^ N a  NMR studies on biological
1 2
samples. He suggested that multinuclear studies using H, D and 
170 NMR in the same system would aid in the interpretation of 
14
proton NMR data . Since then, many investigators have explored
the possibilities of multinuclear NMR experiments on biological
1 13 31 19 14 15 23 25 35
samples including H, C, P, F, N, N, Na, Mg, Cl,
3 9  ^43 _
K and Ca spectroscopy.
The major role of NMR spectroscopy since its discovery in 1946 
is to aid structural elucidation of compounds in synthetic or 
analytical studies. Even though examination of biological material 
began in the 1950’s, it is only in the 197 0's that NMR spectroscopy 
was extensively developed as a new tool for biological and clinical 
research. Since then the pace of NMR development has grown rapidly 
and the advances of high field NMR with increased sensitivity, 
resolution, and dynamic range has given it possibilities for use in 
complex drug metabolism studies.
Conventional methods for drug metabolism studies are 
spectrophotometry and HPLC. The former technique allows only one 
substance to be assayed at any one time and needs careful sample 
preparation and can therefore be very time consuming. Although HPLC 
can be used to assay mixtures, it does not simultaneously provide 
quantification and absolute identification of the compounds to be 
separated (reference compounds are needed). NMR has the advantages 
of being nondestructive and noninvasive and the fact that if the 
experimental conditions are properly chosen, the various resonances 
in the spectrum are assignable to chemically different




For the majority of drugs, drug metabolism is the single major 
determinant of its duration of action. Metabolic transformation 
generally produces more polar compounds than the parent drug, 
thereby enhancing its excretion from the body. Williams (1971)^ 
summarised the possible fate of drugs in the body as follows:
- drugs can undergo enzyme catalysed transformations (e.g. 
aspirin).
- drugs can be excreted unchanged (e.g. cyclamate).
- drugs can undergo spontaneous reactions when given the 
appropriate physical conditions, such as pH (e.g. 
thalidomide).
Most drugs undergo metabolic transformations which are enzyme 
catalysed in the liver, although other tissues (e.g. lung and 
kidney) may also participate. Biotransformation or drug metabolism 
proceeds in two phases, and can be summarised as follows:
Phase I Metabolism
In phase I metabolism, a drug or xenobiotic undergoes 
reactions such as oxidation, reduction or hydrolysis, yielding more 
polar products than the parent compound. As a result of these 
reactions a compound can be made :
- less active or inactive, e.g. oxidation of tolbutamide.
- more active, e.g. prontosil to sulphonilamide.
- converted to a compound v which has similar or different 
activities, e.g. O-dealkylation of codeine to morphine, 
phenacetin to paracetamol and N-dealkylation of ephedrine to 
norephedrine.
Introducing chemical groups such as -CH, -COOH or to the
initial compound allows the next phase of metabolism (phase II
metabolism or conjugation) to occur. However, if a drug contains
suitable groups, it can undergo phase II metabolism directly.
Also, a drug may undergo only phase I metabolism as in the case of
ethanol, which is oxidised mainly to CO^.
Numerous studies have shown that most drugs are oxidised or
reduced by enzymes in the endoplasmic reticulum of tissues, mainly
those in the liver. The hepatic endoplasmic reticulum is a network
of submicroscopic tubules, which extends into almost all regions of
the cytoplasm and comprises two major components: a rough-surfaced
form consisting of lipoid tubules studded with ribosomes and a
16
smooth-surfaced form lacking in ribosomes . On hanogenization,
the reticulum disintegrates to form small vesicles which may be
isolated as "rough" and "smooth" surfaced "microsames" by
X7 18
centrifugation using discontinuous gradient systems ' 
Smooth-surfaced microsomes metabolize drugs more rapidly than do 
the rough-surf aced microsomes^
Microsomal mixed function oxidation reactions are catalysed by 
non-specific multienzyme systems which have a cytochrome (e.g. 
cytochrome P-450) as the terminal oxidase. These non-specific 
cytochromes are located in the endoplasmic reticulum of the cells. 
For the metabolism of many substrates, the oxidative enzymes 
require oxygen and reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) as well as reduced cytochrome P-450. Cytochrome 
P-450/ a carbon monoxide-binding pigment of microsomes, is a 
haemoprotein of the cytochrome "b" type. Unlike most cytochromes 
it is named, not frcm the absorption maximum of the reduced form in 
the visible region, but rather frcm the unique wavelength of the
absorption maximum of the carbon monoxide (CO) derivative of the
reduced form, namely 450 nm. There are at least 11 distinct forms
20
of P-450 which are involved in drug metabolism , each variant,
although being relatively non-specific, having its own "spectrum"
of substrates. In addition, there exsits a second family of
cytochrome "P-450" which is distinguished from P-450 by the fact
that the reduced cytochrcme-CO complex gives a maximum at 44 8 nm.
These cytochromes are consequently named cytochrcme P-448 and have




In phase II metabolism, the products of phase I reactions or 
parent drugs undergo biosynthetic reactions, i.e. conjugations, 
yielding highly polar or water-soluble compounds and frequently 
strong organic acids. Conjugation involves the coupling of a 
compound containing a suitable chemical group (e.g. -CH, -NH2 an(i 
-C00H) witti an endogenous molecule such as glucuronic acid, 
glycine, glutathione, methionine and those containing acetyl, 
sulphate and thio groups.
The conjugation reaction requires an intermediate activated 
nucleotide, derived from either the conjugation agent or the 
compound undergoing conjugation, and a transferring enzyme as shewn 
below:
Conjugating Energy Activated conjugating compound Conjugated
 ►   ►
agent agent nucleotide + Transferase product
, Energy Activated compound „  ^ Conjugated
Compound ^ Conjugating agent
nucleotide + Transferase product
Adenosine triphosphate (ATP) is required as a source of energy to 
form activated nucleotides. The conjugation enzymes involved in 
phase II metabolism are located primarily in hepatic microsomes 
(glucuronic acid), hepatic mitochrondria (glycine), and the soluble 
fraction of the hepatic cell, kidney and intestinal mucosa 
(sulphate).
1.2.2 INDUCTION OF DRUG METABOLISING ENZYMES
A number of drugs, insecticides, carcinogens and other
chemicals are known to stimulate the activity (synthesis) of
drug-metabolizing enzymes in the liver microsomes (e.g. hepatic
mixed function oxidase) and this stimulation is referred to as
enzyme induction. The injection of small amounts of polycyclic
aromatic hydrocarbons, such as 3-methylcholanthrene, 3 ,4-benzpyrene
and 1,2,5,6-dibenzanthracene, rapidly induce several-fold increases
in the activities of liver microsomal enzymes that reduce the azo
22
linkage and N-demethylate arainoazo dyes ; hydroxylate
23 24
3,4-benzpyrene and several drugs ; ring-hydroxylate
25
2-acetylaminofluorene and bind aminoazo dyes in covalent linkage 
26
to protein . Evidence was presented in these early studies that
polycyclic hydrocarbons increase enzyme activity by inducing the
22 23
synthesis of more enzyme protein ' . The stimulating effect of
barbiturates and other drugs on liver microsomal drug metabolism
27was discovered independently by Remmer (1958) while investigating
28
mechanisms of barbiturate tolerance, and Conney and Burns (1959) 
during investigations on the effects of barbiturates and several 
other unrelated drugs on ascorbic acid biosynthesis and drug 
metabolism. Chemical compounds which are known to increase the
activity of hepatic mixed function oxidase are of at least two
types. The phenobarbitone (PB) type induces the formation of
cytochrome P-450 haemoprotelns and its associated enzymes, while
the 3-methylcholanthrene (3MC) type induces the formation of
29,30
cytochrone P-448 haemoproteins . The relatively less toxic
compounds tend to cause an induction pattern similar in nature to
31
that of PB rather than that of 3MC . Thus the characteristic 
changes in absorbance maxima of the reduced cytochrcme-CO complexes 
in the 448-450 nm region are associated with the pattern of enzyme 
induction.
The activity of microsomal cytochrome P-450 may be assessed by
looking at (a) in vivo duration and intensity of drug action when
the drug is metabolised primarily by phase I metabolism or (b)
measurement of enzyme and drug metabolite concentrations in vitro,
e.g. N-demethylation of aminopyrene to form first
324-monomethylaminoantipyrene and then 4-aminoantipyrene 
Similarly, microsomal cytochrome P-448 activity can be assessed by 
the above methods, using e.g. daunorubicin which is metabolised by 
both cytochrone P-450 and P-448.
1.3 METHODS FOR DRUG METABOLISM STUDIES
Numerous methods have been developed to study drug metabolism 
both qualitatively and quantitatively. Due to the large number of 
methods which have been used to study drug metabolism, only two 
methods which are commonly used for the drugs under study will be 
discussed further, i.e. spectrophotometry (section 1.3.1) and high 
performance liquid chranatography (section 1.3.2).
Spectrophotometry and chromatography are considered traditional 
methods compared to newer methods such as NMR spectroscopy which
will also be discussed (section 1.3.3).
1.3.1 SPECTROPHOTOMETRY
The simplest assays involve solvent extraction of parent drug 
and/or metabolic products. Subsequent chemical reaction(s) may be 
required to develop an ultra-violet absorbance or a coloured or 
fluorescent derivative of the metabolite. A disadvantage of 
measuring a compound by spectrophotometry in biological fluids or 
tissues is the high tissue 'blanks’ that are often encountered 
unless the drugs are present in relatively high concentrations.
Colorimetric Analyses
In colorimetric analysis, the procedure involves the
measurement of the light absorbance of a compound in the visible
region of the spectrum (360 to 900 nm). The majority of drug
molecules do not possess an intrinsic absorption in the visible
region and it is necessary therefore, to subject such compounds to
procedures which result in the formation of a molecular species
which has this property. This is generally effected by reacting
the drug with another substance to produce a conjugated derivative
that is coloured. The type of conjugated derivative formed is
dependent upon the functional group(s) of the drug. For example,
the chrcmophore formed by the reaction of nitrous acid with
paracetamol was measured quantitatively by its colour in alkaline 
33
solution . Paracetamol conjugates, glucuronide and sulphate, have 
to be converted enzymatically to the parent drug prior to their 
assay by this method.
In a mixture of drug and its metabolites, the problem of 
accurate quantitation of each compound becomes even more
complicated and separation is required prior to analysis. However,
it is sometimes still possible to assay two closely related
compounds individually even if they are not completely separated by
extraction procedures. By determining the partition behaviour of
the two substances separately under certain fixed conditions, the
relative amount of each compound in a mixture can be calculated
after determining each concentration under each set of conditions
and solving simultaneous equations which define the partition
behaviour. This separation technique was applied in the case of
salicylic acid, which is soluble in carbon tetrachloride and
sparingly soluble in methylene chloride, and salicyluric acid which
has the opposite solubility. To determine salicylic acid and some
of its metabolites, coloured complex formation, a common method in
colorimetric analyses of drugs, was employed, i.e. ferric nitrate
34
(FefNO^)^) was reacted with salicylic acid and salicyluric acid
35
and Folin Ciocalteau’s reagent with gentisic acid . Other 
salicylate metabolites, its phenolic glucuronide and acyl 
glucuronide, were assayed after converting the metabolites to 
salicylic acid with enzyme and alkali respectively.
Difference Spectroscopy
Induction of enzyme activity can be assessed by the increased
22
concentration of enzyme protein measured in colorimetric 
36
analysis . Another spectrophotanetric method used to assess the 
change of microsomal enzymes (cytochrome P-450/P-448) after 
induction is difference spectroscopy described belcw.
In difference spectroscopy, the analyte solution in one state 
is run against analyte in a different condition and provides a 
means of cancelling absorptions. Difference spectroscopy has been
used in the characterisation and quantitation of- cytochrone 
P-450/P-448. Cytochrone P-450/P-448, like other haemoproteins, have 
a characteristic absorption in the visible region. Addition of 
organic or inorganic ligand results in a perturbation of this 
spectrum. Since the particulate nature of microsones gives rise to 
light scattering, which is a function of wavelength, such changes 
in the absolute spectrum are seen as fluctuations along a sloping 
baseline, an undesirable situation for quantitative measurements. 
In difference spectrosocpy, light scattering, non-specific 
absorption and the absolute spectrum of the microsomal cytochromes 
are balanced out by placing microsones in both cells of a 
double-beam spectrophotometer, then only the absorption caused by 
the addition of a ligand to the microsones in the sample cell is 
seen as a difference spectrum.
Ultra-Violet (uv) Analyses
For detection of drugs in body fluids, ultra-violet (uv)
analysis is applicable to a wide variety of compounds that are
capable of absorbing energy fran radiations in the wavelength range
200-350 nm. A major problem is the lack of specificity since most
compounds absorb in the uv region over a fairly wide range of
wavelengths. Nonetheless, the spectrum is usually characteristic
for a given compound, named chranophore or chemical derivative, or
by the utilization of bathochrcraic shift to enhance sensitivity and
37convey specificity. Trevor et al. (1971) claimed that they have 
usually found uv spectrophotometry to be less sensitive than 
colorimetry for estimating drugs in body fluids and also 
encountered more difficulties in eliminating sample blanks.
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1.3.2 CHROMATOGRAPHY
Chromatography is a physical method of separation in which the 
components to be separated are distributed between two phases, one 
as a stationary bed of large surface area and the other as a mobile 
phase that penetrates through or along the stationary bed. Either 
a liquid or gas may serve as the mobile phase while liquids or 
solids function as the stationary phase. The mechanism of solute 
retardation may be adsorption, bonded-phase (reversed phase or 
polar bonded-phase), ion-exchange or partition. Differences in 
these properties are exploited to separate components.
Advances in chromatographic instrumentation have brought 
sophisticated analytical procedures which permit identification by 
co-elution and subsequent quantification of a drug and/or 
metabolites after separation frcm related metabolites and 
biological constituents. Although many different techniques of 
chromatography have been used for over 45 years as a separative and 
analytical technique, high performance liquid chromatography (HPLC) 
and gas liquid chromatography (GLC) are the most successful 
combination of chromatographic separation with routine quantitative 
detection (using standard compounds).
High Peformance Liquid Chromatography (HPLC)
During the last two decades liquid chromatography has been
transformed by technological advances, especially in column design
and packing, into a remarkably versatile quantitative 
3 8 3 9
technique ' . The introduction of chemically bonded phases and
reverse phase materials in particular has permitted highly 
efficient columns for the widespread application of HPLC. In 
general it has been estimated that 6 0-8C% of all HPLC conditions
12
40involve the use of reverse phase materials which consist of
silica covalently bonded with alkyl chains of uniform length.
Variations in the composition of the mobile phase produce a range 
of selectivity to optimise compound separation.
The inherent advantage of HPLC over all other forms of 
chromatographic techniques lies in the combination of reliability, 
sensitivity and efficiency coupled with the versatility of 
retention mechanisms available. The presence of two competing 
phases (mobile and stationary) for selective interaction with 
sample molecules allows a wide variation of conditions for
separations. In addition, a wide choice of detectors e.g. uv, 
fluorescence and electrochemical are available for use in HPLC.
In reverse phase HPLC, where the stationary phase is non­
polar and the more polar compounds (i.e. metabolites) elute first 
from the column, advantages lie in its high chemical selectivity
and the compatibility with biological materials and aqueous 
41
extracts . Minimum sample preparation, such as dilution of the 
sample followed by selective detection of the compound(s) of
interest may be achieved, e.g. in the determination of aspirin and
42 43its metabolites and paracetamol in human urine. However, many
biological samples especially plasma and hepatocytes require
protein removal or compound extraction from biological constituents
prior to analysis to prevent deterioration in column performance.
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1.3.3 NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY
1.3.3.1 BASIC PRINCIPLES OF NMR SPECTROSCOPY
The fundamental property of the atomic nucleus involved in NMR
is the nuclear spin (I) which has values 0, 1/2/ 1, 1^/2, etc. in
units of k/2 7r, (where h is Planck's constant) depending on the mass
number and the atomic number of the nucleus. Nuclei for which I =
^/2 include 1H, 19F, 13C, 31P and 15N. Proton resonance spectra
have been studied in the present work and the description in this
chapter will be largely confined to them. The nuclear spin
interacts with an applied magnetic field such that the nuclear
moment can take up only certain allowed orientations. The nuclei
of nuclear spin I = 2 can adopt only two orientations in a
magnetic field which may be visualised as precession around the
axis of the applied magnetic field, B , with a frequency o> , i.e.o o
the Larmor frequency, and aligned either parallel or anti parallel 
to it as shown in Figure 1.3.1.
A
Mq (Resultant magnetization vector)
-! -^Nuclear spin preoess at 
z Larmor frequency o>0
Fig. 1.3.1 Precession of nuclei around an applied magnetic field
Since there is a slight Boltzmann excess of nuclei aligned
with the magnetic field, these will give rise to a resultant
magnetization vector M in the same direction as B . Theo o
transition energy between these two +z and -z orientations, i.e.
the energy required to cause resonance is given by equation 1.3.1.
7hB
A  E = ___ (1,3 9l)
27r
where Bq is the external magnetic field strength and 7 is 
magnetogyric ratio, characteristic of a particular nucleus. If Bq
is measured in Tesla, the energy,A E, has the units Tesla Ampere
2 -1 -1 
metre and 7 bas the units of radian Tesla second . The
intensity of the signal depends on the excess number of spins in
the +z direction which in turn is governed by the Boltzmann
distribution. From equation 1.3.1 it can be seen that the higher
the field strength, the greater A E  and the higher the excess number
of spins along +z thus giving increased sensitivity.
Pulse Fourier Transform (FT) NMR Spectroscopy
To increase the sensitvity of NMR, a great deal of interest
has centred on FT NMR spectroscopy in addition to the increasing
strength of magnets. In pulse FT NMR the sample is irradiated with
a short powerful pulse which contains a range of radiofrequencies
(RFs) covering the spectral region of interest. If a pulse of
radiofrequency irradiation is applied at the resonant frequency a>Q,
along the x axis (see fig. 1.3.1), this would be equivalent to
applying a static field (B^) along x' of the rotating frame. Since
the bulk magnetization Mq is stationary in the rotating frame, the
I
effect of applying a constant field along x would be to cause Mq
t
to rotate in a clockwise direction about the x with a frequency to
(Lamor frequency). Hence, if the pulse is applied for t seconds, 
then Mq will be rotated through an angle drad. This is shown
in fig. 1.3.2. A spectrometer is normally designed so that it
I
detects signals along the y -axis as sin 6.
Field due to the 
application of RF 
irradiation at coQ 
in laboratory frame
 ! y
MQsin0 (Component of Mq along y7')
Figure 1.3.2 Effect of applying an RF pulse with Larmor frequency
co (the rotating frame reference system) for a time t o
s on the bulk magnetization vector Mq
All nuclei are excited simultaneously and as they relax back 
to their equilibrium populations each at different rates, they 
induce signals of particular frequencies and decay patterns in the 
receiver coil. The net signal obtained in the time domain, called 
"free induction decay" (FID), is digitized and stored in a 
computer. The radiofrequency pulse is repeated and data summated 
until sufficient have been collected to obtain a spectrum with a 
satisfactory signal-to-noise ratio. The time domain signal is 
converted to the frequency domain i.e. the normal spectrum by 
performing a Fourier transformation on the collected data. The
16
relaxation occurs by two processes known as spin-lattice (T^) and
spin-spin (T^) relaxation. The loss of energy from the excited
nuclear spins to the surrounding molecular lattice occurs when the
vector aligned along the z-axis, Mz, returns to Mq characterized by
a relaxation time T^. In the process the nuclear spins
interchange energy with one another, so that some now precess
faster than co while others go slower. The result of this is that o
• f
the spins begin to fan out in the x y plane.
Development of pulse spectrometers was dependent on the
availability of computer programs to undertake Fourier
transformations on a practical timescale. FT spectrometers allow
44-48great flexibility in the type of experiments , such as 
spin-echo experiments and two-dimensional NMR that can be performed 
to obtain extra structural data and information on the dynamics of 
particular systems.
Spectral Characteristics
The usefulness of NMR spectroscopy for structure elucidation 
arises because nuclei in different chemical environments resonate 
at different frequencies according to their local magnetic 
environment which is related to the electron density around the 
nucleus. The s-electrons in a molecule produce a magnetic field at 
the nucleus which is smaller and opposite to the external field. 
The difference between these fields, called nuclear shielding, 
produces an upfield shift of the resonance called a diamagnetic 
shift. Electrons in p-orbitals and other non-spherical orbitals 
produce larger magnetic fields at the nucleus which give a 
deshielding effect or low-field shift called the paramagnetic 
shift.
I17
Resonance frequencies are always measured from a suitable 
reference compound, normally TMS (Tetramethylsilane) in organic 
solvents or DSS (sodium 2,2-dimethyl-2-silapentane-5-sulphonate or 
TSP) in water. The parameter used to indicate the position of a 
signal in a spectrum relative to the reference signal is chemical 
shift, $ , and is defined by equation 1.3.2.
( sample - Preference) _ Jo8 = x 10 ppm (1.3.2)
radio frequency applied
Basic frequency data ( P ) of a spectrum must be quoted with the 
operating frequency of the spectraneter but chemical shift data are 
independent of the frequency. NMR spectra can also yield 
information on the connectivity of functional groups in the 
molecule because signals frcm one nucleus may be split into
particular patterns depending on the number of neighbouring spins. 
The coupling constants (or J values) can be measured frcm the
splittings if the spectrum is first order i.e. where the couplings
are much less than the chemical shift separations.
1.3.3.2 NMR TECHNIQUES FOR DRUG METABOLISM STUDIES 
Quantitative Analysis
Proton NMR can be used quantitatively by electronic 
integration of peaks as the area under a signal is proportional to 
the number of nuclei in the sample causing that signal, or by peak 
heights if the line widths are identical. Internal or external 
standards can be employed. Quantitative analysis is often hampered 
by the lack of sensitivity due to the small excess number of spins 
in the +z direction available to absorb radiation energy. Pulse FT 
NMR spectrometers and higher magnetic fields now offer greater
18
sensitivity and thus have been applied to the quantitative analysis 
of biological fluids. In addition, high field instruments have 
greater resolving power required for complex mixtures.
Pulse FT NMR has advantages for quantitative measurements 
since pulse repetition can increase the ratio of signal to noise if 
the pulse delay is sufficient to allow full relaxation. When a 
pulse of radiofrequency is applied to a spin system, the 
magnetization along the z-axis decreases (see section 1.3.3.1). If 
a second pulse is applied immediately, there is smaller Mz 
magnetization to tip into the y-direction, and consequently a 
smaller signal is acquired as a result. It is therefore important 
to apply a sufficiently long pulse interval, which is dependent on 
the relaxation time, to allow efficient detection of the NMR 
signal. The unpaired electrons of paramagnetic molecules or ions, 
and immobile molecules have a very strong effect on relaxation and 
cause broad and poorly resolved peaks unless precautions are taken 
to exclude them.
Water Suppression
A problem which arises from the applications of FT NMR 
technique on the direct analysis of molecules in dilute aqueous 
solution such as biological fluids is the large water resonance. 
It makes it difficult to detect much weaker resonances from the 
solute molecules because of the limited instrumental dynamic range. 
Several methods have been used to overcome this problem by 
eliminating the water resonance and will be further discussed;
„ _ ^  4 49-51Fast Pulsing
If the sample has a short relaxation time relative to water, 
which is usual in proton spectroscopy of biomolecules, the 
nuclei may be pulsed at a rate which does not allow the water 
to relax completely while still allowing the sample nuclei to 
relax. The water resonance may be reduced to one-quarter of 
its normal height by this means.
52-60Selective Saturation
Secondary irradiation is applied with sufficient power to 
saturate selectively the water resonance between the end of 
accumulation of one FID and the next pulse. This power is 
gated with the irradiation switched off during acquisition to 
minimise radiofrequency interference (hcmogated decoupling). 
The analytical pulse is then applied before the water recovers 
equilibrium and consequently is much reduced.
  61-7 0
WEFT (Water-Eliminated Fourier Transform)
This method capitalizes on the large difference in spin-
lattice relaxation times (T^) exhibited by the resonances of
biological macrcmolecues (<1.0 sec) and that of HDO (5-15
sec), which arises from exchange of protons of the sample or
H^O with D^O. An inversion recovery pulse sequence of the 
o o
form T- 180 (x)-T-90 (x)-acquisition, eliminates HDO frcm
the spectrum. T is a relatively long initial waiting time,
followed by a 18 0° pulse and T is the time required for the
HDO resonance to attain zero net longitudinal magnetization, 
o
The 9 0 pulse results in an FID coming only from the sample 
protons. It is then theoretically necessary to wait for a
20
long time (5T^) for the whole system to equilibrate before 
another pulse sequence can be applied. In practice, however, 
it is often possible to repeat the process after a shorter 
time in order to achieve maximum sensitivity in a given time.
C. 1 4.4 44. 4.4 67,71-78d) Selective excitation
Selective pulse sequences are applied to excite only the
desired spectral regions, leaving the solvent magnetization
oriented along the static field direction, z. Selective
excitation methods consist of either long, weak ('soft') 
71-74pulses or short, strong ('hard') pulses separated by
67,75-78delays
7 9—82e) WATR (Water Attenuation by relaxation)
The spin-spin relaxation time (T^) of the water protons is 
selectively reduced by chemical exchange, and the NMR
spectrum is measured by the Carr-Pureell-Meiboom-Gill (CPMG)
o j o m* 12 9 o
pulse sequence 90 (xJ-^-lSO (y)-l)n-acquisition , where 90
O / w
and 180 are the pulses and L is the interval time between the
o
pulses. By making the time between the 90 pulse and
acquisition of the FID long enough, the water resonance is
completely eliminated. Compounds which have labile protons
can be used as reagents to selectively decrease the of the
water protons by chemical exchange such as ammonium chloride,
guanidium chloride, urea and hydroxylamine hydrochloride whose
82
rate of exchanges are dependent on pH and concentration
21
Of the various techniques described above, those employing
78selective excitation are probably the most successful in
suppressing the water signal, but they have disadvantages in that 
resonances near that of water cannot be observed and they require 
careful pulse adjustment. In the WEFT technique, nuclei whose 
resonances are in this region can be observed if their 
relaxation times are different from those of water protons. 
However, it should be performed with caution in H^O since T^fH^O) 
is considerably less than T (HDO), and field homogeneity and 
accuracy of pulse length are also far more critical, thus the 
conditions for complete recovery of the sample magnetization become 
more stringent. The selective saturation stands out as being 
simple and easy to use-and does not need addition of chemicals as 
in the WATR technique, unless there are no significant resonances 
near the water resonance since they might be slightly irradiated.
Resolution Enhancement
Proton NMR suffers from a rather narrow chemical shift range
which means that there can be problems caused by overlap of
resonances from different molecules present in the same sample.
This problem can be minimised by using spectrometers with higher
magnetic fields (e.g. 4 00 MHz) and a technique known as "resolution
enhancement". The common approach to resolution enhancement is to
multiply the FID by a function that de-emphasizes its beginning and
emphasizes, at least relatively, its tail before doing the Fourier 
83transformation . Various functions have been developed for this
83 84
purpose e.g. trapezoidal window, exponential window , convolution
85 86 48
difference , sine-bell routine , and Gaussian function as
used in present work. The enhancement is paid for by reduced
signal-to-noise ratios and distortions of the spectra which vary in 
extent with the method.
Spin Echo Experiments
The spin echo experiment is of central importance to modern
87pulse NMR. The Hahn spin echo method was first used for the
measurement of "natural" T v a l u e s  (see section 1.1) in liquids.
In this method, a 90* -180° -'t pulse sequence is used (c£. section
1.3.3.2.e). At time 2T, a spin-echo signal is observed. The Hahn
method does not yield true T^'s if there is molecular diffusion.
88Hence Carr and Purcell (CP) modified this method using the pulse
sequence 90°(x)-( -180°(x)- ) - acquisition. All the
radiofrequency (RF) pulses are applied along the x-axis and the
echo signals will be at 2^, 41", 6K, etc. A further modification was
80
described by Meiboom and Gill using identical conditions to the
o
CP pulse sequence except that a phase shift of 9 0 was introduced 
o
in all the 18 0 pulses. The Carr-Purcell-Meiboom-Gill (CPMG) pulse
sequence (see section 1.3.3.2.e) gives the same spin-echo signals,
even in phase-sensitive detection mode, since it compensates the
o
slight mis-settings of the 180 pulse lengths.
o
In the basic spin echo method (see fig. 1.3.3), a 90 pulse is
initially applied to the spin system. After a time /t, the
individual magnetic vectors "fan-out" and lose "phase coherence",
both due to spin-spin relaxation (T^) and magnetic field
inhomogeneity. These magnetic vectors will be inverted if a second 
o
18 0 pulse is applied. Since the rotational sense of their motion 
is unchanged, the vectors refocus along the y -axis and a spin 
echo signal is recorded after the time 2 . The amplitude of the 
signal now differs from the initial value only through true















Fig. 1.3.3 The spin echo experiment: a) application of a 90 (x) 
pulse; b) tansverse magnetization after 90°(x) 
exitation pulse; c) fanning-out of the magnetization 
vectors after timeT; d) application of a 180° pulse;
e) refocused vector after time 2fC.
It follows that the spin echo experiment causes cancellation 
of all effects that result from different Larmor frequencies 
leading to a fanning-out of the macroscopic transverse 
magnetization (T2 relaxation) after the exiting pulse. This
cancellation can be used to eliminate broad signals since they have
w  ^m i 89,90 short T2 values
A situation distinct frcm that described above is met if the
spin-spin coupling (J) to a neighbouring nucleus occurs leading to
the modulation of the signal. At a ^  value of 6 0 ms (^/2 J)
doublets with J approximately equal to 8 Hz are inverted, whereas
91singlets and triplets are upright . This makes it a useful 
assignment aid. However, the phase modulation of coupled signals in
spin echo experiment causes the distortion of the signals, thus 
quantitative measurement can be difficult.
1.3.4 OTHER ANALYTICAL METHODS
In addition to the three methods discussed above, i.e. uv-vis 
spectrophotometry, HFLC and NMR spectroscopy, other methods such as 
fluorescence spectrophotometry, gas liquid chromatography (GLC) and 
radioimmunoassay (RIA) may be used in drug metabolism studies. The 
analytical potency of fluorescence technique is based on the 
emission of light quanta (fluorescence) by a drug following its 
absorption of electromagnetic radiation in the uv-vis region. In 
gas liquid chromatography, the drugs or metabolites to be 
determined are carried at different rates by an inert gas through a 
column packed with a support material coated with a non-volatile 
liquid as the stationary phase. Radioimmunoassay is based on the 
competition between drug and radiolabelled drug binding to 
antibody. Thus the proportion of radiolabelled drug bound to the 
antibody varies inversely as the concentration of the drug under 
investigation. These methods have not been used in this study and 
will not be discussed further.
1.4 ANALYSIS OF DRDGS AND METABOLITES IN BODY FLUIDS BY NUCLEAR 
MAGNETIC RESONANCE (NMR) SPECTROSCOPY
1.4.1 GENERAL
Analysis of biological fluids present special problems in NMR 
spectroscopy, i.e.:
i) a large signal arising frcm water which limits the dynamic 
range of the spectrum and makes observation of small 
resonances nearby difficult.
ii) line-broadening arising fran solutions with high viscosity, 
binding to immobile macranolecules and membranes, the 
macranolecules themselves and the presence of paramagnetic 
ions. 3
iii) complex spectra due to the multicomponent nature of body 
fluids requiring good resolution for identification and 
quantification of signals.
The use of high magnetic fields and FT instrumentation together 
with on-line computer manipulation of the spectra has overcome some 
of the above problems (see section 1.3.3.2).
Intact urine gives minor problems when compared to other 
biological samples because it is less viscous and has a lew content 
of macranolecules. A large number of well resolved signals frcm
mobile protons of low molecular weight metabolites in urine have
92—95 1been obtained frcm NMR spectra . Information yielded by H NMR
monitoring of metabolic alterations can be used to trace toxic and
metabolic disorders in clinical pathology. In the case of diabetes
mellitus, the concentration of glucose in urine can be 
92 96determined ' without interference from other substances such as
92
ascorbic acid and carbohydrates . A large phenylalanine peak was
97
observed in the urine frcm patients with phenylketonuria
Furthermore, the ratio of arcmatic amino acids to branched amino 
1 97acid measured by H NMR in urine or serum frcm patients has
proved a helpful test for determination of the severity of hepatic
failure. NMR has also proved valuable for the diagnosis of
98
certain human metabolic disorders and inborn errors of
99-101
metabolism, especially the organic acidurias such as
propionic acidemia, methylmalonic aciduria, glutaric aciduria type 
I and isovaleric acidemia. Furthermore, an informative pattern was
revealed by NMR of associated biochemical changes derived frcm
the abnormal patterns of metabolic excretion of mercury and cadmium
102,103induced nephrotoxicity of rats . In this case, decreases in
the excretion of creatinine and citrate, and increases in glucose,
glycine, alanine,o^-ketoglutarate, succinate and acetate were found
frcm the NMR urinary metabolite "fingerprints" and quantitative
analysis of the spectra. Thus a correlation could be drawn between
histopathology and enzyme induction data. In addition to
examination of endogenous compounds, metabolites excreted in urine
frcm relatively high therapeutic dosage drugs have been detected
94,104-106
and quantified simultaneously, e.g. paracetamol ,
oxpentifylline which is used in the treatment of vascular
disease^^ and metronidazole^"****. Furthermore, NMR can provide 
information on previously unknown metabolic and excretory
mechanisms of drugs, e.g. N- methyl form amide in rats and
J 109-110 
mice
NMR can also be used to examine endogenous and drug
metabolites in blood, serum and plasma of human and experimental
animals^* Measurement of lactic acid in serum with NMR
spectroscopy"*-^  has been suggested as a possible criterion for the
diagnosis of cancer in humans. It was found that 87% of the serum
specimens from patients with various cancers yielded a proton
signal ascribed to the methyl protons of lactic acid, whereas only
9% of serum specimens from normal controls did so. In tracing
diabetic ketoacidosis by NMR, ketone-bodies (acetone,
acetoacetate and {b -hydroxybutyrate) from serum of patients were
found to be larger than in control serum^*'^'*''*. Raised levels of
116
plasma ethanol and acetate in alloxan-induced diabetic rats were 
also found using NMR. The normal NMR spectra of blood,
serum, plasma, erythrocytes and hepatocytes are too poorly resolved 
to be interpreted readily. However, multiple pulse sequences that 
generate "spin-echoes" permit spectra of small, rapidly tumbling 
molecules to be recorded without interference from the proton 
resonances of slowly moving macromolecules117 (see section
1.3.3.2.). Normal and abnormal metabolites in body fluids were
^ . 4 1 _  ^  ^ 103,112,117-119readily resolved in spin-echo H NMR detection
Quantitation of spin-echo spectra should be done with caution due
to some intensity distortions of the peaks because of phase
modulation (see section 1.3.3.2). In insulin-dependent diabetics,
detection of mobile fatty acids as well as build-up of ketone
bodies were observed in plasma using high-resolution spin echo 
112
NMR . There was also a significant reduction in plasma alanine
and elevation of valine that could be related to metabolic changes
caused by insulin deprivation. In the case of the non-insulin
dependent diabetics with hypertriglyceridaemia, although glucose
was clearly elevated there was no ketoacidosis, and in addition
113
there were very large signals from mobile triglycerides 
Glutathione, lactate, pyruvate,and scxne residues of haemoglobin can 
also be detected, and the production rate of lactate and of the 
reduction of oxidised glutathione upon addition of glucose to the 
erythrocyte suspension can be measured^7 .
In some cases it is necessary to apply preliminary extraction 
procedures to achieve sufficient sensitivity for analysis or to 
isolate compounds of interest whose resonances are not completely 
resolved in the intact body fluid. Preliminary clean-up of samples 
can be done by acid extraction, solvent extraction or column 
chromatography. < In a solvent or acid extract, proteins are left 
behind and their broadening effect is eliminated, with the result
2 8
that twelve amino acids and 19 other intermediary metabolites could
be measured quantitatively with a single NMR spectrum of a 
120cytosolic extract . Free and esterified cholesterol have been
112quantified separately in methanol extracts of plasma . Seme
"uraemic middle molecules’ have been discovered in the plasma of
uremic patients and the urine of healthy subjects by proton and
carbon resonances after isolation with gas, anion-exchange and high
121
performance liquid chromatography . Solid phase extraction 
(using Bond Elut columns) has been used to separate urinary
metabolites of the non-steroidal anti-inflammatory drugs,
122 123
naproxen and ibuprofen . Another way to achieve more
sensitivity frcm very low concentrations of compound is 
106,107,122
lyophilization before redissolution in a suitable
solvent.
A technique which aids assignment of spectra arising from
46-47
complex mixtures is two-dimensional (2D) NMR . Various types
of 2D experiments have been developed and can be roughly divided
into those which correlate chemical shifts (e.g. proton-proton or
proton-carbon) and those which resolve coupling patterns. Proton-
proton chemical shift correlation (COSY) has been applied to a
urine sample concentrated by lyophilization from a person who
ingested lg of paracetamol and provided confirmation of previous
124
assignments of lD-spectra
Several nuclei other than protons have been applied in
13 31 19metabolism studies. The most developed are C, P and F NMR
spectroscopy.,. Unlike the NMR spectrum, which has chemical shift
13range of 10 ppm, the C NMR spectrum's range is about 200 ppm,
13thus individual peaks are more easily resolved. However C NMR is
13inherently less sensitive than of proton since C nuclei have a
natural abundance of only 1.1% and a weaker magnetic moment. The
13reduced sensitivity limits the biomedical applications of C NMR
13
spectroscopy in some ways. Hcwever labelling compounds with C
nuclei, makes it possible to study in vitro metabolism (see section
31
1.5.1). Interest in P NMR developed rapidly for three main
31reasons, (a) the 100% natural abundance of P; (b) the number of
31cytosolic metabolites that contain P is much smaller than those 
1 13
that contain H and C, thus usable resolution is easy to achieve?
and (c) the phosphorylated compounds that can be detected in
biological tissues by NMR are intimately involved in energy
31metabolism. A single P NMR spectrum provides a quantitative 
measure of sugar and nucleoside monophosphates, inorganic 
phosphate, phosphocreatine, nucleoside di- and triphosphates, 
including ADP and ATP, and cofactors such as NAD. It can also be 
used to measure pH and free magnesium concentration in erythrocytes 
or other living cells. ^ P  NMR has been used to characterize the
phosphorus metabolism of various healthy and diseased biological
125-129 19materials . Another nucleus used in metabolism studies is F
which has 10C% natural abundance and a relative sensitivity of
0.83 to that of proton. Despite its lack in most biological 
19molecules, F spectroscopy can be used to monitor the metabolism
of fluorinated drugs in biological fluids without interference frcm
13 0 130 _ „ 131-132
endogenous compounds . Flucloxacillin , 5-fluorouracil ,
133—136and fluoropyrimidine , together with their metabolites, have
been detected in urine or plasma. The possibility of simultaneous
observation of 'free as well as plasma protein-bound
19
fluoropyrimidine demonstrated the suitability of the F NMR
136
procedure for direct drug-protein interaction studies
1.4.2 MODEL DRUGS
Four model drugs with known metabolic pathways, i.e. aspirin, 
paracetamol, acemetacin and D-penicillamine, were chosen for drug 
metabolism studies using NMR spectroscopy and/or
spectrophotometry and HPLC. The relatively high concentrations and 
rapid excretion of aspirin and paracetamol in urine after overdose 
make them suitable candidates for quantitative study by NMR.
1.4.2.1 ASPIRIN (ACET5TLSALICYLIC ACID)
Aspirin (ASA) is a mild analgesic effective against peripheral
13 7 13 8 13 9pain of lew to moderate intensity , with antipyretic ' , and
14 0 141anti-inflammatory ' properties. It has been proposed that its
primary clinical effect is related to inhibition of bradykinin and
prostaglandin systems i.e. to the synthesis and release of these 
140mediators
Disposition and Metabolism of Aspirin
Aspirin is absorbed from the stomach and small intestine.
Absorption is rapid following oral administration of conventional
tablets or capsules, but the rate is affected by gastric emptying
142time and the presence of food in the GI tract . Although the
presence of food in the stomach markedly delays the time to reach
peak concentration of aspirin, there is no significant difference
in the amount absorbed^4"*.
Aspirin is rapidly hydrolysed in the body to salicylic acid
143-144
(SA) with a biological half-life of 15-20 minutes . The drug
is subject to hydrolysis by esterases during absorption in the
145-147 14 8intestinal wall and in the liver . In blood, the drug is
also rapidly hydrolyzed mainly by red blood cell aspirin
14 9esterase . In therapeutic doses, both aspirin and salicylic acid
are bound to plasma proteins, mainly albumin, and this accounts for
150 151,152
80-85% or 9 0-95% respectively of the total salicylate in
plasma.
After aspirin is metabolised to salicylic acid in the
intestinal wall, liver and blood, further metabolism of salicylic
acid occurs primarily in the hepatic and renal endoplasmic
141reticulum and mitochrondria . The metabolic fate of salicylic
153acid was first described by Kapp and Coburn (1942) . The three
main metabolites of salicylic acid (SA) are salicyluric acid (SUA,
the glycine conjugate), the ether or phenolic glucuronide (SPG) and
the ester or acyl glucuronide (SAG). Gentisic acid (GA), the minor
metabolite, is formed by ring hydroxylation of salicylic acid.
154Recently, Zimmerman et al. (1981) have characterised a double
conjugate of SA, namely phenolic glucuronide of salicyluric acid
(SUPG) in the body fluids of uraemic patients. Also, small amounts
of.gentisuric acid are formed by glycine conjugation of gentisic
155acid or hydroxylation of salicylic acid . The main metabolic
pathways of aspirin are outlined in figure 1.4.1.
Plasma half-life of salicylic acid varies frcm about 3 h in
analgesic doses to 20 h or more at anti-inflammatory and toxic
doses^^. Thus, increasing the dose without increasing the interval
between doses may cause accumulation and toxic effects. In the
body, the major route of salicylic acid elimination is via renal
excretion of both salicylic acid and metabolites. Following a
single oral dose of aspirin (1 g) in four healthy volunteers, Hutt,
157Caldwell and Smith (19 82) found a mean recovery of 96.2% of 
administered dose in 0-24 h urine. The major urinary metabolite 
was SUA (63.9%); the remainder of the excreted dose comprised GA
32
(1.3%), SPG (5.9%), SAG (4.C%), SCJPG (6.2%) and SA (13.5%). 
Urinary pH can profoundly alter the proportion excreted as free 
SA158'159.
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Fig. 1.4.1 Metabolic pathways of aspirin
The renal clearance of the drug increases almost exponentially with 
increase in pH above 5.5-6.5. The metabolism of salicylic acid is 
dose dependent due to the limited capacity formation of two primary
metabolites, namely salicyluric acid and salicyl phenolic
16 0 161glucuronide . Levy, Tsuchiya and Amsel (1972) suggested that
the liver was limited in its ability to form these conjugates.
Hence, as the dose is increased, the relative proportion of the
minor metabolites, including salicylic acid, also increases.
Toxicity of Aspirin
Serious adverse reactions occur infrequently with usual
analgesic doses (0.6-lg). Gastrointestinal symptoms such as
gastric distress, heartburn or nausea may occur after therapeutic
doses, particularly in the elderly. Recently, Rees and Turnberg 
162(1980) concluded that although acute exposure of the gastric 
mucosa result in increased blood-loss, abnormal mucosal function 
and short lasting morphological damage, there was little evidence 
that low dose aspirin consumption results in either peptic ulcer or 
acute gastrointestinal bleeding.
High doses of aspirin may cause tinnitus, deafness, nausea,
abdominal pain, respiratory alkalosis^^ metabolic acidosis^4'
v . 166  ^ 167,168 .hyperglycaemia , and hypoprothrombinemia . Blood
salicylate concentrations are used to assess the degree of
toxicity. These concentrations are also frequently used in
conjunction with the Done nomogram (fig.1.4.2) for estimating the
16 9
severity of toxicity from acute salicylate overdose 
Unfortunately it appears that this nomogram cannot be used in 














Fig. 1.4.2. The Done nomogram for estimating severity of acute 
salicylate toxicity
sustained-release aspirin preparations because of the delayed 
release.
In chronic use, salicylates vary in their propensity to induce
gastric ulceration and haemorrhage in man and laboratory
, 141 „ . . u u  ^ . 17 0 _ . . 154
animals . Aspirin may have nephrotoxic and hepatotoxic
effects, but these usually occur in association with diseases such
as rheumatic fever, juvenile rheumatoid arthritis and systemic
lupus erythematosus when aspirin is taken in large doses over a
long period.
1.4 .2 .2 PARACETAMOL fACETAMINOPHEN)
Paracetamol(P), an analgesic and antipyretic drug, is used in 
mild to moderate pain which is not of visceral origin and which is 
not accompanied by significant inflammation. Its antipyretic
35
effect may stem from the inhibition of endogenous pyrogens on the
13 8hypothalamic heat-regulating centres and its analgesic effect 
frcm the inhibition of prostaglandin synthesis.
Disposition and Metabolism
Paracetamol is rapidly and almost completely absorbed frcm the
gastrointestinal tract following oral administration. Its peak
plasma concentration occurs 30-60 minutes after ingestion of the
usual analgesic dose of 0.5-1 g. However, a correlation between
serum level and analgesic effect has not been demonstrated^^. In
addition, gastric emptying time is a major variable in determining
the rate but not the extent of paracetamol absorption. Distribution
of paracetamol is relatively uniform and it is distributed
throughout most body fluids. Although protein binding appears to be
insignificant at therapeutic concentrations, it does increase to
172about 2C% when the drug is present in toxic concentrations
Paracetamol is metabolised in the liver largely (60-90%) as a
result of conjugation with glucuronic acid (PG) and sulphate
(PS). In addition, a small amount of paracetamol (5-10%) is
oxidised by the cytochrome P-45 O-dependent drug-metabolising
enzyme(s) to a reactive intermediate^). This intermediate is
preferentialy conjugated with hepatic glutathione and after further
metabolism to paracetamol cysteine (PC) and paracetamol mercapturic
173acid (PMA) it is excreted in the urine . Hepatic glutathione,
however, is limited and once it is depleted covalent binding to
hepatocytes may occur resulting in cell death, and possibly
irreversible hepatotoxicity. The metabolic pathways of
17 4
paracetamol can be outlined as in fig. 1.4.3.
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Fig. 1.4.3 Metabolic pathways of paracetamol
171
kidneys with a mean plasma elimination half life of about 3 h
and only a small amount (about 5%) is excreted unchanged in urine.
In patients with impaired renal function, the conjugated




Unlike aspirin, paracetamol does not apparently cause gastric
mucosal injury. Adverse reactions occur infrequently and
hypersensitivity only rarely. Paracetamol is a metabolite of
phenacetin and acetanilide, but unlike these drugs, produces little
or no methaemoglobinaemia and reports of haemolytic anaemia have
been rare. Serious toxicity with paracetamol was first recognised
in 1966 when fatal hepatic necrosis after overdosage was 
17 6 17 7
reported ' . Early symptoms of toxicity include nausea,
vcmitting, diarrhoea, diaphoresis, pallor and abdominal pain.
The biochemical mechanism of the hepatotoxicity of paracetamol
17 8
was first suggested by Mitchell et al. in 197 3 . Studies on the
mechanism of paracetamol-induced liver damage in laboratory animals
showed that paracetamol is converted in the body to a chemically
reactive arylating agent that covalently binds to vital
hepatocellular macranolecules. In addition a direct relationship
was demonstrated between the formation of a paracetamol glutathione
conjugate, arylation of hepatic macranolecules and hepatic damage
after paracetamol ingestion. The likelihood of damage occurring
after an overdose of paracetamol may be predicted by measurement of
176
the plasma paracetamol level as expressed in fig. 1.4.4. Despite 
the effect on the liver of acute overdose of paracetamol, there 
have been only a few reports of hepatotoxicity arising as a result
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Fig. 1.4.4 The degree of toxicity after an overdose of paracetamol 
related to plasma concentrations and time after 
ingestion
1.4 .2 .3 ACEMETACIN
Acemetacin (ACE) is a new non-steroidal anti-inflammatory drug 
(NSAID) of the indole group with analgesic and antipyretic effects. 
This drug is a glycolic acid ester derivative of the NSAID 
indomethacin (IN). It was synthesised .at the Research Laboratories 
of Troponwerke, Federal Republic of Germany, and selected out 
of several hundred indole derivatives for further clinical
investigations because of its anti-inflammatory activity and lew
180
ulcer genicity in animal models . In clinical studies it has been
shewn to provide symptomatic relief in moderate to severe
181rheumatoid arthritis (RA) . It is now on general release in 
Federal Republic of Germany, and currently being considered by the 
Committee for Safety of Medicines (CSM) for use in the U.K.
Disposition and Metabolism
There have been several clinical studies on the metabolism of
181acemetacin, and its metabolic pathway is given in fig. 1.4.5.
Following chronic dosing of 180 mg/day acemetacin for 10 days in 12
RA patients, the mean steady state blood level of acemetacin plus
181
indomethacin was 1.85 pn . It was also found that approximately
50% of an orally administered dose of acemetacin appeared in the
serum as indomethacin. In human serum dose-dependent protein
181
binding in the range of 81.5-93% was observed with acemetacin
The metabolites of acemetacin were found to be similar to 
181
those of indomethacin (see fig. 1.4.5). Following absorption
and distribution of acemetacin in man, it is excreted as the
unchanged drug, indomethacin, and their glucuronide-conjugates.
O-demethylation may also occur and the products of this
degradation, desmethylindomethacin and desmethylacemetacin, are
excreted in both free and glucuronide-conjugated forms. Deacylation
occurs and the free and conjugated products, des-p-chlorobenzoyl
indomethacin and des-p-chlorobenzoyl acemetacin, are excreted in
182urine. In addition, experiments in rats have also shown 
indomethacin glycine conjugate which was excreted renally in 
approximately three times greater concentration than it was 
after indomethacin administration. The mean half life
of acemetacin following the last acemetacin dose (180 mg/day for 10 
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Des-p-chlorobenzoil acemetacin Des-p—chlorobenzoil indomethacin
Fig. 1.4.5 Metabolic pathways of acemetacin
1.4.2.4 D—PENICILLAMINE
Penicillamine (PSH). was first identified by Abraham and 
183colleagues in 1943 as a penicillin-hydrolysis product during 
studies to elucidate the structure of penicillin. D-Penicillamine 
is a thiol-containing amino acid, used clinically for Wilson's
184 185 186 187
disease , cystinuria , rheumatoid arthritis (RA) , lead and
188 189
mercury poisoning and morphoea . In spite of RA being the
commonest condition treated with D-penicillamine, the pharmacology
and mode of action of this drug in RA is still not completely
understood. In the treatment of RA, D-penicillamine appears to be
a valuable drug, particularly in severe seropositive RA with
190
visceral complications , in which this agent dissociates
191macroglobulin rheumatoid factor and has immunosuppressive
192
activity to the etiologic stimulus
D-Penicillamine is rapidly absorbed from the intestine after 
193oral administration . The peak plasma concentration of total
D-penicillamine following a single dose was 60 yUM at between 2 to 
1944h . Its absorption was significantly higher when the drug was
195given before food or during fasting than when taken with food
The metabolism of D-penicillamine is complex; it is known to exist
in 5 forms in physiological fluids, excluding a protein-bound
fraction (see fig. 1.4.6). The only metabolically-transformed
metabolite of D-penicillamine identified is S-methyl-
195
D-penicillamine (MPSH) which is methylated in the liver . On the
basis of several experiments it appears that some 8C% of
D-penicillamine present in plasma is protein-bound, around 7% is in
the form of D-penicillamine L-cysteine disulphide (PSSC),
apprximately 6% free D-penicillamine (PSH) and 5% D-penicillamine
disulphide (PSSP). The final 2% is unaccounted for and could be in
the form of methylated metabolites, other disulphides or metal 
195complexes . *.
The percentage of each urinary metabolite appears to vary 
according to the disease being treated. All 5 forms of D- 
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Fig. 1.4.6 Metabolic pathways of D-penicillamine
the urine of cystinuric, Wilson's and RA patients. D-penicillamine
homocysteine disulphide was excreted in excess in Wilson's
195disease patients and S-methyl-D-penicillamine in RA patients . In
14
an experiment using C-labelled D-penicillamine in rats, a
biphasic loss of plasma label occurred196'197 and similar results
have been obtained from studies which measured total
D-penicillamine in human volunteers, showing a rapid elimination
phase (half life about 1-5 h) and a slower phase. Estimates of the
198half life of the second slower phase vary from 4-6 days to 8 
199days
Analysis of D-penicillamine and its metabolites in biological 
fluids is difficult due to the high reactivity of the SH group. 
D-Penicillamine has been assayed using a variety of methods such as
colorimetric and spectrophotanetric assays206'201, ion-exchange
, 202 203 204,205chromatography , gas chromatography radioimmunoassays ,
206titration using ion-selective electrodes , high performance
207-209 . _  , 210 .liquid chromatography and amino acid analysis , but none
have proven to be suitable for routine analytical use.
1.5 IN VITRO DRUG METABOLISM STUDIES BY NUCLEAR MAGNETIC 
RESONANCE (NMR) SPECTROSCOPY
1.5.1 GENERAL
In vitro drug metabolism Gan be studied by NMR after
incubation of a drug (i.e. substrate) with the enzyme system. The
loss of substrate(s) and formation of product(s) can be measured
simultaneously. Some examples of the results that can be obtained
with NMR spectroscopy are the measurement of enzyme kinetics in
211
crude cytosolic extracts , and the detection of a "new"
metabolite of penicillin as an in vitro product of the incubation
212
with serum albumin which was subsequently observed in vivo.
Hepatocytes, as the main site of metabolism in the body, have been
used in in vitro studies. NMR studies of intact hepatocytes,
isolated frcm rat liver, and cell extracts have together provided
213considerable insight into the metabolism of paracetamol
Although it was known that these cells metabolised paracetamol, a 
spin-echo experiment after the incubation did not detect any 
metabolites. However, when the cells were lysed or in cell free 
extract, the presence of metabolites was confirmed. In addition, 
the mobile fatty acids in cellular suspensions of viable 
hepatocytes were detected with high resolution NMR.
Other enzyme systems which have been used to study drug metabolism 
and detoxification are purified isozymes, cytochrome P-450 and 
other cytochromes frcm experimental animal livers. 18,19- 
dehydroxydeoxy-corticosterone, produced frcm 18-hydroxydeoxy­
corticosterone incubated with cytochrome P-450 was identified by 
214NMR . A relationship between the binding and the oxidation of
21 5 216paracetamol and aminopyrine by rat liver cytochrome P-450
using longitudinal relaxation (T^) measurements has also been
observed. Data obtained on specific complex formation between these
substrates and different cytochrane P-450's was found to be in
agreement with the specificity of the enzymatic activity exhibited
in metabolic studies.
The substrate under study may need special labelling if NMR
13
insensitive nuclei are to be observed, e.g. C. Such labelling has
made it possible to characterize biosynthetic pathways of
217 218
glucose and formaldehyde by Escherichia_____ col 1.
Gluco neogene sis, glycoge nolysis and lipogenesis have also been
13observed directly by C NMR of perfused rat liver or isolated
219-222 13
hepatocytes . The metabolism of C labelled aminopyrine by a
perfused liver system has been used to evaluate the hepatic drug
metabolising enzyme activity before and after induction with 
223phenobarbitone . Studies of in vitro metabolism have also been
31 19done using other NMR active nuclei such as P and F. The
31phosphorylation status of rat liver by P NMR spectroscopy and its
220,224 220
impl ications for metabol ic control in vitro and in vivo
have been reported. The incorporation of 5-fluorouracil into RNA
and its conversion to metabolites in intact Escherichia coli cells
19 225
has been followed by F NMR . Although these studies involve 
only animal models, they provide insight into the further
development of such measurements.
1.5.2 MODEL SUBSTRATES
Cytochranes P-450 and P-448 may be induced in vivo by
exogenous agents as discussed in section 1.2.2. It is possible that 
NMR may be used to distinguish which cytochrane has been induced by 
following the metabolism of model substrates utilizing these
46
enzymes. Thus a substrate metabolised primarily by cytochrane P-450 
would have its rate of metabolism increased following induction of 
P-450 but not if the P-448 level was increased. In the present 
study, NMR has been used to follow the metabolism of two model 
substrates, i.e. aminopyrine (metabolised by cytochrome P-450) and 
daunorubicin. (metabolised by cytochrane P-450 and P-448), after 
enzyme induction using phenobarbitone (PB) and 3-methylcholanthrene 
(3MC) as cytochrane P-450 and P-450/P-448 inducers respectively.
1.5.2.1 AMINOPYRINE
Aminopyrine (4-dimethylaminoantipyrine, DMAP) has analgesic,
anti-inflammatory and antipyretic actions, but owing to the risk of
226agranulocytosis its use is discouraged . Aminopyrine undergoes
two N-demethylations by hepatic microsomal enzymes to form first
4-mononethylaminoantipyrine (MMAP) and then ampyrone
32 227(4-aminoantipyrine, AP) ' as shewn in fig. 1.5.1. Aminopyrine
is a model substrate to study N-dealkylation of drugs and thus is 
sometimes used in drug metabolism studies.
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Daunorubicin (DA) is an anthracycline antibiotic for the
228
treatment of acute nonlymphocytic leukemia in adults . Human
metabolism of daunorubicin involves carbonyl reduction, reductive
glycosidic cleavage, O-demethylation, Osulphation and
O-glucuronidation. Its metabolites in human urine have been
identified as daunorubicinol, daunorubicinol aglycone,
deoxydaunorubicin aglycone, deoxydaunorubicinol aglycone, demethyl
deoxydaunorubicinol aglycone, deoxydaunorubicinol aglycone 13-0-(3
-glucuronide, demethyl deoxydaunorubicinol aglycone 4-0-sulphate
22 9
and demethyl deoxydaunorubicinol aglycone 4-0-)3-glucuronide . In
rat tissues and hcmogenates, daunorubicin was found to be
metabolised extensively to daunorubicinol by a soluble enzyme in
the cytosol, and their aglycones, daunorubicin aglycone and
daunorubicinol aglycone respectively, by liver microsomal 
230
enzymes . The pathway for daunorubicin metabolism in rat liver 
230fractions is shown in fig. 1.5.2.
1.6 SCOPE OF THE THESIS
The present study aims to highlight some areas of NMR 
spectroscopy applied to drug metabolism studies. The aims are to 
assess the capabilities and limitations of NMR in the analysis 
of body fluids, such as urine and plasma, and rat liver 
preparations. NMR methods for the determination of aspirin, 
paracetamol, acemetacin and D-penicillamine in biological fluids 
will be developed, and the results obtained compared to those frcm 
more traditional analytical methods (HPLC, W  and visible 
spectroscopy). The capability of NMR as a tool for studying in 
vitro metabolism will be assessed using two model substrates, i.e.
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Fig. 1.5.2 Metabolic pathways of Daunorubicin in rat liver fractions
00
aminopyrine and daunorubicin, in 10,000 g liver fraction as a 
general site of metabolism.
The thesis is divided into five chapters:
- Chapter One has been devoted to an introduction on drug
metabolism, NMR analysis of body fluids and in vitro
metabolism. This chapter includes brief descriptions of the 
model drugs and substrates used in the present study.
- Chapter Two consists of material and methods.
Chapter Three gives the results of drug analysis in body 
fluids using 1H NMR and compares the results to HELC and 
spectrophotometry data.
Chapter Four gives the results for in vitro metabolism studies 
by NMR.







acetoxy-acetic acid), C._ H_ _C1N0_, = 415.8 (Troponwerke21 18 o
GMBH & Co. KG Cologne).
ii) aminopyrine (4-dime thy lam inoantipyr ine), Ci3Hi7N3°' *** = 
231.3 (Sigma Chemical Co.).
iii) ampyrone (4-aminoantipyrine), = 2 03 . 2 (Sigma
Chemical Co.).
iv) 0-anisic acid (0-methoxy benzoic acid), CH^OCgH C02H, MW =
152.2 (Aldrich- Chemical Co. Inc.).
v) daunorubicin ((8S-cis)-8-Acetyl-10[ (3-amino-2,3,6-trideoxy 
- a -L-lyxo-hexopyranosyl)oxy]-7,8,9,lO-tetrahydro-6 ,8,11- 
trihydroxy- l-methoxy-5,12-naphthacenedione) - hydrochloric
acid, C27H2 9NOio*HC1' W  = 564,0 (Ma^ & Baker Ltd.).
vi) gentisic acid (2,5-dihydroxybenzoic acid), sodium salt,
C^H^O^Na, MW = 176.1 (Sigma Chemical Co.).
vii) indomethacin (1-p-c hi or benzoyl) -5-methoxy-2-methylindol-3-
acetic acid), C, rtH, ,C1N0,, = 357.8 (Sigma Chemical Co.)
19 16 4
viii) methionine (2 - amino - 4 - (methylthio) - butyric acid), 
CH3S(CH2 )2.CH(NH2 ).COQH, MW = 149.2 (BDH Chemicals Ltd.).
ix) paracetamol B.P. (N-acetyl-4-aminophenol), C H NO , Mt =
8 9 2
151.2 (Pharmacy, Royal United Hospital, Bath).
x) paracetamol glucuronide (4-hydroxy-N-phenylacetamide-
4-glucuronide), C]_4Hi7NOg' *** = 327.3 (kindly donated by 
Stirling Winthrop, R & D).
xi) paracetamol sulphate (4-hydroxy-N-phenylacetamide-4-
sulphate), C H NSO , MW = 231.2 (kindly donated by
8 9 5
Sterling Winthrop, R & D).
xii) D-penicillamine (dimethylcysteine), (CH^)^C(SH).CH( NH^). 
COOH, MW = 14 9.2 (Sigma Chemical Co.).
xiii) phenobarbitone (5-ethyl-5-phenyl-2,4,6-trioxohexahydro- 
pyrimidine), sodium salt, Mrl = 254.2 (May & Baker Ltd.).
xiv) S-methyl penicillamine, (CH3 )2C(SCH3 ),CH( NH2 ).COOH, MW =
163.2 (kindly donated by Lilly Research Centre Ltd.).
xv) D-penicillamine disulphide (3,3,3',3'-tetramethyl-
cystine), ((CH3 )2CS.CH(NH2 ).COOH)2, MW = 296.4 (Fluka 
AG).
xvi) salicylic acid (2-hydroxy benzoic acid), sodium salt,
C_H. (OH) .COONa, = 16 0.1 (Sigma Chemical Co).
6 4
xvii) salicyluric acid (0-hydroxy hippuric acid), C H NO^, MW =
195.2 (Sigma Chemical Co.).
xviii) TPS (3-(Trimethylsilyl)-l-propane-sulphonic acid), or DSS 
(2,2-dimethyl-2-silapentane-5-sulphonate), sodium salt, 
99+%, MW = 236.3 (Aldrich Chemical Co. Inc.).
xix) L-valine (2-aminoisovaleric acid), (CH3 )2CHCH.NH2 .COOH, MW 
= 117.1 (Sigma Chemical Co.).
Solvents
i) ace tone-d -99.5 atcm %D, CD CO CD , MW = 64.1 (Aldrich 
o 3 3
Chemical Co. Inc.).
ii) deuterium oxide - 99.8 atcm %D, ^O, MW = 20.0 (Aldrich 
Chemical Co. Inc.).
All other solvents were ANALAR grade or in the case of HPLC 
analysis, HPLC grade (Fisons).
) Other Chemicals
i) acetoacetic acid, lithium salt, CH^COCH^COO.Li, IW = 108.0 
(Sigma Chemical Co.).
ii) L-alanine (isolated from natural source), CH^.CH(NH^)•COOH 
MW = 89.1 (Nutritional Biochemicals Co.).
iii) creatine phosphate, disodium salt, C H N 0 PNa .6H 0, MW =
4 8 3 5 2 2
363.2 (Boehrlnger Manheim GMBH),
iv) creatinine standard - clinical reagents 10.0 mM (in 0.1M 
hydrochloride acid), C^H^N^O (BDH Chemicals Ltd),
v) L-cysteine (2-amino-3-mercaptopropanoic acid),
hydrochloride acid, C^H^NSO^ .HC1, = 157 .6(BDH Chemicals
Ltd.).
vi) Folin & Ciocalteau's reagent (Fisons).
vii) D( + )galactose, MW = 180.2 (May & Baker Ltd.).
viii) D(+)glucose, MW = 180.2 (May & Baker Ltd.).
ix) glucose-6-phosphate - (D-glucose-6-dihydrogen phosphate), 
CgH^ 0 P, MW = 26 0.1 (Sigma Chemical Co.).
x) glucurase enzyme (^-glucuronidase or /3 -D-glucuronide 
glucuronoso hydrolase from bovine liver), buffered at 
pH = 5.0, 5 000 units/ml (Sigma Chemical Co),
xi) D-glucuronic acid, CHQH.(CH0H)3 .CH(0).COOH, MW = 194.1
(BDH Chemicals Ltd.). 
xii) glycine, NH2 .CH2 .COOH, MW = 75.1 (Fisons).
xiii) hippuric acid, , C^H^.CO.NH.CH2 .COOH, MW = 17 9.2 (BDH
Chemicals Ltd.).
xiv) L-histidine hydrochloride monohydrate, MW = 209.6 (sigma 
Chemical Co.).
xv) DL-lactic acid, CH^CHOH.COOH, MW = 90.1 (Fisons).
xvi) L-leucine ( 2-amino-4-methylpentanoic acid), (CH^ ^ C HC ^ CH
53
( NH^ ) • COOH, MW = 131.2 (Nutritional Biochemicals Co.). 
xv ii) iso-leucine ( 2-amino-3 -me thy lpentanoic acid), CH^CH^^
(CH3 ).CH(NH2 ).COOH, MW = 131.2 (Nutritional Biochemicals 
Co.).
xviii) mannitol, CH_(OH).(CECE) .CH_OE, MW = 182.17(BDH Chemicals
2 4 2
Ltd.).
xix) D-penicillamine hydrochloride (d-3-mercaptoval ine B[C1),
NSO .HCL. MW = 185.7 (Sigma Chemical Co.).
xx) pyruvic acid, sodium salt, CH3CO.COONa, MW = 110.0 (Sigma 
Chemical Co.).
xxi) sarcosine hydrochloride, C3H^02N.HC1, MW = 125.6 (Sigma 
Chemical Co.).
xxii) succinic acid, (CH2COOH)2, MW = 118.1 (BDH Chemicals Ltd), 
xxiii) sulphatase enzyme (aryl sulphate sulfohydrolase frcm helix 
pomatia-type H5) 19800 units/g with -glucuronidase
activity (Sigma Chemical Co.). 
xxiv) zerolit 3 25 - standard resin, cation exchange resin,
functional group R-S03~H+, from H+ , mesh 14-52 (BDH 
Chemicals Ltd.).
All other reagents were laboratory grade supplied by Sigma 
Chemical Co., BDH Chemicals Ltd. or Fisons.
2.2 SYNTHESIS OF D-PENICILLAMINE L-CYSTEINE DISULPHIDE
The mixed penicillamine-cysteine disulphide (PSSC) was
231prepared as described by Crawhall ^t al. (1964) . 1.5 g of
L-cysteine HCL and 330 mg D-penicillamine HCL were dissolved in 
ammonium hydroxide (4N, 20ml). Ferric chloride (0.2 ml, 5% w/v in 
water) was added and air drawn through the solution for 18 h via a 
wash bottle also containing 4 N ammonium hydroxide. The
precipitated cystine and ferric hydroxide were removed by
o
centrifugation and the supernatant was evaporated at 60 C using a
rotary evaporator. The resulting residue was washed with water
(2x25 ml) and the washings were applied to an ion-exchange
chromatographic column (Zerolit 325 in the H+ form; 12 x 250 mm).
The column was eluted with water (200 ml) followed by ammonium
hydroxide (2 N, 250 ml). The ammonia was removed by evaporation in
o
a rotary evaporator at 6 0 C, leaving a solid residue of the mixed 
disulphide (approximately 200 mg) contaminated with 6.3% 
penicillamine disulphide and 7.7% cystine. The structure was
confirmed by NMR and infra-red spectroscopy.
2.3 HOMAN STUDIES
All human studies (patients and volunteers) received approval 
frcm the Bath Area Health District Research Ethics Committee. All 
volunteers were medically examined and clinical-biochemical tests 
were carried out before and after the studies,
a) Patients
Patients, both male and female, aged 35 to 74 years, admitted 
to the Clinical Pharmacology Unit (CPU) of the Royal United 
Hospital (RUH), Bath, with self-administered overdose of 
paracetamol (P) or aspirin (ASA) were studied. On admission, 
gastric lavage was performed on each patient in the Casualty 
Department. Patients were then transferred to CPU where they 
received glycine oral fluid or urinary alkalinisation treatment for 
ASA overdose, or methionine or parvolex (N- acetylcysteine) 
treatment for P overdose. All urine passed by the patients was 
collected whenever possible until they left the unit. Urine volume 
and pH were measured on the ward. Concentrations of aspirin
metabolites (i.e. SA, SUA and GA) or paracetamol metabolites (i.e. 
P, PG and PS) present in each sample were determined by 
colorimetric assay, HPLC and NMR as described in sections 2.7, 2.8
and 2.9 respectively.
For the D-penicillamine (PSH) study, samples were obtained 
frcm RA patients who visited the out-patient clinic of the Royal 
National Hospital for Rheumatic Diseases, Bath. Blood samples were 
withdrawn by venepuncture as requested by the Consultant. Plasma 
samples not required for routine laboratory analysis were pooled 
for the determination of penicillamine metabolites (e.g. PSH, PSSP, 
PSSC and MPSH) by NMR as described in section 2.10.1.3.
b) Volunteers
Three healthy male volunteers, aged 29, 42 and 43 years who 
were participating in a clinical study on acemetacin (ACE) in the 
Royal United Hospital, Bath, were studied. 90 mg of ACE were taken 
orally twice daily, for eight days. Urine samples were collected 
two hourly for six hours after the first and the last doses for ACE 
and indomethacin (IN) determination by NMR as described in section 
2.9.
2.4 ANIMAL EXPERIMENTS
The experimental animals used were male Wistar Albino rats 
(Bath University strain) weighing between 240-280 g. The rats 
injected with phenobarbitone (PB) were housed individually, and 
other experimented, rats were housed in groups of one to three rats 
per cage (NKP cage). Food pellets (Labsure diet, CRM) and water 
were allowed ad liberturn and a constant light-dark cycle was 
maintained (12 h light 7.00 to 19.00, 12 h dark 19.00 to 7.00) at 
an ambient temperature of 24 °C.
Induction of Bat Liver Enzymes
Phenobarbitone (PB, 101.8 mg ml 1 sodium salt in isotonic 
saline) was administered by intraperitoneal injection using the 
following regime:
- day 1: 50.9 mg kg ^ body weight (b.w.)
- days 2 and 3: 101.8 mg kg ^ b.w.
3-methylcholanthrene (3MC, 18 mg ml ^ in corn-oil) was administered 
by intraperitoneal injection, once only at a dose of 40 mg kg ^ 
b.w.
Control rats for PB received intraperitoneal injections of 0.5 
ml kg ^ b.w. of saline on the first day and 1.0 ml kg ^ b.w. of 
saline on the second and third days. Control rats for 3MC received 
a single injection of 2.2 ml kg ^ b.w. of corn-oil. After the last 
doses of PB or saline and 24 h after the 3MC or corn-oil 
injections, food was withheld from the animals for 24 h before they 
were killed by cervical dislocation. The livers were immediately 
removed and 10,000 g liver fractions and microsomes prepared as 
described in section 2 .6 .
2.5 STORAGE OF BIOLOGICAL SAMPLES
o
All urine and plasma samples were stored at -20 C prior to
analysis. Urine was stored in approximatley 4 x 10 ml aliquots
where possible. Plasma was stored in EDTA tubes. Prepared
o
microsomes were similarly stored at -20 C.
2.6 RAT LIVER PREPARATIONS AND THEIR PROTEIN AND CYTOCHROME ASSAYS
Rat Liver Preparations
The procedure used was a modification of various published 
232 233methods ' . Once the livers had been removed from the control,
PB or 3MC treated rats, the following preparations were immediately 
o
carried out at 0 C.
Each liver was weighed and homogenates were prepared using 2 
volumes of isotonic 1.15% KC1-0.01 M Na+/K+ phosphate buffer, pH
7.4, by homogenizing the minced liver with a teflon and ground-
glass hcmogenizer for about 1 minute. To remove cell nuclei and
mitochondria, the homogenates were centrifuged at 10,000 g for 15 
o
min at 4 C in a MSE High Speed Model 18 centrifuge. The
supernatant fraction, hence called 10,000 g liver fraction, was
taken for (a) protein determination (see below), (b) in-vitro
metabolism (see section 2 .10.2 ) and (c ) microsomal preparation.
Microsomes were obtained after ultracentrifugation of the
o
liver supernatant fraction at 100,000 g for 1 h at 4 C in a Beckman 
Model L8-7 0M centrifuge. The microsomal pellets obtained were 
suspended in fresh 20% glycerol-0.01 M Na+/K+ phosphate buffer, pH
7.4, so that the entire yield of microsomes frcm each rat was
suspended in a final volume of 10 ml. This suspension was
re-homogenised using a ground-glass hand driven homogenizer to
o
obtain a uniform suspension and deep frozen at -2 0 C, until 
required for cytochrcme P-450/P-448 and other cytochrane 
de term ina tions.
Protein Assay of 10, OCX) g Rat Liver Fractions
The method for measuring protein concentration of the 10,000 g
liver fraction was based upon the colorimetric determination of
36
Lowry et al. (1951) .The coloured complex formed between the 
alkaline copper-phenol reagent and the tyrosine and tryptophan 
residues of the protein was proportional to the protein 
concentration.
To 0.4 ml of diluted 10,000 g liver fraction sample containing 
20 to 100 jig of protein (200x dilution of 10,000 g liver fraction 
described in section 2.6a with saline) was added 4.0 ml alkaline 
copper solution (50 ml of 2% NagCO^ in 0.10 N NaOH and 1 ml of 0.5% 
CuS04 .5H20 in 1% NaK tartrate). The solution was mixed well and 
allowed to stand for 10 min at roan temperature. 0.4 ml diluted 
Folin-Ciocalteau reagent (1 volume of the reagent plus 2 volumes of 
distilled water) was added rapidly, mixed and allowed to stand for 
3 0 min at rocm temperature in the dark. The absorbance was read at 
650 nm against the reagent blank using a Perkin-Elmer model 550S 
uv-vis spectrophotometer. The protein concentrations were
calculated frcm a calibration curve prepared using purified bovine 
serum albumin as a standard. The calibration curve was linear over 
the concentration ranges 5 0-400 /Jt.g/ml in saline. A typical 
calibration curve is given in fig. 2 .6 .1.
Assay for microsomal cytochromes
The measurement of microsomal cytochrcme P-45 0 (or P-448 and
P-420) and cytochrome b^ was based on the method of Omura and Sato 
234
(1964) using the carbon monoxide (CO)-difference spectra. Since 
cytochrane P-42 0 is considered to represent degraded cytochrane 
P-450/P-448, the cytochrome P-420 concentration was added to the
59
0.9995
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Fig. 2.6.1 Calibration curve for protein in rat liver supernatant 
fraction
observed cytochrane P-450/P-448 level to arrive at the total 
concentration of cytochrane P-450/P-448. The peak or shoulder at 
420 ran was attributed to small amounts of contaminating haemoglobin 
as identified by the carbon monoxyhaemoglobin minus the 
oxyhaemoglobin spectrum.
a. Cytochromes P-450/P-448
The microsomal suspension was diluted with 2C% glycerol- 0.01 
M Na+/K+ phosphate buffer to give a protein concentration of 
approximately 2 mg/ml and placed in two cells, a reference and 
a sample cell. A baseline was recorded and the sample cell 
was subsequently gassed with carbon monoxide (CO) and its 
absorbance spectra (maximum about 4 20 nm) was scanned. This 
is referred to as the "haemoglobin trace". A few mg of sodium 
dithionite was then added to both cells, the carbon monoxide 
gassing of the sample cell repeated, and the absorbance 
spectrum re-scanned. This is referred to as the cytochrane
"P-450/P-420 or P-448/P-420 trace" (maximum about 450 nm or 
448 nm and 420 nm).
The difference between absorbance at 420 nm on the latter 
trace and the haemoglobin trace, was added to the difference 
between absorbance at 450 nm or 448 nm and 480 nm on the 
P-450/P-420 or P-448/P-420 trace. The concentration of 
cytochrome P-450/P-448 was calculated from the above 
absorbance, assuming an extinction coefficient of 91 cm ^ 
mmol ^ for the reduced hemoprotein-CO complex.
b. Cytochrome b^
The above diluted microsomal suspension was placed in two 
matched cells. A-baseline was recorded and then to the test 
cell was added a few mg sodium dithionite and both cells were 
re-scanned. The concentration of cytochrome b^ was calculated 
from the absorbance difference between the maximum (about 428 
nm) and 500 nm, assuming an extinction coefficient of 185 cm  ^
mmol ^ for the reduced haemoprotein-CO complex.
2.7 INSTRUMENTATION
2.7.1 ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY (SPEC)
Ultraviolet-visible absorption spectra were recorded with a 
microcomputer-controlled scanning double beam spectrophotometer 
(Perkin-Elmer model 550S; Perkin-Elmer & Co. GMBH, Uberlingen), 
with a model 561 recorder utilizing a matched pair of 1 cm path 
length silica cells (scan speed 60 nm/rain, ordinate scale 0.0-3.OA.
2.7.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
The HPLC system was assembled from commercially available
components. The mobile phase was pumped to the column at constant
flow using a Laboratory Data Control (LDC) Constametric III
Metering Pump which provides a pulseless flew using
dual-reciprocating pistons. The samples were introduced into the
system using a Rheodyne injection valve fitted with a constant
volume, 2 0/il loop (Rheodyne 7 2 05, Rheodyne Ltd., California, USA),
and onto an analytical column (15 cm x 4.5 mm i.d.) packed with a
reverse phase micro particle silica (Hypersil ODS 5 m, Shandon
Product Ltd). In the case of aspirin analysis, a pre-column (5 cm
x 4.5 mm i.d.) packed with identical material was placed in line
immediately before the .analytical column. The column end fitting
comprised a lew dead volume Swagelok connection with a 1/ inch
16
outline which was connected to the detector by microbore Teflon
tubing (0.15 mm i.d.). Low dead volume l/.£ inch stainless steel
16
tubing (0.15 mm i.d.) was used to connect the injection valve to 
the top of the column. All other connections were made of 
stainless steel tubing and standard Swagelok fittings (HETP Ltd., 
Macclesfield). Eluted compounds were detected using an LDC 
variable UV detector (Spectromonitor III). Chromatograms were 
recorded using a JJ Model CR550 potenticmetric chart recorder (JJ 
Lloyd Instruments Ltd., Southampton).
All equipment was operated at ambient temperature throughout. 
Mobile phase was filtered through a 0.45 /jum membrane filter 
(Millipore UK Ltd., London) and subsequently degassed by purging 
with helium for 5 min immediately prior to use.
2.7.3 PROTON NUCLEAR MAGNETIC RESONANCE NMR) SPECTROSCOPY
400 MHz spectra were obtained with a Bruker WH400 or a JEOL
GX400 spectrometer and 270 MHz spectra with a JEOL GX270
o
spectrometer at ambient probe temperature (20 + 1 C). Spectra were 
accumulated using 16K data points, a pulse delay of 5s to allow 
proton magnetization to recover by T^ relaxation, and 32, 4 8 or 64 
free induction decays (FIDs) either by single pulses or 
Carr-Purcell-Meibocm-Gill (CPMG) sequence 90°(x)-(/C-180°(y)-^) - 
acqusition, K = 60 ms. Accumulations were begun less than 2 min 
after introduction of the sample into the probe. The sample tube 
spinning speed was approximately 20 Hz, and the total spectral 
accumulation times for 4 8 FIDs were very short (5-10 min). The 
signal due to water was suppressed by homogated secondary 
irradiation. FIDs were zero-filled to 32 K data points before
Fourier transformation, and either an exponential function 
corresponding to a 0.1 Hz line broadening or where indicated a 
Gaussian function for resolution enhancement was applied.
2.8 QUANTITATIVE ANALYSIS BY UV-VIS SPECTROPHOTOMETRY (SPEC)
2.8.1 ASPIRIN METABOLITES
Salicylic acid (SA), salicyluric acid (SUA), salicyl phenolic
glucuronide (SPG) and salicyl acyl glucuronide (SAG) were assayed
235
in human urine according to the method of Brodie et al. (1944)
34with modifications by Trinder (1954) and that for gentisic acid
(GA) according to the method of Smith (1951)"^.
Assay Procedures
For the SA assay, 0.2 ml - 1.0 ml of urine samples (in
duplicate) were extracted by adding 5 ml of carbon tetrachloride
(CC1.) and 0.2 ml of 6N HC1 solution. The mixture was Whirli-mixed 4
for 1 min and then centrifuged at 3500 rpm for 5 min. The aqueous
phase was discarded and 5 ml of 1% ferric nitrate was added to the
organic phase. The mixture was mixed and centrifuged again as
above. The absorbance of the aqueous phase was then read at 53 0 nm
using a spectrophotometer. SA concentration is represented as 'A'.
For the SUA assay, the procedure was as for SA using methylene
chloride (CH-C1) for extraction instead of CC14.
3 4
For the GA assay, 0.5 ml of urine samples (in duplicate) were
extracted by adding 5 ml ether and 0.2 ml of 6N HC1. After 1 min
Whirli-mixing and centrifugation at 3 500 rpm for 5 min, the organic 
phase was placed in a clean tube and 5 ml of 5% NaHCO^ was added.
The mixture was mixed and cenrtrifuged as above and the ether phase
was discarded. Finally, 6 ml of 6N HC1 and 0.5 ml of
Folin-Ciocalteau's reagent was added to the aqueous phase which was
mixed and read in the spectrophotometer at 670 nm.
For the SPG assay, 0.1 ml-0.5 ml of urine samples (in
duplicate) were adjusted to pH 5.0 with 1.0 ml acetate buffer and
_ o
incubated with 0.3 ml of p -glucuronidase (5000 units/ml) at 37 C
for 2 0 h. The samples were then reassayed for SA giving
concentration (B) which represented the amount of SAfSPG. SPG
concentration was taken to be (B-A).
For the SAG . assay, 0.1 ml-0.5 ml of urine samples (in
o
duplicate) were incubated with 1 ml of 2 N NaCH at 37 C for 2 0 h. 
At the end of the incubation period, the mixture was neutralized to 
pH 7.0 with 2N H Q  and then reassayed for SA giving concentration 
(C) which represented the amount of SA+SAG. SAG concentration was 
taken to be (C-A).
Quantif icatlon
Quantification of aspirin metabolites in urine samples were
calculated frcsn the calibration curves prepared using standard SA,
SUA or GA spiked in control human urine. Since SA is sparingly
soluble in and SUA is in CCL^, concentrations of SA and SUA
were achieved each by using two pairs calibration curves, i.e. SA
and SUA extracted in CCl^, and SA and SUA extracted in CH^Cl.
Calibration curves (absorbance vs. concentration) were constructed
and were linear over the concentration ranges of 431-1725 jug/ml (SA
extracted with CC14 or CH^Cl), 500-2000 jug/ml ( SUA extracted with
CH-C1 or CC1.) and 100-300 ttg/ml (GA). The coefficient of variation 
3 4
at 17 25 jmg/ml was 4% for SA extracted with either CCl^ or At
431 juig/ml, the coefficients of variation were 6% for SA extracted
with CC1. and 7% for SA extracted with CH_C1. The coefficients of 4 3
variation at 2000 /ig/ml were 3% for SUA extracted with CH^Cl and 4% 
for SUA extracted with CCl^. At 500 fig/ml, the coefficients of 
variation were 4% for SUA extracted with ^ 3^  an<* 9% for SUA
extracted with CC14 . At 300 jig/ml, the coefficient of variation was 
2% for GA and at 100 /mg/ml GA the value was 9%. Typical
spectroscopic calibration curves are given in fig. 2 .8 .1, fig. 
2.8.2 and fig. 2.8.3 for SA, SUA and GA respectively.
The metabolite concentrations were calculated using the 
following equation from the linear least-squares regression method:
y = mx+c (2.8 .1)
where y is the observed absorbance value of metabolite, x is the 
unknown concentration to be determined and m and c are the 
regression coefficients calculated from the calibration curve.
Accordingly, SA and SUA concentrations were determined from the
following formulae which are derived from the two simultaneous
65
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Fig. 2.8.1 Calibration curves for salicylic acid (SA)
extracted with carbon tetra chloride ( ) and methylene 
chloride ( ) measured by spectrophotometry
0.9996









Fig. 2.8.2 Calibration curves for salicyluric acid (SUA) extracted 
with methylene chloride ( ) and carbon tetra chloride 
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Fig. 2.8.3 Calibration curve for gentisic acid by SPEC
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Fig. 2.8.4 Calibration curve for paracetamol by SPEC
equations, i.e. the total of SA and SUA extracted with CC1, and
4
those with CH^Cl.
y = m1x1+c1 + m2X2+C2
(2.8.2)y- Y V V  + m2'x2+c2*
where y and y' are the observed absorbance values in CC1. and CH.Cl
4 3
respectively, x^ and x2 are the SA and SUA concentrations 
respectively, m^, c^ and m2 , c2 are the regression coefficients 
calculated from the calibration curves of SA and SUA extracted with 
CC14 respectively, and , c^' and m2 ’, c2 * are the regression
coefficients calculated from the calibration curves of SA and SUA 
extracted with CH^Cl respectively.
2.8.2 PARACETAMOL AHD ITS MAJOR METABOLITES
Paracetamol (P) was assayed according to Le Perdiel jit al.
33 236
( 196 8) with modification from Chafetz et al. (196 8) for the
determination of paracetamol (P), paracetamol glucuronide (PG) and
paracetamol sulphate (PS) in human urine.
Assay Procedures
For the P assay, to 0.2 ml - 10 ml of urine samples (in 
triplicate) were added 0.4 ml of 6N HCL and 1.0 ml of sodium 
nitrite. After allowing the solution to stand for 15 min, 15 ml of 
15% sulphonic acid was added to destroy excess nitrous acid. When 
nitrogen evolution had ceased, 3.0 ml of 1C% NaOH was added and the 
solution was diluted to 10 ml (or 5 0 ml for the metabolite assay) 
with distilled water. The absorbance was then read at 43 0 nm using 
a spectrophotometer. Concentration of P was linearly related to 
absorbance. P concentration is represented as 'D'.
For the FG assay, 0.1 ml - 0.5 ml of urine samples (in
triplicate) were adjusted to pH 5.0 with 1.0 ml acetate buffer and
a oincubated with 0.3 ml of p-glucuronidase (5000 units/ml) at 37 C
for 2 0 hours. The samples were then reassayed for P as described
above giving concentration (E) which represented the amount of
P+PG. PG concentration was taken to be (D-E).
For the PS assay, 0.1 ml - 0.5 ml of urine samples (in
triplicate) were adjusted to pH 5.0 with 1.0 ml acetate buffer and
incubated with 0.3 ml of /3-glucuronidase (5000 units/ml) and 10 mg
o
of sulphatase (19800 units/ml) at 37 C for 20 h. The samples were 
then reassayed for P as described above giving concentration (F) 
which represented the amount of P+PG+PS. PS concentration was taken 
to be (F-E).
Quantification
Quantification of P and its metabolites in urine samples were 
calculated from the calibration curve of P prepared using standard 
P spiked in control human urine. Calibration curve (absorbance vs. 
concentration) of P were constructed and were linear over the 
concentration ranges of 1-100 /ig/ml. The coefficients of variation 
for P was 2% at 100 /ig/ml and 9% at 1 yug/ml. A typical 
spectroscopic calibration curve for P is given in fig. 2.8.4. The P 
concentrations were calculated using the equation 2 .8 .1 .
2.9 QUANTITATIVE ANALYSIS BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC)
2.9.1 ASPIRIN METABOLITES
Salicylic acid (SA), salicyluric acid (SUA) and gentisic acid 
(GA) were assayed in human urine according to a modification of
69
42method reported by Cham et al. (1980) , using o-anisic acid (AA)
as the internal standard
HPLC Conditions
Mobile phase 25% acetonitrile
75% orthophosphoric acid (0*1%)
pH 2.5
Flow rate 1.5 ml/min (operating pressure = 2000 psi)
Detection 298 nm
Chart speed 0.4 cm/min
Assay procedure
1 ml of urine samples (in duplicate) were added to 1 ml of 
internal standard (1.0 mg/ml AA in distilled water). 100 /il was 
injected into the column. Under these conditions, the retention 
times for GA, SUA or AA and SA in human urine were 2.6, 3.5, 4.1
and 7.6 min respectively. A typical chromatogram of GA (60/ig/ml), 
SUA (18 0yug/ml), AA (250 /ig/ml) and SA (120 /ig/ml) spiked in 
control human urine is shown in fig. 2.9.1 A. A chromatogram of a 
diluted urine sample from an aspirin overdose patient is shown in 
fig. 2.9.IB.
Quantif ication
Concentrations of aspirin metabolites in urine samples were 
calculated using the method of peak height (metabolite/internal 
standard) ratios from calibration curves prepared using standard 
SA, SUA, GA, and AA spiked in control human urine. Calibration 
curves (peak height ratio vs. concentration) were constructed and 
observed to be linear over the concentration ranges of 80-400 ^ ig/ml 










9.1 Chromatograms of (A) GA (60 ^ug/ml), SOA (180 p.g/ml), AA 
(250 /ig/ml) and SA (120 jug/ml) spiked in control human 
urine and (B) urine sample from an aspirin overdose
patient
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9.2 Calibration curve for salicylic acid (SA) by HPLC
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Fig. 2.9.2 Calibration curve for salicyluric acid by HPLC
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Fig. 2.9.3. Calibration curve for gentisic acid by HPLC
of variation for SA were 2% at 400 ug/ml and 7% at 80 ug/ml. At 600 
ug/ml, the coefficient of variation was 1% for SUA and at 120 ug/ml 
SUA the value was 3%. The coefficients of variation for GA were 2% 
at 200 ug/ml and 5% at 40 ug/ml. /Typical calibration curves by HPLC 
are given in fig. 2.9.2, fig. 2.9.3 and fig. 2.9.4 for SA, SUA and 
GA respectively.
The metabolite concentrations in patient samples were 
calculated using following equation frcm the linear least-squares 
regression method:
where y is the observed peak height ratio of metabolites to 
internal standard in urine, x is the unknown concentration to be 
determined and m and c are the regression coefficients calculated 
from the calibration curves.
2.9.2 PARACETAMOL AND ITS MAJOR METABOLITES
Paracetamol (P) was assayed according to a modification of
43
method reported by Adriaenssens and Prescott (197 8) , using
gentisic acid (GA) as the internal standard, for the determination 
of paracetamol (P), paracetamol glucuronide (PG) and paracetamol 
sulphate (PS).
HELC-Conditions:
Mobile phase : 94.9% 0.0 M KH2P04




Flew rate 1.0 ml/min (operating pressure = 1000 psi)
Detection 254 nm
Chart speed 1.0 cm/min
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Assay Procedures
For the P assay, 0.5 -1.0 ml of urine sample (in triplicate)
was added to 1 ml of internal standard (10 mg/ml GA in distilled
water) and made up to 10 ml with distilled water. 100ytil was 
inj ected onto the column.
For the PG and ps assays, the paracetamol metabolites were
converted to free P as described for spectrophotometry (see section
2.8.2). The samples were then reassayed for P. Under these 
conditions, the retention times for P and GA in human urine were
3.5 and 5.1 minutes respectively. A typical chromatogram of P (0.2 
mg ml ^) and GA (1 mg ml ^) spiked in control human urine is shown 
in fig. 2.9.5A. A chromatogram of a diluted urine sample from a 
paracetamol overdose patient is shown in fig. 2.9.5B.
Quantification
Concentrations of P and its metabolites in urine samples were 
calculated using the method of peak height (drug/internal standard) 
ratio. Calibration curves for P were prepared using standard P 
together with internal standard and GA spiked in control human 
urine. Calibration curves (peak height ratio vs. concentration) of 
P were constructed and were linear over the concentration range of 
1-100 jag/ml. The coefficient of variation for P was 2% at 100 /ig/ml 
and 4% at 1 /ig/ml. A typical calibration curve for P by HPLC is 
given in fig. 2.9.6. P concentrations in urine samples were 




























>.5 Chromatograms of (A) P (0-2 mg/ml) and GA (1 mg/ml)
spiked in control human urine and (B) urine sample 
from a paracetamol overdose patient
r = 0.9999
y = 0.0403 x - 0.0004
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Fig. 2.9.6 Calibration curve for paracetamol (P) by HPLC
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2.10 ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE (1H NMR)
SPECTROSCOPY
2.10.1 ANALYSIS OF DRUGS AND METABOLITES IN BODY FLUIDS
2.10.1.1 ASPIRIN , PARACETAMOL AND METABOLITES
Sample Preparation
Aliquots of urine (0.54 ml, intact or diluted with control
2
urine) were placed in 5 mm NMR tubes and 0.06 ml of H^O as a field 
frequency lock containing internal standard (either valine 17.1 mM;
or 2,2-dimethyl-2-silapentane-5-sulphonate DSS, 31.7 mM) were
added.
NMR Measurement:
The samples were run in a Bruker WH400 or JEOL GX400
spectrometer using the single pulse technique and hcmogated
decoupling for water signal suppression (see section 2.7.3).
Spectra were accumulated using 48 or 64 free induction decays
(FIDs) and resolution enhancement was achieved by applying a
Gaussian function to the FIDs.
Peak Assignments:
The assignments of resonances were confirmed by consideration
of a combination of methods: standard additions, comparison with
literature chemical shifts, analysis of coupling constants. Small
amounts of some major components of urine were spiked into control
human urine resulting in an increase of their relative magnitudes.
Chemical shifts of paracetamol (P), its glucuronide (PG), sulphate
(PS) and mercapturic (PMA) conjugates were recorded in 0.1 M
deuterated phosphate buffer at pH* 5.6-7.3, referenced to DSS (6=
2
0.0 ppn). Over this pH* range (pH read in H2°^' there were no
substantial shifts (>0.02 ppm) in the resonance of paracetamol and
its metabolites. NMR spectra of identical urine samples spiked
with P, FG, PS and PNAC, salicylic acid (SA), salicyluric acid
(SUA) and gentisic acid (GA) were recorded.The spectra were
referenced to either the methyl signal of internal standard (5= 1.0
ppm for valine, 8 = 0.0 ppm for DSS) or the methylene signal of
glycine ( 8 = 3.57 ppm) which do not shift in the normal pH range of 
94
urine (5-8) . Samples were prepared and spectra were recorded
using identical conditions for urine samples from paracetamol and 
aspirin overdose patients (see section 2.3a).
2.10.1.2 ACEMETACIN METABOLITE (INDOMETHACIN)
Sample preparation:
Urine samples were freeze-dried and redissolved inacetone-d -6
2
H^O (3:2 v/v) to concentrate them by 15 to 29 times. Lyophilized
urine samples (0.54 ml) were placed in 5 mm NMR tubes and 0.06 ml 
2
of H^O containing internal standard DSS (4.2 mM) were added.
NMR Measurement:
The samples were run in a JEOL GX270 spectrometer using the 
single pulse technique and hcmogated decoupling for water signal 
suppression (see section 2.7.3). Spectra were accumulated using 48 
FIDs and resolution enhancement was achieved by applying a Gaussian 
function to the FIDs.
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Peak Assignments:
The assignments of resonances were confirmed by consideration 
of a combination of standard additions, chemical shifts and 
coupling constants. Small amounts of some major components of urine
were spiked into control human urine before being freeze-dried and
2 1 redissolved in acetone-d - H O  (3:2 v/v). H NMR spectra of two
6 2
identical lyophilized urine samples after spiking with acemetacin 
(ACE) or indomethacin (IN) were recorded. The spectra were 
referenced to either the methyl signal of DSS (6 = 0.0 ppm) or the 
methylene signal of glycine (5= 3.57 ppm). Samples were prepared 
and spectra were recorded using identical conditions for urine 
samples fran volunteers (see section 2.3b).
2.10.1.3 D-EENICILLAMINE AND ITS METABOLITES
Sample Preparation:
Pooled EDTA plasma samples were extracted with trichloroacetic
2
acid (TCAA), freeze-dried, and redissolved in H^O to concentrate
40-80 times. Lyophilized plasma samples (0.54 ml) were placed in 5
2
mm NMR tubes and 0.06 ml of H^O containing internal standard DSS 
(8.5 mM) were added.
NMR Measurement:
The samples were run in a JE0L GX400 spectrometer using single 
pulse technique and hcmogated decoupling for water signal 
suppression, then re-run using spin echo technique by CPM3 (see 
section 2.7.3). Spectra were accumulated using 64 FIDs and 




The assignments of resonances were confirmed by consideration 
of a combination of standard additions, chemical shifts, coupling 
constants and phase characteristics in the spin echo spectra. Small 
amounts of some major components of plasma were spiked into the 
lyophilized normal EDTA plasma and the spectra re-run resulting in 
an increase of their relative magnitudes. To determine the 
analytical recovery, the NMR spectrum of freeze-dried normal 
EDTA plasma containing 0.3 mM of each penicillamine (PSH), 
penicillamine disulphide (PSSP), penicillamine cysteine (PSSC) and
S-methyl penicillamine (MPSH) was recorded. The spectra were 
referenced to the methyl signal of DSS (§= 0.0 ppn). Samples were 
prepared and spectra were recorded using identical conditions for 
pooled plasma samples frcm patients (see section 2.3a).
2.10.1.4 QUANTIFICATION OF PARACETAMOL AND ITS METABOLITES, 
AND ACEMETACIN METABOLITE (INDOMETHACIN)
Paracetamol (P) and its metabolites (PG and PS) were 
quantified by comparing the integrals (computer-integrated peak 
areas) of their acetyl methyl signals, expected to occur in 
regions devoid of resonances in normal urine, to those of the 
methyl signal of DSS (5= 0 ppm) or valine (§= 1.0 ppO for a few 
samples. Indomethacin (IN) (acemetacin metabolite) was quantified 
by comparing the weights of paper traces of its methyl signal to 
those of the methyl signal of DSS. Only the single pulse spectra 
were used for quantification.
The following general equation is used for the calculation: 
Molarity of m Peak Integration of m
Molarity of s Peak Integration of s
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C MW I N
m s _ m s
C MW I N
s m s m
I N MW __ ov
C C m s m  (2.10.2)
m = s -------
i n m
s m s
whereby C and C are the concentration of metabolite and standard 
m s
respectively, I and I are the integrations or the weight of paper 
m s
traces of metabolite and standard respectively, N and N are the
m s
numbers of their active nuclei and MW and MW are their molecularm s
weights. To test the analytical reliability, calibration curves 
(integration ratio for P, PG and PS and weight of paper trace ratio 
for IN v_s. concentration) were constructed and found to be linear 
over the concentration ranges 0.05-1.78 mg/ml (P), 0.40-2.00 mg/ml 
(PG), 0.22-1.80 mg/ml (PS) and 0.20-1.02 mg/ml (IN). The
coefficients of variation for P were 2% at 1.7 8 mg/ml and 10% at 
0.05 mg/ml. At 0.40 mg/ml the coefficient of variation was 2% for 
PG and at 2.00 mg/ml PG the value was 9%. The coefficients of 
variation for PS were 3% at 1.80 mg/ml and 11% at 0.22 mg/ml. The 
coefficients of variation for IN were 3% at 0.20 mg/ml and 11% at
1.0 2 mg/ml. Typical calibration curves for P, PG, PS and IN by 
NMR are given in fig. 2.10.1, 2.10.2, 2.10.3 and 2.10.4
respectively. Recoveries of P, PG, PS and IN in urine were 
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2.10.2 IN VITRO METABOLISM
Incubation Procedures:
The following solutions were added to a 10 ml flask In order:
1) 0.1 ml of aminopyrine (DMAP, 2 mM) or 0.1 ml daunorubicin (DA, 
2 mM).
2) 0.1 ml of magnesium chloride (MgCl2, 30 moles).
3) 0.2 ml of co-factor mixture containing nicotinamide adenine 
dinucleotide phosphate (NADP, 0.26 mole), glucose-6-phosphate 
(G6P, 6 moles) and nicotinamide (20 moles).
4) 0.6 ml of 10,000 g rat liver fraction containing enzyme 
equivalent to 30 mg protein.
Total volume 1.0 ml. .All solutions were made up in 0.05 M Na+/K+
phosphate buffer pH 7.4. The reaction was carried out in a shaking
o
water bath (120 cycles/min) at 37 for 5,10,20,30 or 60 min in air. 
The blank mixtures (without added substrate) were incubated as 
controls using identical conditions. To stop the reaction, 0.1 ml 
of 55% trichloroacetic acid (TCAA) was added to the mixture. The 
mixture was then centrifuged at 4,000 g for 10 min and the spectra 
of the supernatant were recorded. The spectra of the above mixture 
were also recorded before and after protein precipitation (by 
addition of TCAA).
Sample Preparation:
Supernatants of deproteinated incubation mixtures (0.54 ml),
hence called the acid extract of 10,000 g liver fraction, were
2
placed in 5 mm NMR tubes and 0.06 ml of H^O as a frequency lock 













Fig. 2.10.6 Calibration curve for aminopyrine (DMAP) by NMR
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Fig. 2.10.7 Calibration curve for 4-aminoantipyrine (AP) by NMR
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NMR Measurement
The samples were run in a JEOL GX 270 using the single pulse 
technique and hcmogated decoupling for water signal suppression, 
then re-run using the spin echo technique by CPMG, collecting 32 
FIDs in each case (see section 2.7.3).
Peak Assignment:
The assignments of resonances were confirmed by consideration 
of a combination of methods: standard additions, chemical shifts,
and phase characteristics in the spin echo spectra. NMR spectra 
of three identical acid extracts of 10,000 g control liver fraction 
spiked with DMAP, 4-aminoantipyrine (AP) or DA were recorded and 
referenced to the methyl signal of DSS (6=0.0 ppm).
Quantification of Aminopyrine and its metabolites
Aminopyrine (DMAP) and its metabolites were quantified by 
comparing the integrals of the peaks arising from methyl signals of 
DMAP, monomethyl-4-aminoantipyrine (MMAP) and AP which occurred in 
a region devoid of resonances in the control acid extract of 
10,000g liver fraction, to the integral of methyl signal of DSS (5= 
O ppm). The peaks in the single pulse spectra were quantified 
using equation 2.10.2 (see section 2.10.1.4). To get the optimum 
conditions for the 10,000 g liver fraction to metabolise DMAP, a 
series of identical mixtures containing various amount of 10,000 g 
liver fraction (i.e. enzymes equivalent to 10, 20, 30, 40 and 50 mg 
protein) were incubated for 30 min. The concentration of 
non-metabolised DMAP vs. mg protein is shown in fig. 2.10.5. The 
10,000 g liver fraction enzymes equivalent to 30 mg protein was 
then chosen. To test the analytical reliability of DMAP and AP,
85
calibration curves (integration ratio vs concentration) were 
constructed and found to be linear over the concentration range 
0.02-0.7 and 0.02-1.00 rag/ml respectively. Coefficient of variation
was 7%. At 0.7 mg/ml the coefficient of variation was 1% for DMAP 
and at 1.00 rag/ml AP, the value was 2%. Typical calibration curves 
for DMAP and AP in the acid extract of 10,000 g liver fraction are 
given in fig. 2.10.6 and 2.10.7. Recoveries of DMAP and AP were 
97.3+2.8 % and 96.5_+3.2% (mean+SD, n=4) respectively.









Results are expressed where indicated as the mean +_ standard 
deviation (SD). Further statistical analysis was performed using 
the computer statistical package, Instat. Statistical difference 
was determined using the Student's t-test (two-tailed, paired) and 
the degree of association or correlation assessed using Pearson's 
correlation coefficient (or product moment correlation 
coefficient). Statistical significance was taken at the 5% 
level.
CHAPTER THREE
RESULTS OF QUANTITATIVE STUDIES BY SPECTROPHOTOMETRY,
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND 
PROTON NUCLEAR MAGNETIC RESONANCE
Quantitative studies by proton nuclear magnetic resonance (^H
NMR) have been undertaken using four model drugs, i.e. aspirin
(ASA), paracetamol (P), acemetacin (ACE) and D-penicillamine (PSH). 
In the case of aspirin and paracetamol, the ^H NMR method was 
compared to the more conventional methods of visible 
spectrophotometry (SPEC) and high performance liquid chromatography 
(HPLC).
3.1 COMPARATIVE STUDIES OF ASPIRIN
In the present study, urinary excretion of aspirin (ASA) and
its metabolites following intentional aspirin overdose has been
analysed by visible spectrophotometry, high performance liquid 
chromatography and proton nuclear magnetic resonance. The 
following metabolites were analysed: salicylic acid (SA),
salicyluric acid (SUA), gentisic acid (GA), sal icy1 phenolic 
glucuronide (SPG) and salicyl acyl glucuronide (SAG). The results 
obtained from the three methods were compared.
3.1.1 QUANTITATIVE ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE
NMR) SPECTROSCOPY
Fig. 3.1.1 shows a typical 400 MHz spectrum of intact urine 
from a normal human subject after accumulation of 48 FID's obtained 
within 5 min. The metabolite resonances were identified by making 
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Fig. 3.1.1 400 MHz NMR spectrum of normal human urine containing 10% of H2°* Accumulati°n 48 FIDs at 24°C, using a
60 pulse, 5 s Interval between pulses (PD), and 16 K data points. The water resonance was suppressed by 
hanogated secondary irradiation. An exponential function corresponding to a 1-Hz line broadening was 
applied. Abbreviations for peak assignments are given in table 3.1.1. DSS = 
2,2-dimethyl-2-silapentane-5-sulphonate as reference; N-Me = methyl resonances from choline head group.
O O
O O
Table 3.1.1 Structures and 400 MBz H NMR chemical shifts of some urinary 
endogenous metabolites.
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Compound Abbr ev. Structure
1 a
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a As measured frcm fig. 3.1.2 for normal human urine at pH 5 (s = singlet, 
d = doublet, t = triplet, dd = doublet of doublets, AB = 2nd - order spin 
system, ABX = AB part of ABX spin system). Value depends on pH.
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chemical shifts, peak intensities and characteristic coupling 
constants. Table 3.1.1 gives the structures and NMR chemical 
shifts of major endogenous metabolites in urine, referenced to the 
methyl signal of 2,2-dimethyl-2-silapentane-5-sulphonate (DSS). 
Aspirin metabolites, such as SA, SUA and GA, spiked into the human 
urine gave the chemical shift and coupling constant values shown in 
table 3.1.2. The ASA metabolites could be detected in the 400 MHz 
spectrum of a urine sample frcm a patient who had taken an overdose 
of ASA (fig. 3.1.2). However, their signals extensively overlapped 
with endogenous components and no suitable resonances could be 
quantified, therefore NMR analysis was not pursued further.
Table 3.1.2 Structures, 400 MHz NMR chemical shifts and coupling 
constants of aspirin metabolites in human urine
OH




Salicylic acid SA R=-C00H Ha
= 6.95 (d) Jab =7.5
R =-H Hb
= 7.46 (t) Jac = 1.9
Z
Hc = 6.97 (t)
Hd = 7.82 (d)
Salicyluric acid SUA R =-C0NHCH®C00H
r *=-h 2 Ha = 6.76 (d) J ab = 7.5Z
Hb = 7.31 (t) Jac = 1.9
Hc = 6.64 (t)
Hd = 7.81 (d)
He = 4.00 (s)
Gentisic acid GA R =-C00H Ha = 6.84 (d) Jab = 8.5
R =-0H Hb = 6.99 (dd) Jbc =3.0z
H a 7.30 (d)
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Fig. 3.1.2 400MHz NMR SPECTRUM OF A URINE SAMPLE FROM A PATIENT WHO HAD TAKEN ASPIRIN OVERDOSE. CONDITIONS FOR NMR 
ARE AS DESCRIBED IN FIG. 3.1.1 (B is an expansion of part of the spectrum given under 'A')
>o
3.1.2 QUANTITATIVE ANALYSIS BY VISIBLE SPECTROPHOTOMETRY (SPEC)
Metabolite concentrations were calculated from calibration 
curves constructed for SA, SUA and GA (see section 2.8) based on 
the visible absorptions of each metabolite in SPEC. Measurements 
of SPG and SAG were obtained after their conversion to SA by enzyme 
hydrolysis ( (3 -glucuronidase) and sodium hydroxide (NaOH) 
respectively, which when added to the urine samples resulted in the 
disappearance of SPG and SAG in HPLC chromatograms. Results are 
presented separately for each individual patient since the dose 
taken and the times of urine collections varied widely between the 
patients. Individual results and clinical details are given in 
tables 3.1.3-3.1.6 and are shown graphically in fig. 3.1.3 and 
3.1.4. The results of concentration measurements of aspirin 
metabolites are shown in tables 3.1.7 - 3.1.9.
3.1.3 QUANTITATIVE ANALYSIS BY HIGH PERFORMANCE LIQUID 
CHRQMATGRAPHY (HPLC)
ASA metabolites were identified on the basis of their 
retention times compared to standard metabolites, i.e. 2.6, 3.5,
4.1 and 7.6 min for GA, SUA, internal standard (0-anisic acid, AA) 
and SA respectively, under the conditions described in section 2.9. 
Individual results and clinical details are given in tables 
3.1.3-3.1.6 and are shown graphically in fig. 3.1.3 and 3.1.4. The 
results of concentration measurements of aspirin metabolites are 
shown in tables 3.1.7 - 3.1.9.
Table 3.1.3 Clinical events and mg of urinary aspirin metabolites excreted from a patient (Al, male 21 yr)
after aspirin overdose following treatment with glycine.
Volume mg excreted of SA and
a
its metabolites
Time Event of urine HPLC SPEC
h (ml) SA SUA GA SA SUA GA SPG SAG
18.00 Estimated time of 100 tablets of
h aspirin ingested
18.00 Admitted to Casualty Dept. 
Plasma salicylate 400 ug/ml
19.00 Admitted to C.P.U.
Dextrose administered (1000 ml)
20.15 Glycine administered (8g)
20.30 Plasma salicylate 360 ug/ml
22.15 Glycine administered(4g) 700 230.9 246 .8 122.1 210.6 27 9.2 172.3 98.4 33.1
22.30 Plasma salicylate 3 20 ug/ml .
23.00 Glycine administered (4g) 710 67.5 82.6 15.7 49.0 102.4 43.3 31.1 9.0
00.15 Glycine administered (4g)
02.15 Glycine administered (4g)
04.15 Dextrose administered (1000 ml) 
Glycine administered (4g)
05.15 Glycine administered (4g)
08.15 Glycine administered (4g)
08.45 700 90.7 387.2 65.0 93.8 448.2 66.6 170.3 63.8
10.00 750 26.1 183.4 17.5 24.8 218.6 45.0 81.3 30.2
10.15 Glycine administered (4g)
13.00 750 26.7 299.2 29.7 22.6 349.1 57.0 137.5 51.0
13.15 Glycine administered (4g)
17.00 600 40.9 143.8 1.1 21.6 175.2 19.8 64.3 16.6
23.30 540 43.6 485.5 23.8 21.6 463.0 31.3 74.1 15.5
Total of individual metabolites (mg) 
c (%)
526.4 1828.5 274.9 444.0 2035.7 435.3 657.0 219.2
20.0 69.5 10.5 11.7 53.7 11.5 17.3 5.8
Total recovery (mg) 2629.8 3791.2
a
Expressed as mg of SA equivalents.
24 h after the previous time.c
Based on total SA, SUA and GA in HELCy and SA, SUA, GA, SPG and SAG in SPEC.
Table 3.1.4 Clinical events and mg of urinary aspirin metabolites excreted from a patient (A2, male 21 yr)







mg excreted of SA and its metabolites 
HPLC SPEC
SA SUA GA SA SUA GA SPG SAG
16.30 100 tablets of aspirin ingested
17.45 Admitted to Casulaity Dept.
18.00 Gastric wash-out
21.00 Admitted to C.P.U.
02.30 Plasma salicylate 410 ug/ml
03.30 5% Dextrose administered (500 ml) 
Glycine administered (8g) h
03.45 850 254.0 298.7 NM 170.2 374.6 25.0 110.5 32.3
22.30 Plasma salicylate 320 ug/ml
05.30 Glycine administered (4g)
07.15 Glycine administered (4g) 1650 837.5 250.6 42.7 794.8 243.7 83.2 21.4 107.2
07.30 Glycine administered (4g)
08.30 Plasma salicylate 36 8 ug/ml
09.30 Glycine administered (4g)
11.15 750 116.6 127.3 NM 90.8 132.8 23.8 45.7 49.5
11.30 Glycine administered (4g)
13.30 5% Dextrose administered (1000ml) 
Glycine administered (4g)
870 133.0 217.5 20.0 98.8 261.6 68.2 146.2 59.2
15.30 Glycine administered (4g)
16.30 Plasma salicylate 280 ug/ml 9 80 113.0 165.4 14.9 88.9 150.5 66.7 159.7 67.6
17.30 Glycine administered (4g)
18.10 400 43.6 131.7 20.6 42.6 158.0 37.2 80.0 28.8
19.30 Glycine administered (4g)
23.30 580 32.0 4 86.7 28.4 22.0 537.4 40.6 235.5 99.2
11.55 580 25.9 895.8 14.7 27.2 946.8 37.9 364.2 142.1
Total of individual metabolites (mg)
<%)
1555.6 2573.7 141.3 1335.3 2805.4 382.6 1163.2 585.9
36.4 60.3 3.3 21.3 44.7 6.1 18.5 9.4
Total recovery (mg) 4270.6 6272.4
a
b Expressed as mg of SA equivalents.
c M e a egSUS8tflesk? SA, SUA, GA, SPG and SAG in SPEC.
C O
Table 3.1.5 Clinical events and mg of urinary aspirin metabolites excreted from a patient (A3, female 37 yr)







mg excreted of SA and its metabolites 
HPLC SPEC
SA SUA GA SA SUA GA SPG SAG
18.00 Estimated time overdose asprin 
ingested.
07.45 Admitted to Casulaity Dept.
08.00 Gastric wash-out
10.00 Admitted to C.P.U.
Plasma salicylate 500 ug/ml
10.25 5% Dextrose administered (1000 ml)
10.30 Glycine administered (8g)
11.00 500 243.4 522.8 37.6 211.1 580.1 68.8 277.1 209.9
12.30 Glycine administered (4g)
13.00 600 36.2 121.8 63.1 44.2 154.5 85.3 83.0 35.3
14.00 Plasma salicylate 320 ug/ml
14.30 Glycine administered (4g)
15.30 750 28.0 99.5 75.0 43.2 128.5 91.9 57.9 22.5
16.30 Glycine administered (4g)
17.00 700 10.4 209.6 168.5 21.2 244.3 195.1 135.6 71.8
18.30 Glycine administered (4g)
22.20 Glycine adminsitered (4g)
22.30 200 6.1 155.1 73.9 10.6 191.9 73.5 88.5 48.2
24.10 Glycine administered (4g)
10.00 600 26.9 632.2 129.3 38.4 712.5 142.7 279.5 125.9
Total of individual metabolites (mgl 
b (%)
351.0 1741.0 547.4 368.7 2011.8 657.3 921.6 513.6
13.3 66.0 20.7 8.2 45.0 14.7 20.6 11.5
Total recovery (mg) 2639.4 4473.0
a
k Expressed as mg of SA equivalents.
Based on total SA, SUA and GA in HPLC; and SA, SUA, GA, SPG and SAG in SPEC.
Table 3.1.6 Clinical events and mg of urinary aspirin metabolites excreted fran a patient (A4, male 45 yr)


















75 tablets of aspirin ingested 
Admitted to Casualty Dept.
Gastric wash-out 
Admitted to C.P.U.
Plasma salicylate 600 ug/ml 
5% Dextrose administered (1000 ml) 
Glycine administered (8g)
5% Dextrose administered (500ml) 
Glycine administered(4g)
Plasma salicylate 660 ug/ml 750 1210.6 227.4 76.0 1100.0 230.9 92.7 96.8 NDb
02.30
03.00
5% Dextrose administered (1000 ml) 
Glycine administered (4g)
1.26% Bicarbonate administered 
(500 ml) 550 44.1 107.1 43.5 447.3 108.3 48.7 1.3 ND
04.30 Glycine administered (4g) 875 225.7 27.5 NM° 195.1 57.7 40.9 14.1 ND
05.00
1.26% Bicarbonate adminitered 
(500 ml)




5% Dextrose administered (1000 ml) 
Glycine administered (4g)
Plasma salicylate 450 ug/ml




Glycine administered (4g) 
Glycine administered (4g)




1580 209.7 65.7 NM 154.0 104.3 88.5 96.5 27.3
19.10 720 78.5 73.4 29.8 58.8 93.5 39.9 46.5 8.3
06.00 1565 167.9 712.9 146.6 93.9 863.9 165.7 369.8 185.8
Total of individual metabolites (mg)
a (%)recovery (mg)






28.9 10.5 12.0 3.5
a
b Expressed as mg of SA equivalents.
^ meaiurlcl* due to very low concentration.
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Fig. 3.1.3 Plots of cumulative recovery of aspirin metabolites as a function of time in the urine of two patients 
measured by HPLC and SPEC. Patient events are given in tables 3.1.3 and 3.1.4 . Arrows indicate 
glycine administration. □ =  salicylic acid; V = gentisic acid; A =  salicyluric acid;
■ = salicyl phenolic glucuronide; A =  salicyl acyl glucuronide.
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Fig. 3.1.4 Plots of cumulative recovery of aspirin metabolites as a function of time in the urine of two 
patients measured by HPLC and SPEC. Patient events are given in tables 3.1.5 and 3.1.6. Arrows 
indicate the administration of gycine  )^or bicarbonate ► .  □ = salicylic acid; * = gentisic
acid; a = salicyluric acid; ■ = salycil phenolic glucuronide; a = salicyl acyl glucuronide. OCO
Table 3-1-7 Quantitation of aspirin metabolite, salicylic acid (SA) in









% Diff erenc* 
SPEC/HPLC
Al 0 - 3.15 2.56 2.89 112.9
male 3.15- 4.00 0.84 1.04 123.8
2 1  yr 4.00-13.45 4.00 4.63 115.7
13.45-15.00 1.77 2 . 1 1 119.2
15.00-18.00 2.89 3.37 116.6
18.00-22.00 1.74 2 . 1 1 1 2 1 . 2
k 22.00-28.30 6.51 6 . 2 1 95.4
Pearson's r= 0.990 (PC0.001)
Student's t=-6.90 (P<0.002)
A2 0 - 6.45 2.54 3.19 125.6
male 6.45-10.15 1 . 1 0 1.07 97.3
2 1  yr 10.15-14.45 1.23 1.28 104.1
14.45-16.30 1.81 2.81 155.2
16.30-19.30 1 . 2 2 1 . 1 1 91.0
19.30-21.10 2.38 2 . 8 6 1 2 0 . 2
21.10-26.30 6.07 6.71 110.5
26.30-38.55 11.18 11.82 105.7
Pearson's r= 0.998 (PC0.001)
Student's t= 3.00 (P<0.002)
A3 0 - 1 . 0 0 6 . 8 8 7.64 1 1 1 . 0
female 1.00- 3.00 1.47 1 . 8 6 126.5
37 yr 3.00- 5.30 0.96 1.24 129.2
5.30- 7.00 2.16 2.53 117.1
7.00-12.30 5.61 6.94 123.7
12.30-24.00 7.63 8.59 1 1 2 . 6
Pearson's r= 0.997 (P<0.001)
Student's t= 4.11 (NS)
A4 0 - 4.00 2.19 2.23 1 0 1 . 8
male 4.00- 6.00 1.41 1.43 101.4
45 yr 6.00- 7.30 0 . 2 2 0.48 218.2
7.30- 8.00 0.64 0.51 79.7
8.00-13.00 0.35 0.59 168.6
13.00-15.45 0.44 0 . 6 6 150.0
15.45-20.00 0.30 0.48 160.0
2 0 .0 0 -2 2 . 1 0 0.74 0.94 127.0
22.10-33.00 3.29 4.00 1 2 1 . 6
Pearson's r= 0.9 85 (P<0.001)
Student's t=-2.47 (P<0.05)
a
bAdmission time to C.P.U. is taken as zero time 
cHPLC versus SPEC data (mean value used)
Paired t-test, comparisons with HPLC data 
NS = not significant
Table 3.1.8 Quantitation of aspirin metabolite, salicyluric acid
(SOA) in urine samples from aspirin overdose patients,










Al 0 - 3.15 2.39 2.18 191.2
male 3.15- 4.00 0.69 0.50 72.5
2 1  yr 4.00-13.45 0.94 0.97 103.2
13.45-15.00 0.25 0.24 96.0
15.00-18.00 0.26 0 . 2 2 84.6
18.00-22.00 0.49 0.26 53.1
b 22.00-28.30 0.59 0.29 49.1
Pearson's r= 0.9 8 6 (PC0.001)
Student's t=-2.89 (P<0.05)
A2 0 - 6.45 2.16 1.45 67.1
mal e 6.45-10.15 3.68 3 .49 94.8
2 1  yr 10.15-14.45 1 . 1 2 0 . 8 8 78.6
14.45-16.30 1 . 1 1 0.82 73.9
16.30-19.30 0.83 0 . 6 6 79.5
19.30-21.10 0.79 0.77 97.5
21.10-26.30 0.40 0.27 67.5
26.30-38.55 0.33 0.34 103.0
Pearson's r= 0.981 (PCO.OOl)
Student's t=-2.72 (P<0.05)
A3 0 - 1 . 0 0 3.20 2.78 8 6  .9
female 1.00- 3.00 0.43 0.54 125.6
37 yr 3.00- 5.30 0.27 0.42 155.5
5.30- 7.00 0 . 1 1 0 . 2 2 2 0 0 . 0
7.00-12.30 0 . 2 2 0.38 172.7
12.30-24.00 0.33 0.46 13 9.4
Pearson's r= 0.999 (P<O.OOl)
Student's t= 0.44 (NS)
A4 0 - 4.00 11.69 10.62 90.8
mal e 4.00- 6.00 5.84 5.89 1 0 0 . 8
45 yr 6.00- 7.30 1.87 1.61 8 6 . 1
7.30- 8.00 3.38 3.00 88.7
8.00-13.00 1.64 1.33 81.1
13.00-15.45 1 . 1 0 0.46 41.8
15.45-20.00 0.96 0.70 72.9
2 0 .0 0 -2 2 . 1 0 0.79 0.59 62.0
22.10-33.00 0.77 0.43 55.8
Pearson's r= 0.992 (P<O.OOl)
Student's t=-3. 6 0 (P<O.Ol)
a
^Admission time to C.P.U. is taken as zero time 
HPLC versus SPEC data (mean value used)
Paired t-test, comparisons with HPLC data 
NS = not significant
Table 3.1.9 Quantitation of aspirin metabolite, gentisic acid (SA) in urine










Al 0 - 3.15 1.26 1.78 141.3
male 3.15- 4.00 0.16 0.44 27 5.0
2 1  yr 4.00-13.45 0.67 0.69 103.0
13.45-15.00 0.17 0.43 252.9
15.00-18.00 0.29 0.55 189.6
18.00-22.00 0 . 0 1 0.24 2400.0
k 22.00-28.30 0.32 0.42 131.2
Pearson* s r= 0.961 (P<0.01)
Student's t= 3.97 (P<0.01)
A2 0 - 6.45 NM 0 . 2 1 _
male 6.45-10.15 0.19 0.36 189.5
2 1  yr 10.15-14.45 NM 0.23 -
14.45-16.30 0.17 0.56 329.4
16.30-19.30 0 . 1 1 0.49 445.4
19.30-21.10 0.37 0.67 181.1
21.10-26.30 0.35 0.51 145.7
26.30-38.55 0.18 0.47 261.1
Pearson's r= 0.549 (NS)
Student's t= 6.70 (P<0.01)
A3 0 - 1 . 0 0 0.49 0.90 183.7
female 1.00- 3.00 0.76 1.03 135.5
37 yr 3.00- 5.30 0.72 0 . 8 8 1 2 2 . 2
5.30- 7.00 1.74 2 . 0 2 116.1
7 .00-12.30 2.67 2 . 6 6 99.6
12.30-24.00 1.56 1.72 110.3
Pearson* s r= 0.992 (P<0.001)
Student's t= 3.59 (P<0.02)
A4 0 - 4.00 0.73 0.90 123.3
male 4.00- 6.00 0.57 0.64 1 1 2 . 2
45 yr 6.00- 7.30 NM 0.34 -
7.30- 8.00 0.48 0.50 104.2
8.00-13.00 0 . 2 2 0.25 113.6
13.00-15.45 0.26 0.34 130.8
15.45-20.00 NM 0.40 -
2 0 .0 0 -2 2 . 1 0 0.30 0.40 160.0
22.10-33.00 0 . 6 8 0.77 113.2
Pearson's r= 0.9 84 (P<0.001)
Student's t= 4.17 (P<0.01)
a
.Admission time to C.P.U. is taken as zero timeD
HPLC versus SPEC data (mean value used)c
Paired t-test, comparisons with HPLC data 
NM = not measured, NS = not significant
3.1.4 COMPARISON OF RESULTS
Due to the lack of NMR results for ASA metabolites, only HPLC 
and SPEC data are discussed. The results comparing concentration 
measurements of ASA metabolites by HPLC and SPEC are shown in table 
3.1.7-3.1.9. Statistical analysis of the data (table 3.1.7-3.1.9) 
by Pearson's correlation indicate that the concentrations of SA and 
SUA measured by SPEC were in good correlation (r>0.98, P<0.001)
with those obtained on the same samples by HPLC. The
concentrations of GA measured by SPEC were found to be in good 
correlation in three patients (r>0.9 8, P<0.001 for A3 and A4, 
r>0.96, P<0.01 for Al), but shew no correlation in one patient 
(r=0.5486 for A2) with those by HPLC. Student's t-test for paired 
samples comparing SPEC results to those of HPLC showed only one 
result with no significant difference between the two methods (SA 
frcm A3). SA concentrations measured by SPEC in 3 patients (Al, A2 
and A4) were found to be significantly lower (P<0.05, P<0.05 and 
P<0.01 respectively) than those by HPLC. SUA and GA concentrations 
measured by SPEC were significantly greater than those by HPLC in 
all patients, Al, A2, A3 and A4 (with P<0.01, P<0.002, P<0.02 and
P<0. 01 respectively for SA and P<0.002, P<0.02, P<0.01 and P<0.05 
respectively for SUA).
It can be seen from tables 3.1.3-3.1.6 that the major 
metabolite recovered in patients receiving glycine treatment was 
SUA, measured by both HPLC or SPEC methods. However, SA appeared 
to be the major metabolite in a patient (A3) receiving glycine and 
bicarbonate treatment (table 3.1.6). The SPEC data shows 
approximately 45-54% SUA and 8-22% SA excretion in three patients 
(Al, A2 and A3) and 29% SUA and 45% SA excretion in one patient 
(A3). The ratios of SUA/SA, GA/SA and (SPG+SAG)/SA are also
Table 3.1.10 Urinary aspirin metabolites ratios to SA excreted in urine from patients
taken aspirin overdose measured by HPLC and visible spectrophotometry
Time of
Patient Collection,a _________ HPLC_______    SPEC________________
h.min (SUA)/(SA) (GA)/(SA) (SUA)/(SA) (GA)/(SA) (SPG+SAG)/(SA)
0-3.15 1.069 0.529 1.326 0.818 0.624
3.15-4.00 1.224 0.233 2.090 0.884 0.818
4.00-13.45 4.269 0.717 4.778 0.710 2.4 96
13.4 5-15.00 7.027 0.670 8.814 1.814 4.496
15.00-18.00 11.206 1 . 1 1 2 15.447 2.522 8.341
18.00-22.00 3.516 0.027 8 . 1 1 1 0.917 3.745
22.00-28.30 11.135 0.546 21.435 1.449 4.14 8
0-6.45 1.176 _ 2 . 2 0 1 0.147 0.839
6.45-10.15 0.299 0.051 0.307 0.105 0.162
10.15-14.45 1.092 - 1.462 0.26 2 1.04 8
14.45-16.30 1.635 0.150 2.648 0.690 2.07 9
16.30-19.30 1.464 0.132 1.693 0.750 2.557
19.30-21.10 3.021 0.472 3.709 0.873 2.554
21.10-26.30 15.209 0.887 24.43 1.845 15.214
26.30-38.55 34.587 0.568 34.81 1.393 18.614
0 -1 . 0 0 2.14 8 0.154 2.748 0.3 26 2.307
1.00-3.00 3.365 1.743 3.495 1.930 2.676
3.00-5.30 3.554 2.679 2.974 2.127 1.861
5.30-7.00 20.154 16.202 11.524 9.203 9.783
7.00-12.30 25.426 12.115 18.104 6 .934 12.896
12.30-24.00 23.502 4.807 18.555 3.716 10.557
0-4. 0 0 0.188 0.06 3 0 . 2 1 0 0.084 0.088
4.0 0 -6 . 0 0 0.241 0.09 8 0.242 0.109 0.003
6.00-7.30 0 . 1 2 2 - 0.296 0 . 2 1 0 0.07 2
7.30-8.00 0.189 0.143 0.170 0.167 0.07 8
8.00-13.00 0 . 2 1 1 0.135 0.447 0.183 0.138
13.00-15.4 5 0.398 0.237 1.422 0.738 0.612
15.45-20.00 0.313 - 0.677 0.575 0.627
2 0 .0 0 -2 2 . 1 0 0.935 0.3 80 1.590 0.679 0.791
22.10-33.00 4.246 0.873 9.200 1.765 3.938
calculated for each urine samples by HPLC and SPEC, as shown in 
table. 3.1.10.
3.2 COMPARATIVE STUDIES OF PARACETAMOL
Urinary excretion of paracetamol (P) and its metabolites frcm 
the patients after intentional P overdose has been analysed by 
SPEC, HPLC and ^H NMR. The following metabolites were analysed: P,
paracetamol glucuronide (PG) and paracetamol sulphate (PS) by the 
three methods, as well as paracetamol mercapturic acid (PMA) by ^H 
NMR. The results obtained were compared.
3.2.1 QUANTITATIVE ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE 
(XH NMR) SPECTROSCOPY
Numerous endogenous metabolites, including creatinine,
citrate, hippurate, ketone bodies, and various amino acids, have
been identified in 4 00 MHz ^H NMR spectra of intact human urine
(fig. 3.1.1, table 3.1.1). Fig. 3.2.1 and 3.2.2 show typical 400
MHz spectra for urine from a patient who had taken P overdose,
referenced to the methyl resonance of valine ( 5 = 1 ppm). A
reasonable signal-to-noise ratio was usually achieved after 64-128
accumulations, depending on the concentrations of the metabolites.
Therefore, the spectrum of one sample could be obtained within 5-10
min using the conditions described in section 2.7.3 and
2.10.1. Table 3.2.1 shows the structure, chemical shifts and
coupling constants of P and its metabolites based on standard
104additions and comparison with data of Bales et al . Results are 
presented separately for each individual patient as the dose was
unknown and the times of urine collections varied for each
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Fig. 3.2.1 400MHz NMR SPECTRUM OF A URINE SAMPLE FROM A PATIENT WHO HAD TAKEN PARACETAMOL OVERDOSE AND HAD BEEN • 
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Fig. 3.2.2. AROMATIC REGION OF 400 MHz NMR SPECTRUM OF A URINE SAMPLE FROM A PATIENT WHO HAD TAKEN
PARACETAMOL OVERDOSE AND HAD BEEN TREATED WITH PARVOLEX. CONDITIONS AS DESCRIBED IN Fig 3.1.1.
Table 3.2.1 Structures, 400 MHz NMR chemical shifts and coupling
constants of paracetamol and its metabolites in human urine
HNCOCH
OR.
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Jab = 8.4 
Jac = 1.9
fSd =a£oublet, dd = doublet of doublets, AB = second order AB
tables 3.2.2-3.2.8 (NMR results are not available in table 3.2.7 
and 3.2.8) and are shewn graphically in fig. 3.2.3 - 3.2.5. The 
concentrations of P and its metabolites are shown in table 3.2.9 -
3.2.11. Quantification of P,PG, PS and PAC by 400 MHz NMR was 
based on integrations of their acetyl methyl singlets ( S = 2.14,
2.16, 2.17 and 1.85 ppm respectively) compared to the methyl
resonance of added valine (S= 1.0 ppm) or DSS (6 = 0 ppm). The
reliability of the quantification method was verified by linear 
correlation between the integrations within the concentration range 
and good recoveries (see section 2.10.1.4).
P and its metabolites were monitored by 400 MHz ^H NMR. It can 
be seen from fig. 3.2.3 - 3.2.5 that P, PG and PS were high
initially, followed by an increase in PG and PS after treatment 
with methionine or Parvolex (N-acetylcysteine). *H NMR spectra of 
urine from patients showed P, PG, PS, PMA and methoxy paracetamol 
(PM) resonances in earlier samples, followed by decreases of P and 
PM, increases of PG and PS and appearance of paracetmaol cysteine 
(PC). Table 3.2.12 lists the structures and chemical shifts of 
methionine and parvolex (N-acetylcysteine) in urine. Free 
methionine was not observed in the spectra, but N-acetyl cysteine 
resonances were detected, although no attempt was made to quantify 
them. Also, endogeneous metabolites were monitored to observe 
alterations frcm the normal pattern which might possibly occur. In 
most of ^H NMR spectra of urine frcm patients taken P overdose, 
pyruvate and lactate resonances increased (see fig. 3.2.1 and 
3.2.2), whilst hippurate, acetoacetate, /3-hydroxybutyrate, glycine, 
L-alanine and citrate appeared to vary. In one patient, L-alanine 
completely disappeared and pyruvate increased enormously.
Table 3.2.2 Clinical events and mg of urinary paracetamol and its metabolites excreted frcm a patient (PI, male,







P and its metabolites 
NMR SPEC
ml P PG PS P PG PS PMA P PG PS
02.00 4 8 tablets of paracetamol 
ingested
11.30 Admitted to Casualty Dept.
13.00 Gatric wash-out
Plasma paracetamol (0.26 mg/ml)
14.00 Admitted to C.P.U.
14.40 5% Dextrose administered 
(700 ml)
Parvolex administered (8.7 g)
14.50 Parvolex administered (2.9g)
17.30 200 359.8 1785.4 413.8 298.2 1747.8 258.6 50.2 57 3.4 1721.4 258.6
19.00 5% Dextrose administered 
(1000 ml)
Parvolex administered (5.8g)
02.30 47 5 288.3 3363.0 1271.1 315.4 3235.2 882.1 179.1 893.5 3339.7 882.1
08.45 500 59.5 1101.5 557.0 67.5
NM
1079.5 490.5 128.5 318.0 1527.0 490.5
11.30 650 18.2 155.3 72.8 111.1 39.6 15.6 53.9 117.6 39.6
01.30 2150 32.2 326.8 219.3 NM 268.7 86.0 43.0 361.2 421.4 86 .0
Total of individual metabolites (mg) 
c (%)
758.0 6732.0 2534.0 681.1 6442.3 17 56 .8 416.4 2200.0 7127.1 17 56.8
7.6 67.1 25.3 7.3 69.3 18.9 4.5 19.8 64.3 15.9
Total recovery (mg) 10024.0 929.6 11083.9
a
Expressed as mg of P equivalents
NM = not measured
Based! on total P, PG and PS in HPLC and :SPEC, and P, PG, PS and PMA in NMR '
Table 3.2.3 Clinical events and mg of urinary paracetamol and Its metabolites excreted frcm a patient (P2,
female 27 yr) after paracetamol overdose follcwing treatment with methionine
a
Time Volume mg excreted of P and its metabolites
h Event of urine, ______ HPLC_______   NMR___________________   SPEC
ml P PG PS P PG PS PMA P PG PS
23.00 4 9 tablets of paracetamol 
b ingested




03.00 Plasma paracetamol 
(0.046 mg/ml)
03.0 325 95.2 791.0 318.8 95.5 671.1 309.4 18.5 265.8 877.8 347.4
05.00 Methionine administered 
(2.5g)
08.40 160 5.3 55.0 44.3 NM 51.4 38.4 4.5 31.2 71.7 13.9
12.30 100 2.2 37.0 30.1 NM 34.5 30.2 6.1 30.4 36.5 48.0
Total of individual metabolites (mgl 102.7 883.0 393.2 95.5 757.0 378.0 29.1 327.4 986.0 409.3
(%) 7.5 64.0 28.5 7.6 60.1 30.0 2.3 19.0 57.2 23.8
Total recovery (mg) 1378.9 1259.6 1722.7
a
^Ex^ressed as mg of paracetamol equivalents 
25 h 10 min after the previous timec
NM = not measured
Based on total P, PG and PS in HPLC or SPEC and P, PG, PS and PMA in NMR
Table 3.2.4 Clinical events and mg of urinary paracetamol and Its metabolites excreted frcm a patient (P3,
male 43 yr) after paracetamol overdose following treatment with methionine and Parvolex
a
Time Volume mg excreted of P and its metabolites
h Event of urine, ______ HPLC_______   NMR____________________   SPEC_______
ml P PG PS P PG PS PMA P PG PS
unknown Time of overdose
paracetamol ingested
17.30 Admitted to Casualty Dept.
18.00 Gatric wash-out
19.00 Admitted to C.P.U. 
Methionine administered










5% Dextrose administered 
(700 ml)
Parvolex administered (9.9g) 
Parvolex administered (3.3g)
400





386.1 632.7 204.3 331.2 562.5 180.9 18.9
168.4 511.2 217.6 177.6 458.8 180.0 24.4
436.5 4473.0 2718.0 381.6 3997.8 2072.7 206.1
141.0 2493.4 1061.4 160.5 2295.1 1170.6 118.9
447.3 774.9 ND
212.4 455.2 135.2
1031.4 4278.6 2633.4 
551.8 2607.8 1559.3
Total of individual metabolites (mg)
(%>
Total recovery (mg)
1132.0 8110.3 4200.9 1050.9 7314.2 3604.2 368.3 2242.5




^Expressed as mg of paracetamol equivalents 
^ND = not detected
'Based on total P, PG and PS in HPLC or SPEC, and P, PG, PS and PMA in NMR
Table 3.2.5 Clinical events and mg of urinary paracetamol and Its metabolites excreted frcm a patient (P4,
female 74 yr) after paracetamol overdose follcwlng treatment with methionine and Parvolex
a
Time Volume mg excreted of P and its metabolites
h Event of urine, ______ HPLC_______   NMR____________________   SPEC_
ml P PG PS P PG PS PMA P PG PS
unknown Time of overdose
paracetamol ingested 
11.20 Admitted to Casualty Dept. 
12.50 Gatric wash-out
19.00 Admitted to C.P.U.




14.00 5% Dextrose administered 
(800 ml)
14.20 Parvolex administered (10.5g)
14.35 Parvolex administered (3.5g)
18.00 Parvolex administered (7.Og)
22.0 375 168.7 2076.0
00.20 450 52.6 713.2
02.00 100 5.7 96.7
08.00 56 5 46.9 682.5
12.50 250 42.0 365.5
15.30 125 3.1 54.5
825.4 168.7 2077.1 844.5 52.5 187.5 2071.5 844.5
227 .2 60.7 577.3 318.1 37.3 76.9 715.5 406.3
23.9 8f>9 61.8 21.9 2.4 8.7 91.8 111.7
440.7 NM 613.0 342.4 22.6 54.8 541.3 895.5
95.7 NM 506.5 101.2 14.0 60.2 329.2 511.0
16.5 NM 39.0 12.0 4.0 17.2 49.4 159.6
Total of individual metabolites (mg^ 319.0 3988.4 1629.4 238.3 3874.1 1640.1 132.8 405.3 3798.7 2928.6
(%) 5.4 67.2 27.4 65.8 27.9 2.3 5.7 0.8 52.1 41.1
Total recovery (mg) 5936.8 5885.9 7132.6
a
^Expressed as mg Of paracetamol equivalents 
NM = not measuredc
Based on total P, PG and PS in HPLC or SPEC, and P, PG, PS and PMA in NMR
Table 3.2.6 Clinical events and mg of urinary paracetamol and Its metabolites excreted from a patient (P5,
female) after paracetamol overdose following treatment with methionine
a
Time Volume rag excreted of P and its metabolites
h Event of urine,__ HPLC__________________   NMR_SPEC________
ml P PG PS P PG PS PMA P PG PS
unknown 20 tablets of Panadol
ingested
12.30 Admitted to Casualty Dept.
13.00 Gatric wash-out
14.00 Admitted to C.P.U.
19.00 Methionine administered 
(2.5 mg)
19.30 550 155.1 1959.1 529.6 154.0 1947.0 509.8 78.6 199.6 1898.6 968.0
22.20 610 106.7 1107.8 119.6 1061.4 193.4 193.4 23.8 132.4 982.7 511.2
22.45 Methionine administered 
(2.5g)
02.45 Methionine administered 
(2.5g)
02.50 600 39.0 924.0 199.2 30.6 886.2 231.0 48.0 66.0 741.6 588.6
Total of individual metabolites (mgl 
b (%)
300.8 3990.9 948.4 304.2 3894.6 934.2 150.4 398.0 3622.9 2067.8
5.7 76.2 18.1 5.8 73.7 17.7 2.8 6.5 59.5 34.0
Total recovery (mg) 5240.1 5242.4 5283.4 6088.7
^Expressed as mg paracetamol equivalents
“Based on total P, PG and PS in HPLC or SPEC; and P, PG, PS and PMA in NMR
Table 3.2.7 Clinical events and mg of urinary paracetamol and Its metabolites excreted from a























24 tablets of paracetamol ingested 
Admitted to Casualty Department 
Gastric wash-out 
Admitted to C.P.U.
Methionine administered (2.5 g)








260 47.1 1125.5 362.2 269.9 1066.8 1388.9
13.30 200 20.2 475.8 142.6 122.6 435.8 395.8
Total of individual metabolites (mgl 
b (%)
recovery (mg)








k Expressed as mg of P equivalents 
Based on total P, PG and PS
Table 3.2.8 Clinical events and mg of urinary paracetamol and Its metabolites excreted from a





















20-24 tablets of paracetamol ingested 





20.00 Methionine administered (2.5g)




Methionine administered (2.5g) 
Methionine administered (2.5g)
100 73.8 233.4 539.8 97.6 225.5 596.9
07.00 100 16.5 311.2 100.1 62.0 365.9 199.4
Total
Total

















k Expressed as mg of P equivalents 
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F i g .  3 . 2 . 1 Plots of cumulative recovery of paracetamol metabolites as a function of time in the urine of 
two patients whose details and events are given in Tables 3.2.1 and 3.2.2 measured by HPLC,
SPEC , and NMR as described in the text. Arrows indicate administration of methionine— ► o r
N-acetylcysteine ► .  □ =  paracetamol; v =  paracetamol sulphate; A =  paracetamol glucuronide;







HPLC data —  
SPEC data--7000
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F i g .  3 . 2 . 2 Plots of cumulative recovery of paracetamol metabolites as a function of time in the urine of two 
patients whose details and events are given in Tables 3.2.3 and 3.2.4 measured by HPLC, SPEC, and 
NMR as described in the text. Arrows indicate administration of methionine— ►  or N-acetylcysteine 
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1 . 2 . 3
Hours a f t e r  admission „o u r s  after adlI,isslon
Plots of cumulative recovery of paracetamol metabolites as a fuction of time in the urine of three 
patients whose details and events are given in Tables 3.2.5 - 7 measured by HPLC, SPEC, and NMR as 
described in the text. Arrows indicate the administration of methionine.
□  = paracetamol; V =  paracetamol sulphate; A =  paracetamol glucuronide; ■ =  paracetamol N-acetylcysteine.
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Table 3.2.9 Quantitation of paracetamol (P) from patients after
paracetamol overdose, based on HPI.C, NMR and SPEC methods
Time of 







PI 0 -3.30 11.90+0.21 9. 8 6 +0 .3 0 18.96+0.53 82.9 159.3
male 3.30-12.30 4.01+0.09 4.39+0.38 12.44+0.14 109.5 310.2
30 yr 12.30-18.45 0.79+0.03 1.7 9+0.17 4.21+0.22 226.6 532.9
18.45-21.30 0.18+0.01 NM 0.55+0.03 - 305.5
2jL. 30-35.30 0 .1 0 +0 . 0 1 NM # 1 .1 1 +0 * 0 1 - 1 1 1 0 . 0
Pearson's r=0 .999 r=0.950
Student's t=-o.24(NS) t=2.53*
P2 0 - 2.15 1.94+0.01 1.94+0.0 9 5.41+0.13 1 0 0 . 0 27 8.9
female 2.15- 7.25 0 .2 2 +0 . 0 1 NM 1.29+0.01 - 586 .4
27 yr 7.25-11.15 0.14+0.01 NM 2 .0 1 +0 . 0 1 - 1435.7
Pearson's r=0.9 80(NS)
Student's t=3.03
P3 0 -2.25 2.84+0.04 2.43+0.06 3.29+0.05 85.6 115.8
male 2.25-4.50 2.78+0.01 2.94+0.09 3.51+0.43 105.8 126 .3
43 yr 4.50-14.40 3.21+0.0 2 2.80+0.10 7.58+0.26 87.2 236.1
14.40-23.40 1.43+0.08 1.63+0*09 5.62+0.13 114.0 393.0
Pearson's r=0.917 r=0 .03§( NS)
Student's t=-0 . 6  8 (NS) t=2.28
P4 0 - 8.45 2.98+0.01 2.98+0.09 3.31+0.07 1 0 0 . 0 1 1 1 . 1
female 8.45-11.05 0.77+0.01 0.89+0.0 2 1.13+0.01 115.6 146.7
74 yr 11.05-12.45 0.38+0.01 0.59+0.01 0.57+0.04 155.3 150.0
12.45-18.45 0.55+0.01 NM 0.64+0.03 - 116.4
18.45-23.35 1 .1 1 +0 . 0 1 NM 1.59+0.08 - 143.2
23.35-26.15 0.16+0.01 NM* 0.91+0*04 - 568.7
Pearson's r=0.999 r=0.97 ^
Student's t=0 (NS) t=3.93
P5 0 - 5.30 1 .8 6 +0 . 0 1 1.85+0.0 2 2.40+0.10 99.5 129.0
female 5.30- 8.20 1.16+0.01 1.30+0.01 1.43+0.10 1 1 2 . 1 123.3
8.20-12.50 0.43+0.01 0.34+0.01 0.73+0.01 79.1 169.8
Pearson's r=0.990(NS) r=0.99^(NS)
Student's t=0.16(NS) t=4.47
P6 0 - 4.30 3.22+0.02 4.0 2+0.51 124.8
female 4.30-10.00 0.64+0.003 1.56+0.25 243.7
35 yr 10.00-17.45 0.18+0.001 1.04+0.12 577.8
17.45-22.30 0 .1 0 +0 . 0 0 2 0.61+0*19 610.0
Pearson's r=0 .99£
Student's t=8.64
P7 0 - 0.45 0.7 8+0.01 1.18+0.01 151.3
female 0.45- 3.50 0.74+0.01 0.98+0.002 132.4




cAdmission time to C.P.U. is taken as zero time; HPLC versus NMR and SPEC 
Paired t-test, comparison with HPLC data;NM=not measured; = P<0.05
NS - not significant
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Table 3.2.10 Quantitation of paracetamol glucuronide (PG) from patients
after paracetamol overdose, based on HPLC, NMR and SPEC
Time of Concentration (mM) % Difference
Subject Collection PG NMR/HPLC SPEC/HPLC
h.min HPLC NMR SPEC
PI 0 - 3 . 3  0 59.05+0.35 57.81+2.72 56 .9 4j+2. 6 8 97.9 96.4
male 3.30-12.30 46.83+1.83 45.05+2.02 46.51+1.34 96 .2 99.3
30 yr 12.30-18.45 14.57+0,33 14,28+0.36 2 0 .2 0 +2 . 6  8 90.8 138.6
18.45-21.30 1.58+0.01 1.13+0.09 1 .2 0 +0 . 0  8 71.5 75.9
2jL.30-35.30 1.00+0.04 0.83+0.Q8 1.30+0*05 83.0 130.0
Pearson's r=0.999 r=0.995
Student's t=-0.12(NS) t=0.18(NS)
P2 0 - 2.15 16.10+0.14 13.66+0.43 17.87+0.51 84.8 1 1 1 . 0
female 2.15- 7.25 2.27+0.01 2.12+0.13 2.96+0.15 93.4 130.4
27 yr 7.25-11.15 2.45+0.34 2.28+0*03 2.41+0*01 93.1 98.4
Pearson's r=0.999 r=0.998
Student’s t=-l.2 0 (NS) t=l.50(NS)
P3 0 -2.25 4.65+0.02 4.13+0.22 5.69+0.86 8 8 . 8 122.4
male 2.2 5-4.50 8.45+0.03 7.59+0.11 7.53+0.61 89.8 89.1
43 yr 4.50-14.40 32.88+0.16 29.38+0.11 31.45+1.06 89.4 95.7
14.40-23.40 25.37+0.05 23.36+0*96 26.54+3*30 92.1 113.6
Pearson's r=0.999 r=0.96 5
Student's t=-l.37(NS) t=-0.05(NS)
P4 0 - 8.45 36.62+0.09 36.53+1.50 29.26+2.50 99.8 19.9
female 8.45-11.05 10.48+0.09 10.52+0.6 2 9.86+0.83 100.4 94.1
74 yr 11.05-12.45 6.40+0.03 4.09+0.29 6.07+0.70 63.9 93.7
12.45-18.45 7.99+0.03 7.18+0.50 6.34+0.93 89.9 79.4
18.45-23.35 9.67+0.10 13.40+0.37 8.71+0.71 138.6 90.1
23.35-26.15 2 .8 8 +0 . 0 2 2.06+0*10 2.61+0*35 71.5 90.6
Pearson's r=0.985 r=0.9 8 8
Student's t=-0.41(NS) t=-0 .34(NS)
P5 0 - 5.30 23.56+0.03 23.42+0.42 22.83+2.35 99.4 96.9
female 5.30- 8.20 12.01+0.03 10.65+0.30 11.32+0.99 88.7 94.3
8.20-12.50 10.19+0.0 2 9.31+0*20 8.18+0*67 91.4 80.3
Pearson's r=0.999 r=0.999
Student's t=-1.10(NS) t=-l.23(NS)
P6 0 - 4.3 0 8.01+0.04 7.06+0.66 8 8 . 1
female 4.30-10.00 8.41+0.02 9.4 8+0.76 111.4
35 yr 10.00-17.45 4.32+0.01 4.10+0.36 94.9
17.45-22.30 2.38+0.001 2.18+0*62 91.6
Pearson's r=0.96 8
Student’s t=-0.21 (NS) $
P7 0 - 0.45 2.19+0.01 2.01+0.05 91.8
female 0.45- 3.50 2.33+0.01 2.26+0.17 97.0




Admission time to C.P.U. is taken as zero time; HPLC versus NMR and SPEC c *
Paired t-test, comparison with HPLC data;NM=not measured; = P<0.05
NS - not significant
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Table 3.2.11 Quantitation of paracetamol sulphate (PS) from patients
after paracetamol overdose , based on HPLC, NMR and
SPEC






PI 0 -3.30 13.69+0.47 8.55+0.41 15.07+1.00 62.4 1 1 0 . 1
male 3.30-12.30 17.70+0.28 12.28+0.81 21.92+2.82 69.4 123.8
30 yr 12.30-18.45 7.37+0.22 6.49+0.51 9.97+0.83 8 8 . 1 135.3
18.45-21.30 0.74+0.0 2 0.40+0.02 1.05+0.14 54.0 141.9
2^.30-35.30 0.67+0.01 0.26+0.J1 2.04+0*17 38.8 304.5
Pearson's r=0.9 87 r=0.99£
Student's t=-l.27(NS) t=3.15
P2 0 - 2.15 6.49+0.03 6.3 0+0.23 7.07+0.28 97.1 108.9
female 2.15- 7.25 1.83+0.05 1.59+0.18 1.68+0.30 8 6  .9 91.8
27 yr 7.25-11.15 1.99+0.06 2 . 0  0 +0 * 0  8 3.17+0.32 100.5 159.3
Pearson's r=0.998 r=0 .971( NS)
Student’s t=-l,49(NS) t=3. 1 1
P3 0 -2.25 1.50+0.07 1.33+0.08 ND 88.7
male 2.25-4.50 3.60+0.06 2.98+0.08 4.84+0.33 82.8 134.4
43 yr 4.50-14.40 19.98+0.21 15.23+0.20 23.50+2.0 8 76.22 117.7
14.40-23.40 10.80+0.37 11.91+0*17 12.79+1*82 110.3 118.4
Pearson's r=0.965 r=0.999
Student's t=-0.89(NS) t=3.36
P4 0 - 8.45 14.56+0.0 8 14.90+0.97 14.90+1.00 1 0 0 . 0 102.3
female 8.45-11.05 3.34+0.03 4 . 6 8+0.27 5.97+0.90 103.0 140.1
74 yr 11.05-12.45 1.58+0.03 1.45+0.08 2.46+0.27 91.8 155.7
12.45-18.45 5.16+0.0 2 4.01+0.19 5.24+1.00 70.7 1 0 1 . 6
18.45-23.35 2.53+0.09 2.9 8+0.20 13.52+1.27 1 0 0 . 2 534.0
23.35-26.15 0.87+0.01 0.63+0*03 8.44+0.97 72.4 900.7
Pearson's r=0.988 r=0.5 9§(NS)
Student's t=0.15(NS) t=3.13
P5 0 5.30 6.37+0.05 6.13+0.44 11.64+1.07 96 .2 182.7
female 5.30- 8.20 2.38+0.06 2.10+0.08 5.54+0.81 8 8 . 2 200.3
8.20-12.50 2.20+0.06 2.55+0.p 6.4 9+0.87 115.9 295.0
Pearson's 7r=0.9 87 r=0.9 83(NS)
Student's t=-0 .2 1 (NS) t=6 .9 8
P6 0 - 4.3 0 1.71+0.03 4.88+0.66 285.0
female 4.30-10.00 2.40+0.03 4.56+0.76 190.0
35 yr 10.00-17.45 1.39+0.002 5.34+0.36 384.2
17.45-22.30 0.71+0.01 1.98+0.62 278.9
Pearson's r=0. 6 6 Q(NS)
Student's t=4.50
P7 0 - 0.45 0.53+0.0 5 1.05+0.05 198.1
female 0.45- 3.50 5.40+0.19 5.97+0.4 8 1 1 0 . 6




cAdmission time to C.P.U. is taken as zero time; HPLC versus NMR and SPEC 
Paired t-test, comparison with HPLC data;ND=not detected; *= p<0.05
NS = not significant
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Table 3.2.12 Structures, 400 MHz NMR chemical shifts and coupling 
constants of methionine and Parvolex In human urine
Name, abbrev. R Group Chemical shift, Coupling
ppm constant,J/Hz
Methionine






= 2 . 1 2
2.63
(s) J = 7.5 Hz 
<t) bc
z












H = 4.38 (X)
I:0CH3
c
s = singlet, d = doublet, AB = second order AB multiplet
3.2.2 QUANTITATIVE ANALYSIS BY VISIBLE SPECTROPHOTOMETRY (SPEC)
Metabolite concentrations were calculated frcin calibration 
curves constructed for P (see section 2.8.2) based on the visible 
absorptions of P. Measurements of PG and PS were obtained after 
their enzymatic conversion to P by yft-glucuronidase and sulphatase 
(completely converted to P as observed by HPLC) as previously 
described in section 2.8.2. Individual results and clinical
details are given in tables 3.2.2-3.2. 8  and are shown graphically 
in fig. 3.2.3-3.2.5. The concentrations of P and its metabolites 
are shewn in tables 3.2.9-3.2.11. The reliability of the 
quantification method was verified by the linear correlation 
between the absorbance within the concentration range (see section 
2.8.2).
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3.2.3 QUANTITATIVE ANALYSIS BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC)
P was identified on the basis of its retention time compared 
to standard P, i.e. 3.5 min. under the conditions described in 
section 2.9.2. Metabolite concentrations were calculated from the 
calibration curves constructed for P (see section 2.9.2) based on 
their peak height ratios to that of the internal standard (gentisic 
acid with retention time 5.1 min). Individual results and clinical 
details are given in tables 3.2.2-3.2.8 and are shown graphically 
in fig. 3.2.3-3.2.5. The concentrations of P and its metabolites 
are shown in table 3.2.9-3.2.11. The reliability of the 
quantification method was verified by linear correlation of the 
peak height ratio in the concentration range (see section 2.9.2).
3.2.4 COMPARISON OF RESULTS
Statistical analysis of SPEC, HPLC and NMR data (table 
3.2.9-3.2.11) show that the concentration of P, PG and PS measured 
by 1H NMR and that of PG measured by VIS are strongly correlated (r 
> 0.98) with those obtained on the same samples by HPLC. Since
the acetyl methyl resonances among, P, PMA, PC and PM (5 = 2.14-
2.15 ppm) were close, an attempt was made to get the best 
separation and integration of P resonance by resolution 
enhancement. Statistical analysis of the data (table 3.2.9) 
indicate that the concentrations of P measured by NMR were in good 
correlation (Pearson's) for 3 patients (r>0.99, P<0.05 for PI; 
r>0.91, P<0.05 for P3; and r>0.99, P<0.002 for P4) and not
correlated for 1 patient (P4) with those obtained on the same 
samples by HPLC. Student's t-test for paired samples shewed no
significant difference between P concentrations measured by the two 
methods.The concentrations of P measured by SPEC were found to be 
not correlated with those by HPLC in 4 patients (P2, P3, P5 and P7) 
out of 7 patients. The concentrations of PG (table 3.2.10) measured 
by 400 MHz ^H NMR and SPEC were found to be in good correlation 
with those by HPLC in all patients (r>0.99, P<0.05 except for P4 
where r>0.98, P<0.001 by NMR and for P6, r>0.96, P<0.05 by SPEC). 
The concentrations of PS (table 3.2.11) measured by NMR were in 
good correlation with those by HPLC (r>0.99, P<0.002 for Ply
r>0.99, P<0.05 for P2; r>0.96, P<0.05 for P3; r>0.98, P<0.001 for
P4 and r>0.99, P<0.05 for P5). Similarly, there was no significant 
difference of PS concentrations measured by NMR and HPLC. 
Measurement of PS concentrations by SPEC (table 3.2.11) indicate no 
correlation and significantly different values to those by HPLC in 
5 patients out of 7 patients. The concentrations of PG and PS 
measured by SPEC were significantly higher and those of PS were 
significantly lower compared to their values measured by HPLC in 
most patients(table 3.2.9-3.2.11). The time courses of the urinary 
metabolic profile of P after overdose were followed and PG was the 
major metabolite, followed by PS (fig. 3.2.3-3.2.5).
3.3 ACEMETACIN ANALYSIS BY 1H NMR
270 MHz ^H spectra of lyophilized urine (freeze dried and
2
redissolved in acetone-d : H O  (3:2 v/v) at 25 times the originalo 2
concentrations) fran a control subject and a volunteer taking 
acemetacin (see section 2.10.1.2) are shown in fig. 3.3.1A and 
3.3.IB respectively. Hanogated secondary irradiation of the 
residual water signal was applied and a total of 4 8 FIDs were 
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270 MHz H NMR spectra of lyophilized urine (to increase concentration about 25 x) in acetone-d^: D^O (3:2 
v/v) from (A) control (B) a volunteer after taking 180 mg/day acemetacin for 8 days. Resonances are 
labelled for 2,2-dimethyl-2-silapentane-5-sulphonate (DSS), /J-hydroxybutyrate (Bu), lactate (La), 
L-alanine (Ala), acetone, citric acid, sarcosine (Sar), creatine (Cr), creatinine (Cn), N-Me group, 
glycine (Gly), hippuric acid (Hp), urea (Ur), histidine (His), indomethacin (IN) and acemetacin (ACE). 
For conditions see section 2.7.3 and 2.10.1.2.
Table 3.3.1 Structures, H NMR chemical shifts and coupling constants 
of acemetacin (ACE) and indomethacin (IN) in Acetone-d 
and H O  (3:2 v/v)
Name R Group Chemical shift Coupling Constant
ppm J/Hz
Acemetacin -c hJ xxch^cooh 
2 2
Indomethacin -c h2coo h
H = 3.87 ( s)
£
= 7.00 (d)





H = 3 .93 (s)
Hfe = 4.67 (s)











He = 3.66 (s)
Jblb2 " 8'64
J. » 7.56 d
Jblb2 ” 9’18
Jb2b3 = 2'3°
J, = 8.64 a
(s) = singlet, (d) = doublet, (dd) = doublet of doublets
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Table 3-3.2 NMR quantitation of acemetacin (ACE) and indomethacin




Subj ect 1 Subj ect 2 Subj ect 3
ACE IN ACE IN ACE IN
Day 1, 2 h 27.11 109.27 24.23 128.63 20.81 105.19
Day 1, 4 h 25.68 104.77 NM 113.50 NM 125.13
Day 1, 6 h NMb 99.39 NM 102.62 NM 93.79
Day 8 , 2 h 16.73 97 .19 6.25 27.61 NM 102.82
Day 8 , 4 h 10.23 60.36 8.48 42.84 NM 45.39
Day 8 , 6 h 6 . 6 8 59, 45 6.65 56.32 7.38 61.00
^90 mg dose of acemetacin twice daily for 8 days.
Not measured due to overlap with endogenous urinary components
or lew concentration.
prior to Fourier transformation. All the endogenous metabolites
previously observed in unprocessed urine shown in fig. 3.1.1 were
again detected with more intense signals and some chemical shift 
changes due to solvent and pH differences. Selective deuteration
of the creatinine CH2 group also occurred.
Table 3.3.1 shows the structures, 1H NMR chemical shifts and
coupling constants of acemetacin (ACE) and indomethacin (IN) spiked
in blank urine samples and lyophilized as above. The methyl
resonances of ACE and IN (at 2.29 ppm and 2.31 ppm respectively) 
were chosen and quantified using the weights of the paper traces of 
the spectra. The concentrations of urinary ACE and IN excreted frcm 
3 human volunteers are shown in table 3.3.2. Endogenous metabolites 
in urine spectra were observed and found to vary between the
volunteers. It was found that the urinary glycine resonance in the
NMR spectrum of one subject decreased on the 1st day and was 
constant during the 8th day of the study. Another subject shewed 
no urinary glycine resonance in the NMR spectrum on the 8th day 
eilthough glycine was present on day 1.
3.4 D-PENICILLAMINE ANALYSIS BY *H NMR
270 MIz single pulse NMR spectrum of ’control■ plasma
obtained frcm EDTA-treated blood, are shown in fig. 3.4.1. The
spectrum contains broad overlapping resonances with few sharp
features. The most prominent of the broad resonances can be
102,111
assigned to protons of mobile fatty acids (F^ -F,.) (described
in section 4.2) and to the broad envelope of protein resonances.
In EDTA-plasma spectra where EDTA was used as an anti-coagulant,
2-  2-resonances frcm CaEDTA and MgEDTA were detected (fig. 3.4.2A 
and B). The other peaks assigned are a doublet of L-alanine (Ala,8 
= 1.46 ppm), singlet of creatine (Cr, 8 = 3.04 ppm), glycine (Gly,5 
= 3.54 ppm) and doublet of a-ancmeric proton of glucose (Glu,=5
5.25 ppm).
Removal of plasma protein by ultra filtration (10000 molecular
weight cut off) or by acid extraction with trichloroacetic acid
(TCAA) gave well resolved spectra. For comparison to EDTA plasma
spectrum, spectra of ultra filtered heparin plasma and serum are
presented in fig. 3.4.3 and 3.4.4 respectively. Standard additions
of seme major component of plasma to EDTA plasma before acid
2
extraction, freeze-drying and redissolving in H20, and reference 
112
to the literature were used to assign the peaks which are listed 
in table 3.4.1. The spin-echo spectrum of the same solution gave an 
aid to peak assignment due to its phase modulation.
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Table 3.4.2 shows the structures and chemical shifts of 
D-penicill amine (PSH) and its metabolites (penicillamine disulphide 
- PSSP, penicillamine cysteine - PSSC, and S-methyl penicillamine - 
MPSH) in an acid extract of EDTA plasma following addition of 
standards to the plasma. 80 ml pooled EDTA plasma frcm 10 
rheumatoid arthritis (RA) patients taking PSH treatment was 
extracted with acid to obtain PSH and its metabolites in the non­
protein fraction of plasma. However, PSH and its metabolites were
not detected in the 270 m z  ^H NMR spectra, even after 4Ox
2
concentration by freeze-drying and redissolution in H20 (fig. 
3.4.2A and B). These spectra consist solely of several sharp peaks 
similar to those found in the control spectra frcm normal human 
EDTA plasma.
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Table 3 .4 .1 . STRUCTURE AND CHEMICAL SHIFTS OF SOME ENDOGENOUS COMPOUNDS IN PLASMA





a = 1.93(s )
Acetoacetate Aca CH -C-CE -COOH 3 „ 2
a = 2.29(s) 
b = 3.45(s )
Acetone Act a = 2.24(s )




a c b 







a = 1.21(d) 
b = 2.29 - 2.44(m) 
c = 4.16(q)











a = 3 .3 9( s )
a = 3.2 - 4.0(m) 




Li 0.9 - 1.3
Protein (broad) Pro aromatic residues 
6 - 8
131
TABLE 3.4.2 STRUCTURE AND CHEMICAL SHIFTS OF D-PENICILLAMINE AND ITS 
METABOLITES
COMPOUND STRUCTURE CHEMICAL SHIFT COUPLING
(ppm) CONSTANT (Hz)
Me NK„
\  I i 51
D-PENICILLAMINE C-CH-COOH i,3i
(in phosphate buffer) Me ! b Hb - 3.65 (s)
a SH
PENICILLAMINE-CYSTEINE 
(in D20 + NaOD)
b
a NHMe | 2
^C-CH-COOH 





Ha = 1.43 (s)
1.56 (s)
He = 3.27 (d d ) Jed =
= 3.28 (d d ) Jcc =
Hd = 4.04 (d d )
Hb = 3.84 (s)
Me NH_
\  1 2Me __ C-CH-COOH 
PENICILLAMINE-DISULPHIDE ,
(in D„0 + NaOD) S Ha = 1.45 (s)
2- -  | = 1.55 (s)















3 . 6 3
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Fig. 3.4.1 270 MHz single pulse H NMR spegtrum of EDTA-glasma (EDTA-treated blood) containing 10% H20*
Accumulation of 64 FID's at 24°C, using a 60 pulse, 5 s internal between pules (PD), and 16 K data
points. The water resonances was suppressed by hanogated secondary irradiation. An exponential function
corresponding to a 1-Hz line broadening was applied. Abbreviations for peak assignments are given in
















Fig. 3.4.2 270 MHz H NMR spectra of aci$ e*tract of EDTA-plasma from patients taking D-penic ill amine
afterfreeze-drying and redissolved in H O  (to obtain 40 times of concentration strength) using (A) 
spin-echo sequence ( T ’ = 60 ms) and (B) single pulses (normal acquisition). Other conditions are as
described in fig. 3.4.1. Abbreviations for peak assignments are given in table 3.4.1. Some peaks have 
not yet been assigned.
C O
C O




Fig 3 - 4 ' 3  NMR^CONDITIONS^AS^DESCRIBED^N^Fig'^l^1^ ^ ^  OBTAINED PROM NORMAL VOLDNTEERS
C O
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6 5 4 3 2 1 CPPM
Fig. 3.4.4. 270MHz NMR SPECTRUM OF AN ULTRAFILTRATE OF SERUM OBTAINED FROM
NORMAL VOLUNTEERS. NMR CONDITIONS ARE AS DESCRIBED IN Fig. 3.4.2
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CHAPTER FOUR 
RESULTS OF IN VITRO METABOLISM STUDIES BY 
PROTON NUCLEAR MAGNETIC RESONANCES SPECTROSCOPY
In vitro metabolism in rat liver preparations has been studied 
in the present work after enzyme induction with phenobarbitone or 
3-methylcholanthrene. Enzyme induction by PB and 3MC was compared 
using spectral characteristics. The hepatic system was
investigated by NMR using the 10,000 g liver fraction and enzyme 
induction was assessed by NMR using aminopyrine (DMAP) and
daunorubicin (DA) as model substrates.
4.1 COMPARISON OF PHENOBARBITONE (PB) AND 3-METHYLCHQLANTHRENE
(3MC) INDUCTION OF HEPATIC ENZYME SYSTEM
A summary of the effects of inducers on rat liver weight, 
liver protein concentration and microsomal cytochranes are given in 
table 4.1.1. The ratio of liver weight to body weight is greater 
in PB (0.040+0.002, mean+SD, n=4) and 3MC (0.036+0.002, n=4) 
treated rats than in control rats treated with saline (0.031+0.001, 
n=4) or corn-oil (0.029+p.002, n=4). A significant difference in 
protein content of 10,000 g liver fractions (p<0.001) was observed 
between PB-treated rats and control rats treated with saline (29.83 
_+ 1.34 and 25.49 +_ 1.46 mg/g liver weight respectively) and between 
3MC-treated rats and control rats treated with corn-oil (31.71 +_ 
1.67 and 24.92 _+ 0.73 mg/g liver weight respectively).
A typical CO difference spectra of reduced cytochrome 
P-450/P-448 is given in fig. 4.1.1. The absorbance maximum, X max
= 450nm, of the microsomal reduced cytochrcme-CO complex fran 
PB-treated rats was found to be at the same wavelength as for
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control rats treated either with saline or corn-oil, with 
significantly (P<0.001) larger absorbances (corresponding to
2.3 24+0.185, 0.844+0.0 96 and 0.7 55+0.07 3 nmoles/mg total protein 
respectively, see table 4.1.1). X max in the CO difference spectrum 
of reduced cytochrcme frcm the 3MC-treated rats changed frcm 450 nra 
to 448 nm in response to the induction with a significant increase 
in absorbance (corresponding to 1.525+0.204 nmoles/mg protein,
P<0.01) compared to those of rats treated with saline or corn-oil.
A significant larger amount (P<0.01) of cytochrcme b^ in the 
liver frcm PB-treated rats was also found (0.986+0.095 nmoles/g 
protein) compared to those of saline or corn-oil treated rats 
(0.663+0.0 52 and 0.597+0.0 52 nmoles/mg protein respectively). 
Cytochrcme b5 in the liver frcm 3MC treated rats (0.749+0.067 
nraoles/g protein) was not significantly greater than those of 
control rats. The two haemoproteins in liver microsoraes, i.e. CO 
binding cytochrcme P-450/P-44 8 and cytochrcme b^ (maximum at 
450/448 and 428 nm respectively), could be distinguished from 
difference spectra (fig. 4.1.1).
•P-448
P-450
Fig. 4.1.1 CO difference spectra of reduced cytochromes after 
treatment with (A) phenobarbitone and (B) 3-methylcholanthrene
■ -0.5
400 450 500




















PB 333+26b 13.25+1.51 0.040+0.002 29.83+1.34 2.324+0.185 0.9 86+0.095
sal ine 331+21 10.23+0.5 2 0.031+0.001 25.49+1.46 0.844+0.096 0.663+0.052
3MC 334+24 11.99+1.22 0.036+0.002 31.71+1.67 1.525+0.204 0.749+0.067
Corn-oil 358+17 10.38+0.84 0.029+0.002 24.92+0.73 0.755+0.073 0.597+0.052
a
b Fraction of rat liver homogenate suspended in isotonic buffer (pH 7.4). 
Mean SD, P<0.001 compared to controls.
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4.2 NMR ANALYSIS : CONTROL SPECTRA OF THE 10,000 G LIVER FRACTION
A single pulse and a spin-echo NMR spectra of the 10,000 g 
liver fraction (co-factors included, see section 2.10.2) are shown 
in fig. 4.2.1. The single pulse spectrum contains broad 
overlapping resonances with few sharp features. The most prominent
of the broad resonances can be assigned to protons of unsaturated
_ .. . _ 112,113,237,238 /T1  ^ ^  ^  .fatty acids (F, ,terminal-CH.; F_, -(CH.) -; F.,
1 3 2 2 n 3
-CH^CH^CO-; F , -CH^CO-; F , -CH=CH). The spin-echo spectrum of
the same suspension results in the elimination of many of the broad
resonances. The sharper resonances due to protons with longer T
relaxation times still remain, i.e. the F^ and F^ protons of mobile
fatty acids, probably part of triglycerides and phospholipids.
The other peaks in the NMR spectrum are the lower intensity
resonances of some sharp singlet resonances (5 = 3.1-3.3 ppm) due
to +N-(CH^) groups of the phospholipids, betaine or 
103,237,238
carnitine . Glucose resonances at 3.40-3.95 ppm were
identified as by spiking the 10,000 g liver fraction and were 
revealed as broadened peaks. The remainder of the signals arise 
f ran the co-factor, nicotinamide, in the aromatic region ( 5 = 
7.5-9.0 ppm) but other co-factors, NADP and G6P, are not detected.
Fig. 4.2.2A and B show the spectra of an acid extract (with 
trichloroacetic acid, TCAA) of the 10,000 g liver fraction from 
PB-treated rats incubated without drugs added for 60 min. Even 
though the acid extraction caused the disappearance of signals from 
the most mobile fatty acids due to precipitation, some more 
resolved resonances (L-alanine at 1.56 pm, lactate at 1.41 ppm,p 
-hydroxybutyrate at 1.23 ppm and DSS at 0 ppm) were found due to 
the dissociation of these molecules frcm proteins.
Endogenous liver compounds were observed in the spectra of the
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acid extract of the 10,000 g liver fraction (fig. 4.2.2A and B, 
table 4.2.1), but no attempt was made to quantify them accurately. 
However, estimation of the intensity of seme endogeneous compounds 
with respect to the internal standard (DSS) can give an indication 
of concentration changes. Because of the broad signals and the 
suppression of . resonance near the water signal, its was difficult 
to quantify the glucose signals (6= 3.4 - 3.95 ppm). However, with 
careful phase correction it was possible to monitor the changes of 
peak intensities by estimating the peak in this region. Over a 
period of 120 min, the "control" 10,000 g liver fractions obtained 
from untreated rats and incubated without substrate showed a 
reduction in the intensity of the glucose signal and increases in 
those of lactate and L-alanine, while the j3“hYdroxYbutYrate signal 
appeared to be constant. In the two controls, PB- and 3MC- 
treated, there was a 0.6-0.8 fold reduction of glucose and a 
2.9-3.9 fold increase in L-alanine intensities after 120 min 
incubation. Lactate intensity increased over 120 min in all 10,000 
g liver fractions, i.e. 4.5 fold in PB-treated and 1.6-2.4 fold in 
3MC-treated and untreated rats.
4.3 NMR ANALYSIS: ASSESSMENT OF ENZYME INDUCTION USING AMINOFYRINE
Aminopyrine (DMAP) is metabolised by cytochrome P-450. Its 
metabolism is shown in section 1.5.2.1. Induction of cytochrome 
P-450 will be expected to increase its rate of metabolism but that 
of cytochrome P-448 should have no effect. Aliquots of 10,000 g 
liver fraction, each containing 30 mg protein, were incubated in 
the presence of 2 mM DMAP (see section 2.10.2) and monitored by 270 
MHz ^H NMR at intervals over periods of up to 120 min. Fig. 
4.3.1A and B shew the spin-echo and single pulse NMR spectra
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Table 4.2.1 Structures and 270 MRz H NMR chemical shifts of some 
endogenous compounds of the acid extract of 10,000 g 
liver fraction
Compound Abbr ev. Structure 1 a H Chemical Shift/ppm
Acetate Ac h3c-cooh 2.09( s )
L-Alanine Ala H.N-CH-COOH 1.56(d)
Glucose Glu H f-CH-(CHOH)4-0 
OH*---------- 1
3.40-3.95
3-D-Hydroxybutyrate Bu H C-CJH-CH -C00H 
OH
1.23(d)





Pyruvate Pyr H^-Cf-COOH 2.66 (s)
a
As measured fran fig. 4.2.2 (s = singlet, d = doublet).
Table 4.3.1 Structures and 270 ftBz H NMR chemical shifts of 
aminopyrine (DMAP) and its metabolites in the acid 
extract of 10,000 g liver fraction, co factors and MgCl2-
Rs__^CH,b
. N 
cr' n " '"Chf;
4*
Name Abbr ev. R group
a
Chemical shift, 1 ppm
'
Dimethyl-4-aminoantipyrine DMAP -N 3 Ha = 3.340(s)
or Aminopyrine ^ CH3 Hb = 2.4 91(s)
® H 3.350(s)
o = 7.360-7.740(dd)u






4-Aminoantipyrine AP -nh2 Hb = 2.418 (s)
HP = 3.230(s)
< = 7.400-7.800(dd)









Fig. 4.2.1 270 MHz 1H NMR spectra of Phenobarbitone treated 10,000 g liver fraction (contained 30 mg protein),
cofactors and MgCl2 (as described in section 2.10.2) in 0.1 M phosphate buffer (pH 7.4), obtained using (A) 
spin echo sequence ( ‘f = 60 ms) and (B) single pulses (normal acquisition). Peaks have been assigned for 
nicotinamide, glucose, N-methyl groups (including choline head group of phospholipid at 3.2 ppm), lactate,
mobile fatty acids (F1# -CH3; F _(CH2)n; F., -CH2CH2CO-; F4, -CH2CO-; F§, -CH=CH-); and, in B, a broad 














.2.2 270 MHz H NMR spectra of acid extract of Phenobarbital treated 10,000 g liver fraction (contained 30 mg 
protein) obtained using (A) spin echo sequence ( T  = 60 ms) and (B) single pulses (normal acquisition). 
Resonances are labeled for 2,2-dimethyl-2-silapenthane-5-sulphonate (DSS), -hydroxybutyrate (Bu), ^
L-alanine (Ala), acetate (Ac), pyruvate (Pyr) and NADP in addition to those seen in fig. 4.2.1. tp*
C O
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recorded after 30 min incubation of DMAP. Peak assignments of DMAP 
and its metabolites (table 4.3.1) were aided by spiking the 10,000 
g liver fraction with standard metabolites. Fig. 4.3.2 shews the 
spectra from a series of experiments using 10,000 g liver fraction 
from PB-treated rats at different times (0,5,15,30, 60 and 120 min) 
after addition of DMAP. The intensity of the singlet resonance at
2.4 9 ppm due to the methyl protons of DMAP decreased with time. 
Appearance of the metabolites was first observed at 5 rain 
(4-moncmethylaminoantipyrine, MMAP), 15 min (4-aminoantipyrine,AP) 
and 60 min (unknown). However, no peak corresponding to the unknown 
metabolite appeared in the spectra of 3MC-treated or control rats 
within the 120 min incubation period. The resonances at the 
aliphatic region were at constant chemical shift, whereas those at 
the arcmatic region were shifted possibly due to the slightly 
varied pH of samples.
Quantification of DMAP and its metabolites (MMAP and AP) was 
based on integrations of their methyl singlets (6= 2.49, 2.45 and
2.42 ppm respectively) compared to those of the internal standard 
DSS (5= 0 ppm) added. The results of these measurements over 30 
min in different 10,000 g liver fractions (PB, saline, 3MC and 
corn-oil pretreatment) are shown in table 4.3.2. Statistical 
analysis of the data shews that the concentration of DMAP and 
metabolite MMAP in the 10,000 g liver fractions of PB- and 
3MC-treated rats are strongly correlated (r>0.96, P<0.02, table 
4.3.2) with those of control rats. Student’s t-tests for paired 
samples were also performed. The concentration of DMAP in the 
liver of PB-treated rats was significantly lewer (P<0.01) and those 
of metabolite MMAP was significantly higher (P<0.02) than those in 
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Fig. 4.3.1 270 MHz H NMR spectra of acid extract of Phenobarbitone treated 10,000 g liver fraction (contained 30 mg
protein) after 30 min incubation with 2 mM aminopyrine (DMAP) (A) a spin echo spectrum ( T  = 60 ms); (B)
single pulse NMR spectrum. Resonances are labelled for aminopyrine (I), monomethyl-4-aminoantipyrine (II) 
and 4-aminoantipyrine (III) in addition to those seen in fig. 4.2.2. Note that I, II and III resonances are 
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Fig. 4.3.2 A stacked plot shewing the 270 MHz H NMR spectra of acid extract of PB treated 10,000 g liver fraction 
after incubation with 2 mM aminopyrine (I) at 0.5,15,30,60 and 120 min. The reduction of I and the 
appearance of its metabolites (II, monomethyl-4-aminoantipyrine; III, 4-aminoantipyrine; and IV, unknown) <*^*5 
can be seen. The slightly various pH's of the samples are reflected in the shifts of the resonances at 
aranatic region, whereas those aliphatic region do not change. Resonance is labeled for IV in addition to 
those seen in fig. 4.3.1.
AFig. 4
□  DMAP, I 
A MMAP, II 
V AP, III





□  DMAP, I 
A  MMAP, II 





0 10 20 30
Time (min)
3.3 Mean values of concentration vs time of aminopyrine and its metabolites, monanethyl-4-aminoantipyrine and 
4-aminoantipyrine in (A) Phenobarbitone, saline, and (B) 3-methylcholanthrene and corn-oil treated 10,000 
g liver fraction (each equivalent to 30 mg protein) as measured by 270 MHz ;1H
Table 4.3.2 Concentration of aminopyrine and Its metabolites in control and PB or 3MC treated 10,000 g liver 
fraction (equivalent to 30 mg protein) as measured by H NMR from integrations of methyl 
resonances (6= 2.41-2.49 ppm) compared to that of DSS (6- Oppm) in slngle-pulse experiments.
Inducer Incubation Concentration (pg/ml DMAA equivalent )a Total Substrate.
or Control Time (minutes) DMAP MMAP AP (jig/ml) Found (1%)
PB 0 380.77 + 3.94 ND ND 380.77 97.28
5 245.96 + 1.01 42.13 + 0.32 ND 288.09 73.61
■ 10 221.96 + 5.74 58.06 + 1.92 18.9 8 + 0.2 5 299.00 76.39
20 201.00 + 1.72 63.43 + 1.21 31.97 + 0.75 296 .40 75.73
30 189.19 + 3.92 74.53 + 1.51 30.39 + 0.62 294.11 75.14
Pearson' r= 0.985(P<0.01) r=0.964(P<0.02) r= 0.911(NS)
Student1se t=-9.81 (P<O.Ql) t=5.70 (P<to.02) t= 1.25 (NS)
Saline 0 3 84.08 + 0.38 ND ND 384.08 98.13
5 290.07 + 4.06 35.71 + 0.38 ND 325.78 83.23
10 270.50 ± 1.89 43.88 + 1.13 18.94 + 0.31 333.32 85.16
20 250.06 + 3.68 46.47 + 1.36 27.96 + 1.03 324.49 82.90
30 219.46 + 2.87 60.23 + 1.51 32.12 +_ 0.83 311.81 79.67
3MC 0 379.56 + 4.76 ND ND 379.56 96 .97
5 288.87 ± 2.05 37.13 + 0.35 ND 326.00 83.29
10 264.94 + 6 .81 40.14 + 1.08 19.14 + 1.15 324.22 82.84
20 241.24 + 2.26 43.78 + 0.66 29.04 + 0.73 314.06 80.24
30 222.52 + 3.48 61.03 + 1.43 33.15 + 0. 23 316.70 80.91
Pearson's r=0.999 (P<0.001) r= 0.977(P<0.02) r= 0.946 (NS)
Student's t=o.54 (NS) t=-0.92 (NS) t=-0.50 (NS)
Corn-oil 0 383.50 + 4.31 ND ND 383.50 97 .98
5 291.27 + 3.06 37.26 + 1.69 ND 328.53 83.94
10 264.81 + 6.32 44.42 + 0.43 19.18 + 0.19 328.41 83.91
20 239.63 + 3.654 45.95 + 0.91 32.45 + 1.48 318.03 81.25
30 219.23 + 3.35 59.24 + 0.88 31.83 + 0.77 310.30 79.28
DMAP, MMAP, and AP stand for aminopyrine, monanethyl-4-aminoantipyrine and 4-aminoantipyrine 
respectively.
Initial concentration of aminopyrine is 391.40 jig/ml. c Mean +_ SD
PB versus saline or 3MC versus corn-oil e Paired t-test between PB and saline, or 3MC and corn-oil ^
ND = not detected NS = not significant 00
the concentration of metabolite AP was the same in all liver 
preparations. The mean concentrations of DMAP, MMAP and AP in the
10,000 g liver fraction of various treated rats are plotted vs.
time over a 30 min period in fig. 4.3.3.
A major difference between the NMR spectra of the 10,000 g 
liver fraction in the presence of 2 mM of DMAP and the controls was 
that the resonances for glucose increased in the former spectra, 
whereas for controls, resonances in this region decreased in 
intensity (see section 4.2). Hew ever, the increases in methyl 
doublets of L-alanine (5=1.56 ppm) and lactate (5=1»41 ppm) were 
found to be similar to those in control 10,000 g liver fractions 
fran PB, saline, 3MC or corn-oil treated rats.
4.4 NMR ANALYSIS : ASSESSMENT OF ENZYME INDUCTION USING
DAUNQKUBICIN
Daunorubicin is metabolised in the liver by cytochrane P-450 
and P-448 and its metabolic pathways were examined with different 
types of enzyme induction. Its metabolism is shown in section 
1.5.2.2. Various 10,000 g liver fractions (i.e. fran PB, saline, 
3MC or corn-oil treated rats), each containing 30 mg protein, were 
incubated in the presence of 2 mM daunorubicin (DA) and monitored 
by 270 MEz NMR at intervals over a period of 30 minutes. Fig. 
4.4.1, 4.4.2 and 4.4.3 show the spin-echo and single pulse NMR 
spectra of 10,000 g liver fraction fran EB, 3MC and corn-oil 
treated rats recorded after 30 min incubation with DA. The spectrum 
after saline treatment is not presented but showed identical 
resonances to those after corn-oil treatment. Table 4.4.1 shews the 
peak assignments of DA which were aided by spiking the 10,000 g 
liver fraction with standard compound. Fig. 4.4.4A and B, and fig.
4.4.5A and B, shew a series of the above experiments at different
reaction times (0, 10 , 20 and 30 min) after the addition of DA
using 10,000 g liver fraction fran saline, PB, corn-oil and 3MC
treated rats respectively. Of these four types of supernatants, 
that employing PB treatment gave the most rapid rate of DA 
metabolism as assessed by the decrease in the methyl signal 
intensity at 1.31 ppm. The appearance of metabolites could be 
seen in the spectrum of the 10 min incubation, i.e. DA^ (6=1.25 
and 1.28 ppm) and DA^ ( 6=1*20 and 1.23 ppm). In the 10,000 g
liver fraction frcm 3MC-treated rats, the spectrum shewed one other 
metabolite, i.e. DA^ ( 6 =1.06 and 1.09 ppm). No attempt was made 
to extract these metabolites and determine their structures due to 
the lack of time.
The DA preparation used in the present studies contained 
mannitol as a stabilizer, which gave signals in the range 3.86-3.93 
ppm in the experimental conditions employed. Hence the glucose 
intensities at 3.4-3.95 ppm could not be monitored. Hcwever, the 
intensities of L-alanine signals over a 30 min incubation period 
with DA added were found to increase 2.8-3.5 fold. The lactate 
intensities over 30 min incubations were also found to increase , 


















Fig. 4.4.1 27 0 MHz H NMR spectra of acid extract of Phenobarbital treated 10,000 g liver fraction (contained 30 mg
protein) after 30 min incubation with 2 mM daunorubicin (DA) (A) a spin echo spectrum ( T  = 60 ms); (B) 
single pulse NMR spectrum. Resonances are labelled for DA and its metabolites (DA^ and DA2) in addition to 
those seen in fig. 4.2.2. Note that DA,DA^ and DA2 resonances (about 1.2-1.3 ppm) are suppressed due to 
phase modulation and relaxation effects. Inset: expansions of methyl region, 1.0-1.5 ppm.
BA
Fig. 4.4.2 270 MHz H NMR spectra of acid extract of 3-methylcholanthrene treated 10,000 g liver fraction (contained 
30 mg protein) after 30 min incubation with 2 mM daunorubicin (DA) (A) a spin echo spectrum ( T  = 60 ms); 
(B) single pulse NMR spectrum. Resonances are labelled for DA and its metabolite, DA in addition to those 
seen in fig. 4.2.2. Note that DA and DA^ resonances (about 1.04-1.35 ppm) are suppressed due to phase 
modulation and relaxation effects. Inset: expansions of methyl region, 1.0-1.5 ppm.
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4.4.3 270 MHz H NMR spectra of acid extract of corn-oil treated 10,000 g liver fraction (contained 30 mg
protein) after 30 min incubation with 2 mM daunorubicin (DA) (A) a spin echo spectrum ( -x - 60 ms); (B)
single pulse NMR spectrum. Resonance is labelled for DA in addition to those seen in fig. 4.2.2. Note that 
DA resonance ( 6  = 1.32 ppm) is suppressed due to phase modulation and relaxation effects. Inset: expansions 
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Fig. 4.4.4. Stacked plots showing aliphatic regions of the 270 MHz XH NMR spectra of acid extract of (A) saline, and 
(B) Phenobarbitone treated 10,000 g liver fraction (each contained 30 mg protein) after incubation with 2 
mM daunorubicin (DA) at 0, 10, 20 and 30 min. Inset: expansions of methyl region, 1.1-1.4 ppm. A small 
reduction of DA intensity is found in A and a large one in B, along with the appearance of DA metabolites, 































4.4.5 Stacked plots showing the aliphatic regions of 270 MHz H NMR spectra of acid extract of (A) corn-oil, and 
(B) 3-methylcholanthrene treated 10,000 g liver fraction (each contained 30 mg protein) after incubation 
with 2 mM Daunorubicin (DA) at 0, 10, 20 and 30 min. Inset: expansions of methyl region, 1.1-1.4 ppm. A 
small reduction of DA intensity is found in each A and B, along with the appearance of small intensity of 





APPLICATION OF PROTON NUCLEAR MAGNETIC RESONANCE 
IN DRUG METABOLISM STUDIES 
DISCUSSION
The application of NMR in drug metabolism studies has been
investigated and will be discussed belcw. Assessment of NMR in
quantitative studies has been undertaken and compared to
spectrophotometry (SPEC) and HPLC analysis of urinary excretion of
aspirin and paracetamol. The use of quantitative NMR for different
drugs in body fluids has also been investigated using acemetacin in
urine and D-penic ill amine in plasma. Alternatively, in vitro 
metabolism and enzyme induction were studied by NMR using
aminopyrine and daunorubicin as substrates.
5.1 QUANTITATIVE STUDIES BY NMR
5.1.1 COMPARATIVE STUDIES OF ASPIRIN
The major urinary excretion products of aspirin, i.e. salicylic 
acid (SA), salicyluric acid (SUA) and gentisic acid (GA) were
quantified by SPEC and NMR and compared to analysis by HPLC. The 
aromatic resonances of SA, SUA and GA, and N-acetyl methylene 
resonance of SUA could be detected in 400 MHz 1H NMR spectra (fig.
3.1.1 and tab. 3.1.2) of intact urine from a patient suffering from 
aspirin overdose, but were too extensively overlapped with 
endogenous compounds (hippurate resonances at 4 ppm, 7.5-7.9 ppm 
and indoxyl sulphate resonances at 7.2-7.7 ppm) for quantification 
to be attempted. It is easier to quantify a methyl signal (three 
magnetically equivalent protons) than the single proton of doublet, 
triplet or multiplet as are often the case in the arcmatic region,
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providing interfering compounds are absent. In the present study 
the problem arose from the overlapping signals of aspirin 
metabolites (even at high field) which meant that quantification of 
aspirin metabolites by NMR was Abandoned leaving SPEC and HPLC 
methods for quantitative analysis.
The present study has shown significantly lcwer 
(P<0.05-P<0.01) amounts of SA in 3 out of the 4 patients studied 
compared to the HPLC results (see table 3.1.7) using Student's t- 
test. In contrast, the SPEC results of SUA and GA in all patients 
were significantly larger (P<0.05-P<0.002) than those obtained by 
HPLC (see section 3.1.8-3.1.9). The lower SA values by SPEC may be 
the result of incomplete extraction or the loss of sample during 
extraction prior to the determination of electronic absorption 
which is based on a purple colour given by the salicylate ion with 
ferric salts in weakly acidic solutions'*4'235. larger SPEC
results may be due to interference frcm other compounds(s) 
extracted with SUA (giving a purple complex with ferric salts) or 
with GA (giving a green complex with the Folin-Ciocalteau
4.N34reagent)
In the case of moderate aspirin poisoning treated with glycine 
(orally), the percentage of glycine conjugate of SA excreted in the 
urine as SUA was found to be lower (45-54% of the total salicylate 
excreted, table 3.1.3-3.1.6)than that after a therapeutic dose. 
Thus, after aspirin overdose, urinary excretion of SA, GA, SPG and 
SAG was increased and these metabolites therefore make a greater 
contribution towards overall salicylate elimination (fig.
3.1.3-3.1.4). In contrast, in a patient (A4) with severe poisoning 
(treated with bicarbonate for urine alkalinisation), SA was the 
major urinary metabolite (45.1%) with only 28.9% of the excreted
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product being SUA. Urinary SA was higher in a patient treated with
urine alkal inisation compared to those treated with glycine. This
was attributed to the higher urine pH (above pH 7.0) in the former,
239 240
which caused an increase in renal clearance of SA ' . The net
effect was a decrease in unionised SA entering the systemic
circulation by passive tubular reabsorption for further metabolism,
as is reflected by reduced fractional excretion of other
metabolites (SUA, GA, SPG and SAG). The reduced urinary excretion
of SUA demonstrated in the present work suggests that SA formation
and/or elimination may be capacity limited. Following an 
241 242intravenous or oral administration of SUA, it was found that
SUA elimination was fast and not rate-limited. Published work
suggests that the rate-limiting step after aspirin overdose is SUA
241 242
formation rather than renal elimination '
5.1.2 COMPARATIVE STUDIES OF PARACETAMOL
In the present study 1H NMR has been used to investigate the 
urinary excretion of paracetamol (P) and its metabolites 
paracetamol glucuronide (PG) and paracetamol sulphate (PS) in P 
overdose patients. ^H NMR quantitative data has been compared to 
that obtained from HPLC and SPEC.
Typical 400 M3z 1H NMR spectra of urine from patients 
suffering frcm P overdose (fig. 3.2.1 and 3.2.2) are shown. P and 
its metabolites as well as various endogenous metabolites were 
readily detected, each with characteristic shifts, intensity ratios 
and sometimes spin-spin coupling patterns (table 3.2.1 and 3.1.1 
for P metabolites and endogenous metabolites respectively). The 
large signal of H20 in urine samples was adequately overcome by 
applying hanogated secondary irradiation at the H20 resonance (6 =
4.8 ppm). In the present case, the N-acetyl methyl signals of P and 
its metabolites gave sharp peaks which could be quantified as this 
signal was in a region of the urine NMR spectrum where there were 
few signals fran endogenous metabolites. A problem arose from the 
partially overlapping peaks in the narrow range of resonances
(2.13-2.17 ppm) of the N-acetyl groups of the metabolites. However, 
these signals could be well-resolved using high field strength 
spectrometers, i.e. at 400 MHz, where their signals were better 
dispersed. Moreover, the resolution was enhanced by application of 
a Gaussian function to the FID before Fourier transformation, with 
careful attention to phase correction.
■^ H NMR spectra of P and its metabolites have other
characteristic resonances in addition to the N-acetyl methyl 
resonances described above, i.e. the aromatic ring protons which 
gave certain coupling patterns and other resonances in the 
aliphatic region (table 3.1.18). Examination of the urinary 
metabolic profile of P after overdose by ^H NMR revealed PG as .the 
major metabolite (59-73%) followed by PS (18-30%) in total urine 
collected over 13-48 h (unknown in 2 patients) based on the total 
recovery of P, PG, PS and PMA, in P overdose. Fran table 3.1.12,
PG / PS was initially found to be 2.0 to 3.5 and as well as the
(PG+PS)/ PMA ratios were found to decrease with time, in all 
patients after treatment with methionine orally or N-acetylcysteine 
intravenously.
In the present study, the acetyl methyl peaks of P, PG and PS 
in NMR spectra have been successfully quantified and gave reliable 
results compared to those of HPLC. Paracetamol cysteine (PC) was 
detected, but not quantified due to its extensive overlap with 
paracetamol mercapturic acid (PMA) and methoxy paracetamol.
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However, PMA could be quantified easily from its side-chain 
N-acetyl methyl resonance at 1.86 ppm without interference from 
other metabolites. Another possibility of interference is the 
resonances of methionine, the drug administered for P overdose 
treatment, which gives signals at 2.12 ppm for the methyl and 2.16 
ppm for the methylene groups. However, free methionine signals 
were either not detected or present in very lew concentration in 
the urine sample studied.
The NMR results of mean concentrations of urinary P, PG and PS 
in intervals after P overdose were statistically similar (P>0.05) 
to those of HPLC (table 3.2.9-3.2.11). Hcwever, quantification by 
NMR appeared to give more variable results with SD up to 8%, 
whereas HPLC gave SD value less than 1%. The major problem that 
arises from NMR quantification is sensitivity. NMR can quantify 
the metabolite down to 0.1 mM, whilst HPLC gives results in uM 
range. However, the high concentrations of metabolites in overdose 
gave no problem in quantitative analysis by NMR.
In the case of the SPEC method, only PG determinations gave
reliable results (i.e. no significant difference) compared to
those by HPLC. P and PS concentrations gave significantly higher
values than those by HPLC (P<0.05). The common SPEC method for P
236
determination proposed by Chafetz jet al. was reported to give
no interference from structurally similar drugs such as phenacetin 
and p-aminophenolk Paracetamol requires preliminary nitrosation
with nitrous acid to form 2-nitro-acetamidophenol which can be 
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The SPEC results obtained could indicate that acid- or 
alkaline-labile metabolites(s) present in urine were converted to P 
in the method used giving a higher result. PG and PS were measured 
indirectly by converting them to P with enzymes, /8-glucuronidase 
for PG, and sulphatase and /8-glucuronidase for PG and PS. In the 
case of PS, another metabolite(s) may be "converted" by sulphatase 
which is subsequently detected by SPEC giving a higher value than 
that obtained by HPLC. Pretreatment of P metabolites was also 
required for HPLC determination, however, the separation process 
prior to detection by HPLC is considered to give more reliable
results.
The metabolic mechanism of the toxicity of P has already been
described .(section 1.4.2.2).In a minor pathway accounting for about
5% of the dose, P is converted to a reactive intermediate, thought
243to be N-acetyl-p-benzoquinone imine , which combines with hepatic
17 8glutathione prior to urinary excretion . After overdose,
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however, the hepatic glutathione may be depleted, thus liver damage 
may occur as a result of covalent binding of the reactive 
intermediate with cellular macranolecules.
As described above, NMR spectra can be used to monitor drug 
metabolites and endogenous metabolites concomitantly. Therefore 
any alteration frcm normal or therapeutic conditions can be 
detected. The decrease of the ratio of PG/PS (table 3.2.12) after 
methionine and N-acetylcysteine treatment may suggest the 
increasing availability of sulphate, therefore aiding P elimination 
and hence reduce the amount of the oxidised intermediate. Even 
though paracetamol glutathione was not detected in the NMR
spectra, its subsequent metabolic products, paracetamol cysteine 
(PC) and paracetamol mercapturic acid (PMA) were observed. It is 
thought that cysteine is obtained from methionine through 
homocysteine and cystathionine, or by straight conversion from 
N-acetylcysteine. The increasing pyruvate concentration observed in 
the spectra can be explained by the formation of its partial 
oxidative degradation to pyruvate and subsequent reduction to 
lactate by lactate dehydrogenases (fig. 5.1.1). Hence the lactate 
and pyruvate resonances were increased. In one patient, the 
disappearance of L-alanine was observed, suggesting a raised serum 








Cysteine N-Ace ty 1 cy st ei ne
7 -glut amyl X.oxidation
cysteine Cysteine sulphonic acid
, t





Fig. 5.1.1 Possible fate of amino acids administered and 
endogenous amino acids in cases of paracetamol 
poisoning
5.1.3 ACEMETACIN
Section 3.1 and 3.2 described the 270 MHz NMR spectra of 
endogenous compounds and drug metabolites (aspirin and paracetamol) 
in untreated urine samples with the aid of a simple solvent 
suppression method. However, free acemetacin (ACE) and its 
hydrolysis product, indomethacin (IN), gave resonances which were 
either very weak or not detected in unprocessed urine samples from 
3 volunteers who took therapeutic doses of acemetacin. In order to 
increase the metabolite concentrations necessary for quantitative 
analysis, the urine samples were freeze dried and redissolved in
164
2
acetone-cL and H.O (3:2 v/v) to give 20-25 times the original 6 2
concentrations. Despite the appearance of the acetone methyl 
resonance (2.2 ppm), this simple procedure also overcame the 
dynamic range problem caused by the strong water signal. Hcwever, 
since the signal-to-noise ratio of endogenous urinary metabolites 
was simultaneously improved, there were fewer spectral regions 
which provided little or no background interference. The loss of 
volatile components and the deuteration of acidic or exchangeable 
protons were not relevant in this case, thus allowing this method 
to be applied.
ACE and IN gave some resonances (table 3.3.1), the methyl
resonances at 2.29 ppm and 2.31 ppm respectively showing the least
interference frcm endogenous metabolites (fig. 3.3.1).
Quantification of ACE and IN frcm 27 0 tfiz NMR spectra was based
on measurenents of peak area for these singlet methyl resonances
which were obtained by cutting and weighing paper traces. This
technique allows accurate results in situations where the
linewidths of the peaks are varied and the peaks of interest are
slightly or partially overlapped (with acetoacetate signals, fig.
3.3.1), particularly when relatively insensitive low to medium
field spectrometers are being used. The addition of seme standard
solution to 4 blank urine samples, freeze drying and redissolving
2
in acetone-d and H O  (section 2.3) showed that the analytical o 2
recovery of IN was good (92.0+5.7%, n=4). Table 3.3.2 shews
concentrations of urinary IN and very lew concentrations of urinary 
ACE (not measured in some cases), suggesting that most ACE 
administered was converted to IN in the body.
270 m z  NMR spectra of freeze dried urine samples from a
subject who had taken ACE (fig. 3.3.1) shewed more endogenous
metabolites compared to those of intact urine (fig. 3.1.1, table
3.1.1) which were taken to be ACE metabolites. Hcwever, lack of
standard metabolites available did not permit confirmation of these
signals as ACE metabolites. The urine spectra of 1 subject showed
a decrease in urinary glycine on the 1st day and in another
volunteer no glycine was detected on the 8th day. This finding
suggests that the pathway of metabolism of ACE involves conjugation
with glycine in the liver, possibly depleting this endogenous
substrate. Several other endogenous metabolites were monitored and
found to vary. This is in agreement with previous HELC findings
which indicated that higher concentrations of glycine conjugated
metabolite were excreted in volunteers who had taken ACE than those 
182
who had taken IN
5.1.4 D-FENIOLLAMINE METABOLITES
NMR spectra of whole blood have been previously shewn to
117 8 9
contain resonances from both erythrocytes and plasma '
Hcwever, the spectra frcm whole blood were not well-resolved and
reproducible. Spin-echo *H NMR spectra frcm resuspended red cells
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have also been observed . Well-resolved spectra were generally 
obtained although the spectra sometimes contained only H^O or broad 
unresolved resonances^\ This problem was thought to be due to 
small amounts of paramagnetic deoxyhaemoglobin in the venous blood 
and also to erythrocyte sedimentation and movement during the 
course of spectral accumulation. NMR spectra frcm plasma alone 
were more highly resolved and reproducible^^. Hence, in the 
present study plasma was chosen for the study of various endogenous 
metabolites as well as drug metabolites (table 3.4.1 and 3.4.2 for 
endogenous metabolites and D-penicillamine metabolites 
respectively). EDTA stabilised the D-penicillamine (PSH) in the
o
reduced form at roan temperature or 4 C by complexing trace metals
244
which catalysed thiol oxidation , and hence EDTA plasma was used
to examine PSH and its metabolites.
270 MHz single pulse NMR spectra of EDTA plasma using
secondary irradiation of the water signal (fig. 3.4.1) was hampered
by the large number of overlapping resonances frcm macrcmolecules
such as proteins and fats. Hcwever, in the spin echo technique
broad resonances frcm macrcmolecules and relatively immobile groups
disappeared via spin-spin (T2  ^ relaxation during the waiting
periods ( )  of the two pulse sequence (see section 1.3.3.4).
Sufficient time (2 'C = 120 ms) then elapsed for the net
magnetization associated with most broad resonances (short T^) to
decay to zero and thus not contribute to the spectrum. A large
number of well-resolved signals frcm mobile protons of lew
molecular weight metabolites in plasma EDTA have been assigned
(table 3.4.1). Hcwever, in quantitative studies the intensities of
resonances have to be interpreted with caution since they may be
influenced by both T^ and T relaxation. All spectra were
accumulated with similar pulse repetition rates so that T^ effects
were likely to be similar in each case. The factors affecting
include the binding of small molecules to macrcmolecules, to
2+paramagnetic ions (e.g. Cu ) and viscosity differences between
plasma samples. A study of creatinine concentration in plasma by 
1 245spin-echo H NMR has shown only 70% recovery of this compound.
In contrast, creatinine concentrations measured by NMR and the
Jaffe/ method in urine where protein concentrations are negligible,
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have been reported to be in good agreement . Thus, although spin 
echo technique was carried out to minimize the Interference frcm 
macrcmolecules as well as to provide an aid to the assignment, some
factors remained that interfered with analysis by NMR,
especially quantitatively. Therefore, in the present study
an attempt was made to measure penicillamine (PSH) and its 
metabolites in the non-protein fraction of plasma sifter acid 
extraction. For comparison, NMR spectra of serum and heparin plasma 
ultra-filtration (fig. 3.4.2 and 3.4.3 respectively) were recorded 
and showed similar resonances as those of EDTA plasma except for 
the resonances of EDTA and trace metal complexes.
Several investigators have reported measuring plasma
concentrations of PSH by spectrophotometry, chromatography or
radioimmunoassay (see section 1.4.2.4). The occurranee of side
effects in RA patients treated with PSH and the variation in
efficacy seen with the drug might be related to plasma levels of
246the drug and its metabolites (1-10 mg/1) . Technical
difficulties in developing assays to routinely measure the drug in
biological fluids have led to a lack of information regarding this
situation. In the present study, hcwever, PSH and its metabolites
in the non-protein fraction of plasma EDTA were not detected in the
spectra (fig. 3.4.2), although the plasma samples had been
2
lyophilized and redissolved in H^O to obtain a 40 times 
concentration. Resonances of PSH and its metabolites (0.3 mM for 
each concentration) spiked in piasma-EDTA as described in section
2.10.1.3 (table 3.4.2) were obtained. This fact suggests that the 
non-appearance of PSH and its metabolites in the pooled plasma 
spectra from RA patients were due to the lew concentration of the 
drug present in plasma. In addition, as in the case of acemetacin, 
lyophilized samples used to increase drug concentration also 
increased the signal-to-noise ratio of plasma components thus 
aggrevating the problem of "chemical noise" in drug measurement.
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However, the appearance of low molecular weight endogenous 
compounds in intact and acid extract plasma (listed in table 3.4.1) 
should be of value in clinical and biochemical analysis.
5.2 IN VITRO METABOLISM STUDIES OF AMINOPYRINE AND DAUNORUBICIN 
BY NMR SPECTROSCOPY
5.2.1 GENERAL
In vitro metabolism of aminopyrine (DMAP) and daunorubicin
(DA) was studied using NMR spectroscopy. Rat livers used were
gently homogenised in an isotonic phosphate buffer, a process that
ruptures the plasma membrane but leaves most of the internal
organelles intact. The liver hcmogenates contain the subcellular
organelles, e.g. nuclei, mitrochrondria and endoplasmic reticulum,
which differ in size and specific gravity and thus sediment at
different rates following differential centrifugation.
Centrifugation at 10,000 g for 10 min sediments the nuclei,
mitochondria and debris, leaving the endoplasmic reticulum, cytosol
and soluble portion of the cell cytoplasm in the supernatant
fraction. The subcellular organelles catalyse different metabolic 
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reactions . For example, the cytosol contains substrates and 
enzymes needed in glycolysis, gluconeogenesis, the phosphogluconate 
pathway, activation of amino acids and fatty acid synthesis. The 
cytochrane oxidase enzymes are located in the endoplasmic 
reticulum, whereas the enzymes of the citric acid cycle, electron 
transport and those concerned in conservation of oxidative energy 
in the form of ATP are located in the mitochrondria.
The 10,000 g liver fraction of the rat, which contained both 
the microsomal and soluble fractions, was used in the present study 
to compare the metabolism of DMAP or DA after enzyme induction by
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phenobarbltone (PB) or 3-methylcholanthrene (3MC). Microscmal 
fractions (without the soluble fraction), which contained the 
cytochranes (obtained frcm the 10,000 g liver fraction after 
centrifugation at 40,000 g for 60 min), were also considered for 
use. The disadvantage of using only the microscmal fraction for in 
vitro metabolism was that little or no metabolites were observed by 
NMR spectroscopy due to low metabolic activity leading to lew 
concentrations of metabolites. The low metabolic activity of the
40,000 g pellet (i.e. microsoraes) could be attributed to the loss 
of microsomal enzymes in the isolation of the microsomal fraction 
and possibly due to the lack of cofactors. In vitro metabolism of 
DMAP and DA was more successful using the 10,000 g fraction and 
therefore this fraction was used routinely in the study despite the 
fact that phase II conjugation reactions might also occur and 
complicate the “^H NMR spectra.
The supernatant fraction used contained glucose-6-phosphate 
(G6P) and glucose-6-phosphate dehydrogenase (G6PDH) which in the 
presence of nicotinamide adenine dinucleotide phosphate (NADP) 
generate the reduced form, NADPH, required for drug metabolism 
according to the following reaction:
Glucose-6-Phosphate + NADP+ ^  ^  6-Phosphogluconolactone + NADPH+H+
Mg2+, G6PDH
When the 10,000 g liver fraction is used as the drug metabolising
enzyme preparation, there is no need to add G6PD since it is
present in this fraction. It can be seen frcm the above reaction
2+
that G6P, NADP and Mg need to be added as cofactors. G6P must be 
added to the enzyme preparation since livers from starved rats for 
24 h had low concentration of G6P due to increased
170
glucose-6-phosphatase and decreased glucokinase activities 
2+
Mg must also be added to in vitro preparations since it forms
complexes with the phosphate groups of the glycolytic
intermediates, e.g. G6P, which provide the binding sites for many
224
of the glycolytic enzymes . Also, in order to prevent
destruction of the pyridine nucleotide (part of NADP) by tissue 
nucleosidases, especially in a long incubation time, nicotinamide 
was added to the in vitro incubation mixture.
Monooxygenase enzymes (cytochrcmes P-450/P-448) in the
microscmal fraction carry out specialised oxidative reactions, e.g. 
hydroxylation and carboxylation, in which one of two oxygen atans 
is incorporated into the main substrate, the other being reduced to 
H^O with two H atoms donated by the cosubstrate. Since they oxidise
to different substrates simultaneously, they are also called
mixed-function oxidases. In the present study, NADPH was used as 
the cosubstrate. The most numerous and complex monoxygenation 
reactions are those employing the cytochrcme P-450 family of haem 
proteins. The general reaction equation for monoxygenases can be 






In the case of DMAP, the above reaction can be modified for
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-► RNH2 + ECHO
H Cytochrcme P-450 N-demethylated Hydroxylated
product product
For DA, the metabolism pathways in the rat liver is shown in fig.
1.5.2. The above figures show the simplified outline of the action
of cytochrcme P-450, which has many complex intermediate steps. 
Cytochrcme P-450, which participates in enzymatic monoxygenases, 
accepts two electrons from NADPH and introduces one oxygen atcm 
into the substrate.
In the present study, livers were obtained frcm rats pre­
treated with PB, 3MC, saline (control for PB), or corn-oil (control 
for 3MC). PB and 3MC differ in the course and intensity of
cytochrcme induction. The microscmal portion obtained frcm control 
livers contained cytochrcme P-450 which could be characterized from 
the carbon monoxide (CO) complex of its reduced form which absorbs 
light maximally at 4 50 nm (see fig. 4.1.1). The CO complex of 
reduced cytochrcme after PB induction exhibited an increased
absorption compared to those of controls at 450 nm (see table
4.1.1). Thus cytochrcme P-450 concentration had been induced after 
PB treatment (see section 4.1). After 3MC induction, the peak
absorbance of the CO reduced cytochrcme complex had been shifted 
frcm 450 to 448 nm, indicating the presence of cytochrcme P-448. 
The concentration of cytochrcme as an enzyme protein can be related 
to the protein concentration in the microsomal and soluble fraction 
to indicate the extent of the induction.
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It is now well known that there are various forms of
microscmal mono-oxygenases with different substrate specificities
and inducibilities, but the 'P-450' family of cytochrcmes plays a
large role in drug metabolism. A detailed study of the interaction
of cytochrcme P-450 with various substrates is needed to understand
the mechanism of catalysis of this protein. This interaction is
249 250usually studied by optical methods ' which gives no idea of
the spatial structure of the enzyme-substrate complexes. NMR has
been used to study the relationship between drug or substrate
binding and its oxidation by the two cytochrcmes P-450 or P-448
215,216
induced by PB or 3MC respectively (see section 1.5.1). A
number of similar studies have been performed by NMR
longitudinal relaxation rate measurements. Even though the binding
studies give more detailed information, they cannot be readily
adapted to study increased activity of drug metabolising enzymes
induced by foreign compounds or the metabolic pathways of drugs.
Enzyme induction increases the activities of drug metabolising
enzymes which leads to an accelerated biotransformation of drugs in 
248vivo . The activity of all enzymes will have seme influence on 
the rate of the pathway, but seme will be much more important than 
others.
An NMR method has been presented for the determination of
the effect of compounds that stimulate the biosynthesis of liver 
microscmal drug metabolising enzymes, cytochrcme P-44 8 and/or P-450 
and their activities towards two substrates, aminopyrine (DMAP) and 
daunorubicin (DA). NMR spectra were obtained frcm PB, 3MC,
saline or corn-oil pretreatments with or without drug substrates 
added. NMR spectra can be obscured by the presence of certain
endogenous macrcmolecules such as fats. For this reason, rats were
starved for 24 h before being killed. During starvation, the whole
direction of intermediary metabolism is switched to the net
production of glucose by glycogenolysis, and, as fasting continues,
by gluconeogenesis frcm pyruvate, lactate, glycerol and amino
acids. During starvation, the energy requirements of the liver are
supplied by the oxidation of fatty acids. Thus, the fatty acids
which would give problems in centrifugation and in the
determination of protein concentration, as well as broadening the
NMR spectra, were eliminated.
Water suppressed NMR spectra of 10,000 g liver fraction are
shown in fig. 4.2.1. The spin echo pulse sequence results in the
elimination of many of the broad resonances in the normal spectrum
due to protons of macrcmolecules which have short spin-spin
relaxation times (T2 values), such as proteins and unsaturated 
_ ^  4 _ 112,113,237,238 , , _
fatty acids . In the single pulse spectrum, hcwever,
seme sharper resonances were superimposed on the broad envelope of
overlapping resonances. Seme signals, at 0.9 and 1.3 ppm (F^ and
237 238
F^), still remain (fig. 4.2.1) and can be assigned ' to the
terminal -CH. and -(CH.) - protons respectively of mobile fatty 
3 2 n
acids, probably part of triglycerides and phospholipids. Canioni
251 13
et al. attributed some sharp C NMR signals from liver observed
by topical magnetic resonances to fatty acids in phospholipids.
Triglycerides account for about 9-30% of the total lipids in liver,
and phospholipids are about 65%. The glucose resonances, in the
region 3.40-3.95 ppm, are broadened in the single pulse experiment
and are phase modulated in the spin echo experiment (fig. 4.2.1A
and B). Three sharp singlet resonances appeared in the region
237
3.1-3.3 ppm. According to Birdsall et al. and Frost and
23 8 1 2
Gunston the H NMR spectra of [ H.]methanol extracts of
4
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lyophilized liver cells contained intense characteristic resonances
for the phosphatidylcholine head group and fatty acyl chains of
phospholipids. This suggests that the singlet resonances observed
around 3.2 ppm in intact cells of liver are also from choline head
groups. Other possibilities of resonances in this region are
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betaine and carnitine . In the intact microscmal and supernatant 
sample, no peaks appeared in spectra corresponding to DSS added as 
the internal reference and standard. The disappearance of DSS 
might be due either to localisation within small intracellular 
compartments or to binding to macrcmolecules. A sharp doublet 
assignment for lactate (6= 1.40 ppm) appeared in the single pulse 
spectrum and phase modulated in spin echo spectrum.
In the intact microsomal and supernatant spectra, problems 
arose frcm the broadened resonances in the single pulse experiment 
and the phase modulated resonances in the spin echo experiment 
which would not permit quantitative measurement. To overcome these 
problems, the reconstituted samples were extracted by 
trichloroacetic acid (TCAA) after set incubation times to disrupt 
cells, and denature and precipitate proteins. Frcm fig. 4.2.2, it 
can be seen that the spectra of acid extracted microsomal and 
supernatant fraction contain more well resolved resonances for 
cellular metabolites. The single pulse spectrum (fig. 4.2.2.B) 
includes resonances for amino acid (L-alanine), ketone body ( jft- 
hydroxybutyrate), acetate, lactate, pyruvate, glucose and the 
internal standard DSS. Signals for the mobile fats observed in the 
non-extracted spectra were notably absent in the spectra of the 
acid extracted sample, except that of F^. Such fats may 
precipitate with protein and cell membranes and be removed by 
centrifugation. The spin echo NMR spectrum of the acid extract
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was essentially the same as those of the non-extracted sample 
except for shifts due to pH differences between the samples. The 
N-methyl resonances, shifted to 3.2-3.4 ppm, were now better 
resolved. Hcwever, there was a loss of seme signals in this 
region, further confirming that the resonances at this position 
were due to the choline head group of a phospholipid. The broad 
envelope resonances of protein disappeared in the region of 1.0-3.4 
ppm, but the broad signal due to macrcmolecules still existed at
3.4-4.4 ppm. Although these broad signals were eliminated in the 
spin echo spectra, there was a decrease in singlet resonance 
intensities and the seme doublet resonances intensities observed at 
lew concentration disappeared. These results suggest that the use 
of spin echo experiments quantitatively or for the monitoring of 
lew concentrations of sample components is not advisable.
The single pulse spectra of the acid extract of the 10,000 g
liver fraction gave more resolved resonances for drugs and their
metabolites (discussed belcw) and seme endogenous components, in
the region between 1.0-3.4 ppm. The extraction with TCAA was also
used to stop the in vitro metabolism at various time intervals due
to its ability to inhibit enzyme activities by denaturation and
precipitation (with no change of peak intensities in acid extract
o
spectra after 24 h, 4 C). Spectra of acid extracted 10,000 g liver 
fraction obtained frcm untreated, PB- or 3MC-treated rats were 
monitored using ^H NMR spectroscopy. Over a 30 min incubation (see 
2.10.2), glucose intensities were reduced by 0.6 to 0.8 fold with 
an increase in lactate and L-alanine resonances, this may be 
evidence for glycolysis occurring in the reconstituted enzyme 
system resulting in synthesis of pyruvate which in the presence of 
NADPH+H+ and lactate dehydrogenase, was converted subsequently to
lactate. Hcwever, the increase in lactate concentration in PB 
treated samples over 30 min incubation was greater (3.3 fold) than 
that found after 3MC, saline or corn-oil treated samples (1.2-1.7 
fold). In the 10,000 g liver fraction there was an increase in 
L-alanine 2.1-2.4 fold over the 30 min incubation period indicating 
that pyruvate could also be converted to L-alanine through a 
transaminase enzyme. Endogenous metabolites such as pyruvate are 
produced and utilised very rapidly and hence may be the reason for 
the variable small amounts detected over the 30 min incubation. The 
concentration of a ketone body, -hydroxybutyrate, which is the 
product of fatty acid oxidation in mitochondria, was found to be 
constant in all the NMR spectra. This fact suggested that the
10,000 g liver fractions were contaminated by -hydroxybutyrate
frcm mitochrondria in the homogenizing process. Hcwever, pyruvate 
and the high level of lactate found indicated that the 10,000 g 
liver fraction were separated frcm mitochondria since they are 
converted to acetyl CoA in the mitochondria and further oxidised 
through the citric acid cycle for energy production. Seme of the 
enzymes were differentially induced by PB and 3MC as shown by the 
changes of endogenous lactate between the two treatments. The 
reconstituted enzyme systems appeared to be active for endogenous 
catalysis, seme served in the catabolism (e.g. glycolysis), and 
some functioned in the synthesis of cellular metabolites (e.g. 
lactate and L-alanine).
5.2.2 AMINOPYRINE
The reconstituted enzyme systems above consisted of both 
microsomal and soluble fractions and added cofactors which were 
then incubated in the presence of DMAP or AP, as the model
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substrates. In contrast to the control spectra, the resonances in
the region expected for glucose seemed to be broadened and
featureless, but increased in intensity in the presence of DMAP and
its metabolites. This result is in agreement with that of an
252
experiment performed by Nicholson et al. when paracetamol was
incubated with hepatocytes. They considered that the endogenous
metabolite might be an intermediate in glycogenolysis needed for
glucuronide formation, even though the NMR spectrum of a
2
solution of glycogen in H^O was found to be broad and featureless. 
Hcwever, the increased intensities of lactate in 10,000 g liver 
fraction incubated with DMAP were found to be the same as those of 
control and may indicate glycolysis. The rate of increase of 
L-alanine resonance intensities were found to be lcwer than those 
of the control spectra (1.5-1.6 fold and 2.1-2.4 fold 
respectively), suggesting that DMAP inhibits the transamination 
reaction.
When DMAP was incubated with liver microsomal and soluble 
o
fractions at 37 C for 30 min, three new singlet resonances were 
observed at = 2.50, 3.34 and 3.35 ppm and aronatic resonances at
7.4-7.8 ppm by spin echo NMR. Hcwever only that at 2.50 ppm 
appeared in single pulse spectrum since the other two peaks were 
obscured by the broad envelope of macrcmolecules (6 = 3.4-4.8 ppm)
and peak distortion by water irradiation. The intensity of the
singlet resonance at 2.50 ppm due to the methyl signal of DMAP had 
decreased after 30 min incubation. Hcwever, no peaks appeared in 
the spectral region corresponding to DMAP metabolites (for 
metabolic pathways of DMAP, see fig.1.5.1). Characteristic, well 
resolved resonances for the metabolite, 4-aminoantipyrine (AP), 
were observed in the NMR spectrum when a standard addition of AP
was made to this suspension. This result is similar to that
252obtained by Nicholson et al. with paracetamol. Paracetamol 
metabolites expected after 20 min incubation with hepatocyte cells 
were not observed in the NMR spectrum of the suspension. They 
suggested that the non-appearance of the metabolites was due to the 
weak concentrations which were difficult to observe in the presence 
of cells when the signal-to-noise ratios were low and was not due 
to adverse line broadening resulting frcm (extracellular) diffusion 
in inhanogenous fields created by the cell membranes. The problem 
in this study was overcome by acid (TCAA) extraction where the 
appearance of DMAP and its metabolites,4-monomethylaminoantipyrine 
(MMAP), AP and unknown compounds, could be observed and monitored 
(see fig. 4.3.2).
Cytochrcmes were found to be active in the reconstituted 
systems, the liver microscmal and soluble fractions with added 
cofactors as shown by DMAP N-demethylation (see fig. 4.3.2). 
Demethylation activity (see metabolic pathway of DMAP in fig.
1.5.1) was followed in 270 Ifiz 1H NMR spectroscopy by the 
disappearance of DMAP and the formation of its metabolites, MMAP 
and AP. Over the 30 min in vitro incubation, DMAP, the initial 
substrate in the PB treated samples was metabolised rapidly. Its 
disappearance was significantly faster than in 3MC treated or 
control samples (see table 4.3.2 and fig. 4.3.3). The formation of 
the metabolite MMAP was significantly higher in the PB treated 
samples, although another metabolite, AP, formed at the same rate 
as it occurred in 3MC treated or control samples. These results 
revealed that cytochrcme P-450 which plays a central role in DMAP 
metabolism in the liver microscmes frcm PB treated rats had been 
induced. It was found that PB increased the enzyme activity in
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N-demethylation of the first step, i.e. DMAP to MMAP, but not that 
of the second step, MMAP to AP. The disappearance of substrate, 
DMAP, and the formation of the metabolites, MMAP and AP, in the 3MC 
treated samples were found to be the same as those of control 
samples. This suggests that the cytochrome P-448 induced by 3MC 
(see section 4.1) does not increase the metabolic rate of DMAP. 
Quantitative NMR analysis of DMAP at the beginning of the 
reaction revealed about 98% recovery (see table 4.3.1). The 
recovery after the reaction (at 4,10,20 and 30 min) of DMAP and its 
equivalent in metabolites was only about 75%. The appreciable 
amount of substrate disappearance (25%) found in the early stages 
of the reaction (see table 4.3.2), which could not be accounted for 
by metabolic products may be derived directly from the substrate 
through another pathway. In all the 10,000 g liver fractions that 
were incubated with DMAP, the substrate DMAP concentration was 
still decreasing after 20 min, but MMAP was produced with a higher 
rate than previously while the concentration of AP, a product of 
MMAP, was reasonably constant (see fig. 4.3.3). The unknown 
metabolite found in the PB treated samples at 60 and 120 min 
suggested alternative pathways arising frcm DMAP and MMAP, and not 
frcm AP since the unknown metabolite appearance was accompanied 
only by decrease of DMAP and MMAP. These results are in agreement 
with the metabolic pathways of DMAP described in section 1.5.2.1 
(fig. 1.5.1).
5.2.3 DADNORDBICIN
In the spectra of the samples where DA were incubated (fig.
4.4.1-4.4.3), it was impossible to monitor the resonances within 
the usual chemical shift range of sugars since the DA preparation
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used contained mannitol as a stabilizer which resonated at
3.86-3.93 ppm. The lactate resonances appeared to be induced by DA 
or mannitol in the 3MC, saline or corn-oil treated samples (2.1-2.3 
fold), but not in the EB treated one (3.4 fold) where the 
concentration was found to be the same as the EB treated control
samples, presumably due to the maximal enzyme activity in the
system. Mannitol is not absorbed after oral intake, but there may
be a possibility that it is converted to a glycolytic intermediate 
in the in vitro incubation resulting in a higher concentration of 
lactate. In contrast to the samples for DMAE metabolism, DA or 
mannitol seemed to increase L-alanine resonance intensities, 
compared to those of control spectra (2.8-3.5 fold and 2.1-2.4 fold 
respectively).
Fig. 4.4.4A and B, and 4.4.5A and B give typical spectra for 
DA following incubation for 0,10,20 and 30 min. The concentration 
of DA was too small to be accurately quantified and the data 
obtained was largely qualitative. In the reconstituted system, 
consisting of the microscmal and soluble fractions and co-factors, 
the rate of DA metabolism was greatest in EB treated samples, 
followed by those of 3MC and control samples respectively, 
monitored by the disappearance of the substrate. DA metabolite 
resonances which appeared in EB treated samples (DA^ and DA^) were 
in different positions to the one frcm 3MC treated samples (DA^). 
In the control samples, no metabolites were observed, presumably 
due to their low concentration. These results indicate that EB and 
3MC induce different metabolic pathways of DA.
5.3 APPLICATION OF 1H NMR SPECTROSCOPY TO DRUG METABOLISM STUDIES
■^ H NMR spectroscopy has been used to detect a wide range of 
intermediary metabolites present in human biological fluids such as 
urine and plasma, and microsomal and soluble fractions of rat 
liver. NMR is also capable of providing full quantitative
analysis of drugs, metabolites and endogenous substrates
simultaneously. In the present study, the potential of NMR has 
been demonstrated for widespread application in drug metabolism
studies and the following conclusions can be drawn :
5.3.1 URINE ANALYSIS
Urinary excretion of drugs and their metabolites plays a large
role in providing information in drug metabolisn studies. Using
NMR, measurement of urinary excretion can usually be achieved
without extensive physical preparation or chemical pretreatment if
compounds are present in sufficiently high concentration. In the
present study urine analysis by NMR was applied to aspirin,
paracetamol and acemetacin. Successful analysis by NMR, compared to
HELC and spectrophotometry methods when available, was only
obtained for paracetamol and its metabolites, and the acemetacin
metabolite, indomethacin. The detection of metabolites in
unprocessed urine samples is possible provided they have suitable
resonances and are present in the mM concentration range. Reliable
quantification of drug metabolites in urine samples requires the
molecules to give signals in spectral regions low in "chemical
107noise" (see fig. 3.1.1). Wilson et al. have stated that the 
spectral region of low chemical noise is where background 
interference frcm other molecules is small. This condition is most 
easily achieved in analysis of drugs which have large therapeutic
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doses or in overdose when their concentrations are much larger than 
those of endogenous compounds. High field strength spectrometers 
(e.g. those operating at 400MHz) have been used in order to obtain 
maximal sensitivity and good dispersion of signals. This minimises 
overlap of drug metabolite resonances and those frcm the more 
abundant endogeneous urinary components. Moreover, the use of 
resolution enhancement techniques, e.g. application of a Gaussian 
function to the FID prior to Fourier transformation, can partially 
overcome the problem of reduced signal dispersion, especially at 
lower field strengths (e.g. 270 Jfiz). Quantification cannot be
carried out when a compound does not have isolated resolved signals 
in its spectrum or if they overlap with endogeneous compounds, as 
proved the case for aspirin.
Apart frcm chemical noise, analysis using NMR has another 
disadvantage, i.e. insensitivity. Owing to the inherent 
insensitivity of NMR, higher concentrations of compounds are 
required than those for HELC when ng or even pg quantities can be 
detected. However, the limitations of sensitivity by NMR (found to 
be approximately 0.1 mM) can be overcome by lyophilization, i.e. 
freeze drying and redissolving of urine samples to get higher 
concentrations. This result gives recoveries and reproducibility 
as good as those obtained frcm unprocessed samples, as found in the 
measurement of the acemetacin metabolite, indomethacin.
In the drug metabolism studies described above, NMR has been 
used to provide detailed metabolic information on both exogenous 
(drugs and their metabolites) and endogenous compounds 
concurrently, which may be of importance in assessing changes as a 
result of treatment or overdose. A major advantage of NMR is that 
it provides a "fingerprint" picture on a variety of metabolites
specifically, without the need to preselect the detection 
conditions provided the metabolites possess protons suitable for 
observation by NMR spectroscopy. In contrast, HELC requires sample 
preparation and column separation to give only a single peak for 
each metabolite which is subsequently detected. In the case of 
SPEC, there is a need for sample pretreatment, such as extraction 
and/or chemical reaction(s) to give a species which absorbs the 
visible light selectively, giving only one peak for one metabolite 
in one time. This, hcwever, is often difficult to achieve.
The typical "finger-prints" of endogenous metabolites can be 
substantially altered following drug therapy. For example, i) after 
paracetamol overdose, providing indication of liver damage (e.g. 
large concentration of lactate), ii) after treatment with 
methionine and/or Parvolex and iii) after acemetacin administration 
(see section 3.1, 3.2 and 5.1). Given the rapid, direct and 
simultaneous estimation of low molecular weight metabolites, it 
seems likely that, while NMR instrumentation is expensive the
technique may be of value in clinical and biochemical 
investigations and particularly in toxicological studies.
5.3.2 PLASMA ANALYSIS
The ”^H NMR spectra of plasma (fig. 3.4.1) contains fewer
resolved resonances than the spectra of urine. Macrcmolecules such 
as fats and protein which are present in large concentration in 
plasma, hamper quantitative analysis of drug metabolites. Hcwever, 
metabolic information frcm plasma samples may be available frcm NMR 
studies, but such measurements rely on the spectral simplication
achieved by applying spin echo techniques, providing the compounds
can be detected by NMR (see section 5.2). The spin echo method has
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the advantage of phase modulation of multiplets as an aid to peak
assignment. Accurate quantification of peak areas in spin echo
spectra is complicated by the effects of molecular diffusion (if
there is B field inhcmogenity), T. decay or binding with o 2
macrcmolecules. This problem can be overcome by extracting 
macrcmolecules frcm plasma, e.g. by protein denaturation or 1000 
molecular weight cut off ultrafiltration. Using these techniques, 
more resolved spectra can be obtained and quantitative analysis 
could be attempted providing a suitable resonance is present in 
the NMR concentration range (as in urine analysis). Despite its 
detection in a non-protein plasma fraction after spiking control 
plasma with standard compounds (see section 2.10.1.3), 
D-penicillamine and its metabolites could not be observed in 
patient samples, even in pooled concentrated plasma. However, the 
application of the method described above should enable NMR to 
provide a wide variety of useful information on plasma, such as the 
metabolic pattern of endogenous components in normal or disease 
states where concentrations are greater than 0.1 mM.
5.3.3 IN VITRO METABOLISM
10,000 g liver fraction gave similar problems to those of 
plasma in NMR analysis. However, acid extracted samples used in 
the study indicate that *H NMR spectroscopy may be a useful method 
in in vitro metabolism studies. In vitro studies involved 
incubation of the parent drug with liver microscmes, soluble 
fractions, or both. The drug and/or its metabolites can be analysed 
by *H NMR quantitatively or qualitatively and may be a useful 
complement to kinetic studies in vivo. In vitro metabolism studies 
by ^H NMR are well suited for exploring the metabolism of new drugs
providing the parent drug and its metabolites give suitable NMR 
signals and sensitivity problems can be overcome. An advantage is 
the possibility of examining endogenous and exogenous metabolites 
simultaneously.
NMR spectroscopy can also indicate in vivo enzyme induction 
of EB or 3MC using a model substrate. Aminopyrine (DMAP) used as a 
model substrate was metabolised rapidly by PB induced enzymes, i.e. 
cytochrcme P-450. Daunorubicin (DA) metabolism was found to be 
induced by both PB and 3MC which gave different metabolic 
product s.
It is well known that many drugs have the capability of 
inducing one or more of the drug metabolising enzymes. Metabolism 
can lead to either more polar and less pharmacologically active 
(toxic) metabolites or to potentially toxic compounds such as 
epoxides and arene oxides. "Reactive" metabolites or intermediates 
are generally formed by the action of microscmal cytochrcmes, 
although there are some examples where the metabolic activation is 
dependent on the activity of conjugating enzymes. Pretreatment of 
animals with an inducer can increase the toxicity of drugs, at 
least in part, by enhancing the activity of the microsomal 
cytochrcmes which produce toxic metabolism. Thus inhibiting enzyme 
activity may diminish the toxicity. On the other hand, the toxicity 
of drugs which are metabolised to non-toxic products will be 
decreased by enzyme induction. The balance of toxifying and 
detoxifying pathways thus depends on the balance of various enzyme 
activities. Since NMR spectroscopy has proved to be a useful 
tool in studying in vitro metabolism and enzyme induction, it has 
potential in the study of toxifying and detoxifying pathways.
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